tokens,ner_tags,id,nct_id,text,ner_manual_ct_target
"['A', 'Phase', 'I', 'Clinical', 'Trial', 'of', 'BAT4406F', 'Injection', 'on', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'in', 'Patients', 'With', 'Neuromyelitis', 'Optica', 'Spectrum', 'Disorders', '|', 'This', 'study', 'is', 'a', 'phase', 'I', 'clinical', 'study', 'of', 'the', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'BAT4406F', 'injection', 'in', 'patients', 'with', 'neuromyelitis', 'optica', 'spectrum', 'disorders', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04146285,NCT04146285,"A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders | This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.","[(28, 36, 'DRUG', 'BAT4406F'), (114, 153, 'CONDITION', 'Neuromyelitis Optica Spectrum Disorders'), (248, 256, 'DRUG', 'BAT4406F'), (284, 323, 'CONDITION', 'neuromyelitis optica spectrum disorders')]"
"['Acupuncture', 'for', 'the', 'Prevention', 'of', 'Emergence', 'Delirium', 'in', 'Children', 'Undergoing', 'Myringotomy', 'Tube', 'Placement', '|', 'Myringotomy', 'tube', 'placement', 'is', 'one', 'of', 'the', 'most', 'commonly', 'performed', 'operations', 'in', 'children', '.', 'Emergence', 'delirium', 'after', 'such', 'procedures', 'is', 'common', '.', 'During', 'emergence', 'delirium', 'children', 'can', 'become', 'both', 'a', 'danger', 'to', 'themselves', 'and', 'others', 'around', 'them', ',', 'including', 'family', 'members', 'and', 'hospital', 'staff', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'acupuncture', ',', 'when', 'used', 'in', 'combination', 'with', 'standard', 'anesthetic', 'management', ',', 'decreases', 'the', 'incidence', 'of', 'emergence', 'delirium', 'in', 'pediatric', 'patients', 'following', 'myringotomy', 'tube', 'placement', '.', 'Patients', 'with', 'and', 'without', 'premedication', 'of', 'midazolam', 'will', 'be', 'included', '.', 'A', 'secondary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'our', 'institution', ""'s"", 'actual', 'incidence', 'of', 'emergence', 'delirium', 'for', 'this', 'operation', 'using', 'a', 'validated', 'scale', ',', 'the', 'Pediatric', 'Anesthesia', 'Emergence', 'Delirium', '(', 'PAED', ')', 'scale', '.', 'We', 'will', 'also', 'compare', 'rates', 'of', 'emergence', 'delirium', 'in', 'patients', 'that', 'received', 'a', 'premedication', 'of', 'midazolam', 'versus', '(', 'V', ')', 'those', 'that', 'did', 'not', '(', 'NV', ')', '.', '\n\n', 'This', 'is', 'a', 'randomized', 'double', '-', 'blinded', 'trial', '.', 'We', 'will', 'enroll', '100', 'children', 'aged', '1', '-', '6', 'years', 'old', '.', 'Premedication', 'with', 'midazolam', 'will', 'be', 'decided', 'by', 'the', 'anesthesiologist', '.', 'If', 'needed', ',', 'the', 'patient', 'will', 'receive', 'a', 'standard', 'does', 'of', 'oral', 'midazolam', 'plus', 'acetaminophen', '(', 'V', ')', '.', 'If', 'the', 'patient', 'does', 'not', 'require', 'premedication', 'with', 'midazolam', ',', 'oral', 'acetaminophen', 'will', 'be', 'given', 'alone', '(', 'NV', ')', '.', '\n\n', 'Patients', 'will', 'then', 'be', 'randomized', 'to', 'receive', 'either', 'acupuncture', 'with', 'standard', 'general', 'anesthesia', 'care', '(', 'A', ')', 'or', 'to', 'receive', 'standard', 'anesthetic', 'care', 'alone', '(', 'S', ')', '.', 'Patients', ',', 'their', 'family', 'members', 'and', 'recovery', 'registered', 'nurses', '(', 'RNs', ')', 'will', 'not', 'know', 'if', 'acupuncture', 'was', 'performed', '.', 'Intraoperative', 'anesthetic', 'techniques', 'will', 'be', 'standardized', 'and', 'include', 'inhaled', 'inductions', 'with', 'nitrous', 'oxide', 'and', 'sevoflurane', '.', 'Anesthesia', 'maintenance', 'will', 'be', 'inhaled', 'sevoflurane', 'and', 'the', 'usual', 'pain', 'medication', 'ketorolac', 'will', 'be', 'given', 'intramuscularly', 'prior', 'to', 'emergence', '.', 'Acupuncture', 'needles', 'will', 'be', 'placed', 'after', 'anesthesia', 'induction', 'and', 'removed', 'prior', 'to', 'leaving', 'the', 'operating', 'room', '.', 'A', 'total', 'of', '4', 'needles', 'will', 'be', 'placed', ',', 'one', 'in', 'each', 'wrist', 'at', 'the', 'Heart', '7', '(', 'HT7', ')', 'point', 'and', 'one', 'in', 'each', 'ear', 'at', 'the', 'Shen', 'Men', 'point', '.', 'The', 'needles', 'will', 'be', 'inserted', 'bilaterally', 'to', 'a', 'depth', 'of', '1.8', 'mm', '.', '\n\n', 'In', 'the', 'PACU', ',', 'a', 'blinded', 'study', 'observer', 'will', 'evaluate', 'the', 'patient', 'at', 'four', 'time', 'points', 'using', 'the', 'PAED', 'scale', ':', 'time', 'of', 'awakening', 'and', '5', ',', '10', '&', '15', 'minutes', 'after', 'awakening', '.', 'Follow', 'up', 'phone', 'calls', 'will', 'be', 'made', 'one', 'day', 'and', 'one', 'week', 'after', 'surgery', '.', 'Families', 'will', 'be', 'asked', 'about', 'behavior', 'after', 'discharge', ',', 'sleep', 'and', 'bed', '-', 'wetting', '.']","['B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02383004,NCT02383004,"Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement | Myringotomy tube placement is one of the most commonly performed operations in children. Emergence delirium after such procedures is common. During emergence delirium children can become both a danger to themselves and others around them, including family members and hospital staff.

The primary objective of this study is to determine if acupuncture, when used in combination with standard anesthetic management, decreases the incidence of emergence delirium in pediatric patients following myringotomy tube placement. Patients with and without premedication of midazolam will be included. A secondary objective of this study is to determine our institution's actual incidence of emergence delirium for this operation using a validated scale, the Pediatric Anesthesia Emergence Delirium (PAED) scale. We will also compare rates of emergence delirium in patients that received a premedication of midazolam versus (V) those that did not (NV).

This is a randomized double-blinded trial. We will enroll 100 children aged 1-6 years old. Premedication with midazolam will be decided by the anesthesiologist. If needed, the patient will receive a standard does of oral midazolam plus acetaminophen (V). If the patient does not require premedication with midazolam, oral acetaminophen will be given alone (NV).

Patients will then be randomized to receive either acupuncture with standard general anesthesia care (A) or to receive standard anesthetic care alone (S). Patients, their family members and recovery registered nurses (RNs) will not know if acupuncture was performed. Intraoperative anesthetic techniques will be standardized and include inhaled inductions with nitrous oxide and sevoflurane. Anesthesia maintenance will be inhaled sevoflurane and the usual pain medication ketorolac will be given intramuscularly prior to emergence. Acupuncture needles will be placed after anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the Heart 7 (HT7) point and one in each ear at the Shen Men point. The needles will be inserted bilaterally to a depth of 1.8 mm.

In the PACU, a blinded study observer will evaluate the patient at four time points using the PAED scale: time of awakening and 5, 10 & 15 minutes after awakening. Follow up phone calls will be made one day and one week after surgery. Families will be asked about behavior after discharge, sleep and bed-wetting.","[(0, 11, 'OTHER', 'Acupuncture'), (34, 52, 'CONDITION', 'Emergence Delirium'), (76, 102, 'CONDITION', 'Myringotomy Tube Placement'), (105, 131, 'CONDITION', 'Myringotomy tube placement'), (194, 212, 'CONDITION', 'Emergence delirium'), (253, 271, 'CONDITION', 'emergence delirium'), (445, 456, 'OTHER', 'acupuncture'), (488, 518, 'OTHER', 'standard anesthetic management'), (598, 624, 'CONDITION', 'myringotomy tube placement'), (669, 678, 'DRUG', 'midazolam'), (787, 805, 'CONDITION', 'emergence delirium'), (938, 956, 'CONDITION', 'emergence delirium'), (1002, 1011, 'DRUG', 'midazolam'), (1159, 1168, 'DRUG', 'midazolam'), (1270, 1279, 'DRUG', 'midazolam'), (1285, 1298, 'DRUG', 'acetaminophen'), (1355, 1364, 'DRUG', 'midazolam'), (1371, 1384, 'DRUG', 'acetaminophen'), (1463, 1474, 'OTHER', 'acupuncture'), (1480, 1512, 'OTHER', 'standard general anesthesia care'), (1531, 1561, 'CONTROL', 'standard anesthetic care alone'), (1652, 1663, 'OTHER', 'acupuncture'), (1773, 1786, 'DRUG', 'nitrous oxide'), (1791, 1802, 'DRUG', 'sevoflurane'), (1843, 1854, 'DRUG', 'sevoflurane'), (1885, 1894, 'DRUG', 'ketorolac'), (1945, 1956, 'OTHER', 'Acupuncture')]"
"['Evaluation', 'of', 'the', 'Animal', 'Intervention', 'Used', 'as', 'Therapy', '.', 'Impact', 'of', 'Animal', '-', 'assisted', 'Therapy', 'on', 'the', 'Well', '-', 'being', 'in', 'Patients', 'With', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'animal', '-', 'assisted', 'therapy', '(', 'AAT', ')', 'is', 'now', 'considered', 'a', 'non', '-', 'drug', 'care', 'and', 'is', 'often', 'used', 'in', 'geriatrics', '.', 'Many', 'studies', 'have', 'shown', 'a', 'link', 'between', 'the', 'presence', 'of', 'the', 'animal', 'and', 'the', 'psycho', '-', 'behavioral', 'symptoms', 'decrease', 'in', 'dementia', '(', 'PBSD', ')', 'such', 'as', 'depression', ',', 'anxiety', 'or', 'irritability', 'that', 'affects', 'their', 'quality', 'of', 'life', 'and', 'improved', 'cognitive', 'abilities', '.', 'However', ',', 'many', 'methodological', 'flaws', 'in', 'these', 'researches', 'exist', '.', '\n\n', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'AAT', 'on', 'the', 'well', '-', 'being', 'of', 'patients', 'with', 'Alzheimer', 'disease', '(', 'AD', ')', 'at', 'the', 'stage', 'of', 'Major', 'Neuro', 'Cognitive', 'Disorder', '(', 'NCD', ')', 'at', 'short', 'and', 'medium', 'term', '(', 'before', 'care', ',', 'during', 'care', '(', 'at', 'the', 'beginning', 'and', 'end', 'of', 'each', 'session', ')', ',', '1', 'week', 'after', ',', '2', 'weeks', 'and', '1', 'month', 'after', 'the', 'last', 'session', ')', 'compared', 'to', 'a', 'group', 'receiving', 'the', 'same', 'stimulation', 'without', 'the', 'dog', ""'s"", 'response', '.', '\n\n', 'Patients', 'will', 'be', 'seen', 'in', 'groups', 'of', '4', 'to', '6', 'people', 'at', '8', 'workshops', '.', '2', 'groups', 'will', 'be', 'formed', ':', 'AAT', 'group', 'versus', 'control', 'group', '.', 'The', 'only', 'difference', 'between', 'these', 'two', 'groups', 'is', 'the', 'intervention', 'of', 'the', 'dog', 'at', 'each', 'workshop', 'in', 'the', 'AAT', 'group', '.', '\n\n', 'Each', 'workshop', 'will', 'consist', 'of', 'three', 'identical', 'times', '.', 'It', 'will', 'begin', 'with', 'a', '15', 'minute', 'introductory', 'activity', ',', 'the', 'first', 'goal', 'will', 'be', 'to', 'establish', 'a', 'relationship', 'with', 'patients', '(', 'patients', '-', 'patients', 'and', 'patients', '-', 'caregivers', ')', 'and', 'a', '40', 'minute', 'cognitive', 'stimulation', ',', 'identical', 'in', 'the', '2', 'groups', ',', 'will', 'be', 'proposed', 'and', 'finally', '5', 'minutes', 'will', 'be', 'devoted', 'to', 'the', 'closing', 'of', 'the', 'session', 'This', 'study', 'should', 'highlight', 'a', 'positive', 'effect', 'of', 'animal', 'assisted', 'therapy', 'on', 'the', 'well', '-', 'being', ',', 'PBSD', ',', 'depression', ',', 'anxiety', 'and', 'cognitive', 'abilities', 'and', 'a', 'long', '-', 'term', 'retention', 'of', 'these', 'positive', 'effects', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02829801,NCT02829801,"Evaluation of the Animal Intervention Used as Therapy. Impact of Animal-assisted Therapy on the Well-being in Patients With Alzheimer's Disease | The animal-assisted therapy (AAT) is now considered a non-drug care and is often used in geriatrics. Many studies have shown a link between the presence of the animal and the psycho-behavioral symptoms decrease in dementia (PBSD) such as depression, anxiety or irritability that affects their quality of life and improved cognitive abilities. However, many methodological flaws in these researches exist.

The aim of the study is to evaluate the effectiveness of AAT on the well-being of patients with Alzheimer disease (AD) at the stage of Major Neuro Cognitive Disorder (NCD) at short and medium term (before care, during care (at the beginning and end of each session), 1 week after, 2 weeks and 1 month after the last session) compared to a group receiving the same stimulation without the dog's response.

Patients will be seen in groups of 4 to 6 people at 8 workshops. 2 groups will be formed: AAT group versus control group. The only difference between these two groups is the intervention of the dog at each workshop in the AAT group.

Each workshop will consist of three identical times. It will begin with a 15 minute introductory activity, the first goal will be to establish a relationship with patients (patients-patients and patients-caregivers) and a 40 minute cognitive stimulation, identical in the 2 groups, will be proposed and finally 5 minutes will be devoted to the closing of the session This study should highlight a positive effect of animal assisted therapy on the well-being, PBSD, depression, anxiety and cognitive abilities and a long-term retention of these positive effects.","[(18, 37, 'OTHER', 'Animal Intervention'), (65, 88, 'OTHER', 'Animal-assisted Therapy'), (124, 143, 'CONDITION', ""Alzheimer's Disease""), (150, 173, 'OTHER', 'animal-assisted therapy'), (175, 178, 'OTHER', 'AAT'), (290, 312, 'OTHER', 'presence of the animal'), (360, 368, 'CONDITION', 'dementia'), (384, 394, 'CONDITION', 'depression'), (396, 403, 'CONDITION', 'anxiety'), (609, 612, 'OTHER', 'AAT'), (648, 665, 'CONDITION', 'Alzheimer disease'), (667, 669, 'CONDITION', 'AD'), (687, 717, 'CONDITION', 'Major Neuro Cognitive Disorder'), (719, 722, 'CONDITION', 'NCD'), (911, 954, 'CONTROL', ""same stimulation without the dog's response""), (1011, 1020, 'OTHER', 'workshops'), (1047, 1050, 'OTHER', 'AAT'), (1131, 1154, 'OTHER', 'intervention of the dog'), (1179, 1182, 'OTHER', 'AAT'), (1423, 1444, 'OTHER', 'cognitive stimulation'), (1607, 1630, 'OTHER', 'animal assisted therapy'), (1656, 1666, 'CONDITION', 'depression'), (1668, 1675, 'CONDITION', 'anxiety')]"
"['Evaluation', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'PRJ212', 'on', 'Improving', 'the', 'Memory', 'of', 'Patients', 'With', 'Mild', 'Severity', 'Alzheimer', ""'s"", 'Disease', ':', 'A', '6', '-', 'month', 'Randomized', ',', 'Double', '-', 'blind', 'and', 'Placebo', '-', 'controlled', ',', 'Followed', 'by', 'a', '6', '-', 'month', 'Open', 'Label', 'Extension', 'Study', '|', 'A', '6', '-', 'month', 'randomized', ',', 'double', '-', 'blind', 'and', 'placebo', '-', 'controlled', ',', 'followed', 'by', 'a', '6', '-', 'month', 'open', 'label', 'extension', 'study', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02991235,NCT02991235,"Evaluation of the Efficacy and Safety of PRJ212 on Improving the Memory of Patients With Mild Severity Alzheimer's Disease: A 6-month Randomized, Double-blind and Placebo-controlled, Followed by a 6-month Open Label Extension Study | A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.","[(41, 47, 'DRUG', 'PRJ212'), (89, 122, 'CONDITION', ""Mild Severity Alzheimer's Disease""), (163, 170, 'CONTROL', 'Placebo'), (273, 280, 'CONTROL', 'placebo')]"
"['A', 'Phase', 'II', 'Open', 'and', 'Parallel', 'Safety', ',', 'Immunogenicity', 'and', 'Reactogenicity', 'Trial', 'of', 'Mencevax', 'ACW135', 'Polysaccharide', 'Vaccine', 'Comparing', 'Three', 'Groups', ':', '2', '-', '4', 'Year', ',', '5', '-', '14', 'Year', 'and', '15', '-', '29', 'Year', 'Old', 'Ethiopians', '|', 'Primary', 'objective', ':', '\n\n', 'To', 'assess', 'the', 'immunogenicity', 'of', 'the', 'Mencevax', 'ACW135', 'polysaccharide', 'vaccine', 'at', '28', 'days', '(', '+6days', ')', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', 'and', 'compare', 'the', 'immunogenicity', 'between', 'these', 'age', 'groups', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'estimate', 'the', 'incidence', 'of', 'common', 'adverse', 'events', 'following', 'immunization', '(', 'AEFI', ')', 'of', 'GSK', 'Nm', 'ACW135', 'polysaccharide', 'vaccine', 'at', '1h', ',', '1d', ',', '2d', ',', '3d', ',', '7d', 'and', '28', 'days', 'post', '-', 'vaccination', '\n', 'To', 'assess', 'the', 'persistence', 'of', 'antibody', 'against', 'meningitis', 'A', ',', 'C', 'and', 'W135', 'at', '11', 'and', '23', 'months', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', '\n\n', 'Study', 'site', ':', 'Two', 'rural', 'communities', '(', 'Kebele', ')', 'in', 'Butajira', 'district', ',', 'Ethiopia', '.', '\n\n', 'Methods', ':', '\n\n', 'Phase', 'II', ',', 'open', 'and', 'parallel', 'safety', 'and', 'immunogenicity', 'trial', '.', '\n', '234', 'younger', 'children', '(', '2', '-', '4', 'years', ')', ',', '145', 'older', 'children', '(', '5', '-', '14', 'years', ')', 'and', '33', 'adults', '(', '15', '-', '29', 'years', 'of', 'age', ')', 'were', 'randomly', 'selected', 'from', 'the', 'demographic', 'surveillance', 'database', 'and', 'enrolled', 'after', 'screening', 'and', 'consenting', '.', '\n', 'Study', 'participant', 'received', 'Mencevax', 'ACW', 'polysaccharide', 'vaccine', '50', 'mg', 'in', '0.5ml', 'subcutaneously', '.', '\n', 'Blood', 'samples', 'for', 'measuring', 'SBA', 'titres', 'were', 'collected', 'at', 'pre', 'vaccination', 'and', 'on', 'day', '28', '(', '+6', 'days', ')', 'post', 'vaccination', '.', '\n', 'Active', 'follow', 'up', 'for', 'AEFI', 'on', 'post', 'vaccination', 'day', '0', ',', '1', ',', '2', ',', '3', ',', '7', ',', '&', '28', '.', '\n', 'Primary', 'end', 'point', 'was', 'vaccine', 'response', 'defined', 'as', 'sero', '-', 'conversion', '(', 'in', 'subjects', 'initially', 'seronegative', ')', 'or', 'a', '4', 'fold', 'increase', '(', 'in', 'subjects', 'initially', 'seropositive', ')', 'in', 'serum', 'bactericidal', 'antibodies', '(', 'SBA', ')', 'against', 'serogroups', 'Men', 'A', ',', 'C', 'and', 'W135', ')', 'on', 'post', 'vaccination', 'day', '28', '.', 'In', 'addition', 'seroconversion', 'was', 'assessed', 'by', 'ELISA', 'Men', 'A', 'IgG', 'on', 'day', '0', 'and', 'day', '28', 'post', 'vaccination', '.', '\n', 'Secondary', 'endpoints', 'were', 'incidence', 'of', 'general', 'and', 'local', 'symptoms', 'and', 'other', 'adverse', 'events', 'following', 'immunisation', 'during', 'the', 'post', 'vaccination', 'period', 'day', '0', 'to', '28', 'and', 'immune', 'persistence', 'on', 'post', 'vaccination', 'month-11', 'and', 'month-23', '.', '\n\n', 'Results', ':', '\n\n', 'No', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'general', 'or', 'local', 'AEFI', 'was', 'observed', 'between', 'the', 'age', 'groups', '\n', 'The', 'statistical', 'analysis', 'for', 'the', 'Immunogenicity', 'data', 'is', 'in', 'progress']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00994695,NCT00994695,"A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians | Primary objective:

To assess the immunogenicity of the Mencevax ACW135 polysaccharide vaccine at 28 days (+6days) post vaccination in 2-4, 5-14, 15-29 year age groups and compare the immunogenicity between these age groups.

Secondary Objectives:

To estimate the incidence of common adverse events following immunization (AEFI) of GSK Nm ACW135 polysaccharide vaccine at 1h, 1d, 2d, 3d, 7d and 28 days post-vaccination
To assess the persistence of antibody against meningitis A, C and W135 at 11 and 23 months post vaccination in 2-4, 5-14, 15-29 year age groups

Study site:Two rural communities (Kebele) in Butajira district, Ethiopia.

Methods:

Phase II, open and parallel safety and immunogenicity trial.
234 younger children (2-4 years), 145 older children (5-14 years) and 33 adults (15-29 years of age) were randomly selected from the demographic surveillance database and enrolled after screening and consenting.
Study participant received Mencevax ACW polysaccharide vaccine 50 mg in 0.5ml subcutaneously.
Blood samples for measuring SBA titres were collected at pre vaccination and on day 28 (+6 days) post vaccination.
Active follow up for AEFI on post vaccination day 0, 1, 2, 3, 7, & 28.
Primary end point was vaccine response defined as sero-conversion (in subjects initially seronegative) or a 4 fold increase (in subjects initially seropositive) in serum bactericidal antibodies (SBA) against serogroups Men A, C and W135) on post vaccination day 28. In addition seroconversion was assessed by ELISA Men A IgG on day 0 and day 28 post vaccination.
Secondary endpoints were incidence of general and local symptoms and other adverse events following immunisation during the post vaccination period day 0 to 28 and immune persistence on post vaccination month-11 and month-23.

Results:

No significant difference in the incidence of general or local AEFI was observed between the age groups
The statistical analysis for the Immunogenicity data is in progress","[(80, 118, 'DRUG', 'Mencevax ACW135 Polysaccharide Vaccine'), (257, 295, 'DRUG', 'Mencevax ACW135 polysaccharide vaccine'), (541, 570, 'DRUG', 'ACW135 polysaccharide vaccine'), (668, 692, 'CONDITION', 'meningitis A, C and W135'), (1152, 1187, 'DRUG', 'Mencevax ACW polysaccharide vaccine'), (1624, 1641, 'CONDITION', 'Men A, C and W135'), (1720, 1725, 'CONDITION', 'Men A')]"
"['A', 'Randomized', 'Cross', '-', 'Over', 'Clinical', 'Trial', 'Comparing', 'Two', 'Non', '-', 'Surgical', 'Treatments', 'for', 'Severe', 'Blepharoptosis', '|', 'This', 'clinical', 'trial', 'will', 'evaluate', 'two', 'non', '-', 'surgical', 'devices', 'designed', 'to', 'improve', 'eye', 'lid', 'opening', 'for', 'patients', 'with', 'severe', 'Blepharoptosis', '(', 'incomplete', 'opening', 'of', 'the', 'eyelids', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04678115,NCT04678115,A Randomized Cross-Over Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis | This clinical trial will evaluate two non-surgical devices designed to improve eye lid opening for patients with severe Blepharoptosis (incomplete opening of the eyelids).,"[(53, 76, 'OTHER', 'Non-Surgical Treatments'), (81, 102, 'CONDITION', 'Severe Blepharoptosis'), (143, 212, 'OTHER', 'non-surgical devices designed to improve eye lid opening for patients'), (218, 239, 'CONDITION', 'severe Blepharoptosis')]"
"['Action', 'of', 'the', 'Amantadine', 'on', 'Post', 'Stroke', 'Aphasic', 'Patients', ""'"", 'Language', 'and', 'Communication', '|', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'test', 'the', 'action', 'of', 'the', 'amantadine', ',', 'as', 'DOPA', '-', 'agonist', ',', 'in', 'a', 'double', 'blind', 'cross', '-', 'over', 'trial', ',', 'amantadine', '/', 'placebo', ',', 'on', 'the', 'verbal', 'fluency', 'of', 'chronic', 'post', 'stroke', 'aphasic', 'patients', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'O']",NCT00821691,NCT00821691,"Action of the Amantadine on Post Stroke Aphasic Patients' Language and Communication | The objective of the study is to test the action of the amantadine, as DOPA-agonist, in a double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post stroke aphasic patients.","[(14, 24, 'DRUG', 'Amantadine'), (28, 39, 'CONDITION', 'Post Stroke'), (40, 47, 'CONDITION', 'Aphasic'), (143, 153, 'DRUG', 'amantadine'), (208, 218, 'DRUG', 'amantadine'), (221, 228, 'CONTROL', 'placebo'), (255, 274, 'CONDITION', 'chronic post stroke'), (275, 282, 'CONDITION', 'aphasic')]"
"['Prospective', 'Comparative', 'Multicenter', 'Study', 'on', 'the', 'Medico', '-', 'economical', 'Impact', 'of', 'the', 'Brindley', 'Technique', 'in', 'the', 'Management', 'of', 'Neurogenic', 'Bladder', 'in', 'Patients', 'With', 'Injured', 'Spinal', 'Cord', '|', 'Bladder', 'dysfunction', 'is', 'a', 'major', 'problem', 'in', 'patients', 'with', 'complete', 'spinal', 'cord', 'lesions', '.', 'For', 'patients', 'presenting', 'incontinence', 'or', 'risk', 'for', 'kidney', ',', 'two', 'major', 'conventional', 'alternatives', 'are', 'possible', ':', 'conservative', 'therapies', '(', 'muscarinic', 'receptor', 'antagonists', ',', 'vanilloids', 'drugs', 'and', 'botulinum', 'toxin', 'in', 'association', 'with', 'catheterization', ')', 'and', 'surgical', 'techniques', 'intervening', 'in', 'the', 'nervous', 'and', 'urinary', 'system', '.', '\n\n', 'Among', 'these', 'last', 'alternatives', ',', 'the', 'Brindley', 'technique', '(', 'anterior', 'sacral', 'root', 'stimulation', 'with', 'posterior', 'rhizotomy', ')', 'is', 'the', 'only', 'technique', 'allowing', 'for', 'the', 'restauration', 'of', 'bladder', 'function', ',', 'continence', ',', 'and', 'micturition', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'Brindley', 'technique', 'with', 'the', 'first', 'conventional', 'approach', 'in', 'France', 'from', 'a', 'medical', 'and', 'economical', 'point', 'of', 'view', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00221767,NCT00221767,"Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord | Bladder dysfunction is a major problem in patients with complete spinal cord lesions. For patients presenting incontinence or risk for kidney, two major conventional alternatives are possible : conservative therapies (muscarinic receptor antagonists, vanilloids drugs and botulinum toxin in association with catheterization) and surgical techniques intervening in the nervous and urinary system.

Among these last alternatives, the Brindley technique (anterior sacral root stimulation with posterior rhizotomy) is the only technique allowing for the restauration of bladder function, continence, and micturition. The purpose of the study is to compare the Brindley technique with the first conventional approach in France from a medical and economical point of view.","[(81, 99, 'SURGICAL', 'Brindley Technique'), (121, 139, 'CONDITION', 'Neurogenic Bladder'), (157, 176, 'CONDITION', 'Injured Spinal Cord'), (179, 198, 'CONDITION', 'Bladder dysfunction'), (235, 263, 'CONDITION', 'complete spinal cord lesions'), (611, 629, 'SURGICAL', 'Brindley technique'), (631, 688, 'SURGICAL', 'anterior sacral root stimulation with posterior rhizotomy'), (835, 853, 'SURGICAL', 'Brindley technique')]"
"['Chronic', 'Treatment', 'of', 'Alzheimer', ""'s"", 'Disease', 'With', 'Gamma', 'Frequency', 'Stimulation', '|', 'In', 'this', 'trial', ',', 'the', 'safety', 'and', 'effect', 'of', 'daily', 'exposure', 'to', 'light', 'and', 'sound', 'stimulation', 'on', 'people', 'with', 'mild', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', 'will', 'be', 'studied', '.', '\n\n', 'COVID-19', 'Amendment', ':', 'Due', 'to', 'the', 'ongoing', 'suspension', 'of', 'all', 'in', '-', 'person', 'humans', 'subject', 'research', 'across', 'MIT', 'in', 'response', 'to', 'the', 'COVID-19', 'pandemic', ',', 'all', 'enrolled', 'participants', 'who', 'have', 'not', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'have', 'their', 'visit', 'postponed', 'to', '9', 'months', 'with', 'a', 'follow', 'up', 'at', '18', 'months', '.', 'Subjects', 'who', 'have', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'still', 'be', 'instructed', 'to', 'continue', 'and', 'return', 'at', 'Month', '12', 'for', 'an', 'evaluation', '.', '\n\n', 'OPTIONAL', ':', 'If', 'the', 'subject', 'would', 'like', 'to', 'come', 'in', 'for', 'an', 'evaluation', 'between', 'Month', '9', 'and', '18', ',', 'we', 'will', 'invite', 'participants', 'to', 'come', 'on', 'Month', '12', 'to', 'complete', 'cognitive', 'testing', 'and', 'EEG', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04055376,NCT04055376,"Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation | In this trial, the safety and effect of daily exposure to light and sound stimulation on people with mild Alzheimer's Disease (AD) will be studied.

COVID-19 Amendment: Due to the ongoing suspension of all in-person humans subject research across MIT in response to the COVID-19 pandemic, all enrolled participants who have not completed their 6-month visit will have their visit postponed to 9 months with a follow up at 18 months. Subjects who have completed their 6-month visit will still be instructed to continue and return at Month 12 for an evaluation.

OPTIONAL: If the subject would like to come in for an evaluation between Month 9 and 18, we will invite participants to come on Month 12 to complete cognitive testing and EEG.","[(21, 40, 'CONDITION', ""Alzheimer's Disease""), (46, 73, 'OTHER', 'Gamma Frequency Stimulation'), (116, 161, 'OTHER', 'daily exposure to light and sound stimulation'), (177, 201, 'CONDITION', ""mild Alzheimer's Disease""), (203, 205, 'CONDITION', 'AD')]"
"['Genetic', 'Study', 'of', 'Age', 'Related', 'Hearing', 'Loss', '|', 'Age', '-', 'related', 'hearing', 'loss', ',', 'or', 'presbyacusis', ',', 'is', 'one', 'of', 'the', 'most', 'common', 'chronically', 'handicapped', 'conditions', 'for', 'the', 'elderly', '.', 'Many', 'factors', 'including', 'genetics', ',', 'diet', ',', 'diseases', ',', 'drugs', ',', 'socioeconomic', 'factors', 'and', 'environmental', 'variables', 'were', 'considered', 'to', 'be', 'related', 'to', 'the', 'development', 'of', 'presbyacusis', '.', 'Evidences', 'have', 'shown', 'that', 'genetic', 'factors', 'play', 'an', 'important', 'role', 'on', 'presbyacusis', '.', 'However', ',', 'which', 'genes', 'or', 'their', 'genotypes', 'are', 'associated', 'with', 'presbycusis', 'remain', 'unknown', '.', '\n\n', 'The', 'aim', 'of', 'this', 'project', 'was', 'to', 'evaluate', 'the', 'association', 'between', 'the', 'genotype', 'of', 'candidate', 'genes', 'and', 'presbyacusis', 'by', 'cross', '-', 'section', 'and', 'case', '-', 'control', 'study', '.', 'In', 'the', 'first', 'stage', ',', 'the', 'investigators', 'plan', 'to', 'select', '700', 'healthy', 'subjects', 'older', 'than', '50', 'with', 'symmetric', ',', 'sensorineural', 'hearing', 'loss', '.', 'The', 'subjects', 'will', 'receive', 'basic', 'otologic', 'examination', ',', 'pure', 'tone', 'audiometry', ',', 'questionnaire', ',', 'and', 'genotype', 'analysis', '.', 'Because', 'gender', 'and', 'age', 'would', 'affect', 'hearing', 'loss', 'significantly', ',', 'The', 'investigators', 'will', 'convert', 'the', 'hearing', 'level', 'of', 'all', 'subjects', 'into', 'a', 'gender', 'and', 'age', 'independent', 'Z', '-', 'score', 'according', 'to', 'ISO', '7029', 'standard', '.', 'And', ',', 'The', 'investigators', 'define', 'subjects', 'within', 'higher', '30', '%', 'of', 'Z', '-', 'score', 'as', 'the', 'presbyacusis', 'group', ',', 'and', 'subjects', 'within', 'lower', '30', '%', 'of', 'Z', '-', 'score', 'as', 'the', 'control', 'group', '.', 'Finally', ',', 'The', 'investigators', 'perform', 'Chi', 'square', 'analysis', 'to', 'test', 'the', 'association', 'between', 'genotype', 'of', 'candidate', 'genes', 'or', 'their', 'combinations', 'in', 'both', 'groups', ',', 'and', 'calculate', 'the', 'odds', 'ratio', 'for', 'presbyacusis', 'between', 'different', 'genotype', 'of', 'candidate', 'genes', '.', 'Further', 'more', ',', 'we', 'will', 'evaluate', 'the', 'effect', 'of', 'genotype', 'of', 'candidate', 'genes', ',', 'environment', 'factors', ',', 'and', 'gene', '-', 'environmental', 'interaction', 'on', 'the', 'severity', 'of', 'presbyacusis', 'by', 'multivariate', 'logistic', 'regression', '.', '\n\n', 'In', 'the', 'second', 'stage', ',', 'The', 'investigators', 'wish', 'to', 'know', 'the', 'pattern', 'of', 'genotype', 'and', 'hearing', 'level', 'in', 'the', 'high', 'risk', 'families', ',', 'according', 'to', 'results', 'from', 'the', 'first', 'stage', ',', 'by', 'description', 'and', 'case', '-', 'control', 'study', '.', 'The', 'investigators', 'will', 'perform', 't', '-', 'test', 'to', 'evaluate', 'the', 'difference', 'of', 'Z', '-', 'score', 'in', 'both', 'groups', '.', 'Besides', ',', 'The', 'investigators', 'try', 'to', 'evaluate', 'the', 'effects', 'of', 'genotypes', ',', 'environment', 'factors', ',', 'and', 'gene', '-', 'environmental', 'interaction', 'on', 'hearing', 'level', 'in', 'high', 'risk', 'families', 'by', 'multivariate', 'logistic', 'regression', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01732289,NCT01732289,"Genetic Study of Age Related Hearing Loss | Age-related hearing loss, or presbyacusis, is one of the most common chronically handicapped conditions for the elderly. Many factors including genetics, diet, diseases, drugs, socioeconomic factors and environmental variables were considered to be related to the development of presbyacusis. Evidences have shown that genetic factors play an important role on presbyacusis. However, which genes or their genotypes are associated with presbycusis remain unknown.

The aim of this project was to evaluate the association between the genotype of candidate genes and presbyacusis by cross-section and case-control study. In the first stage, the investigators plan to select 700 healthy subjects older than 50 with symmetric, sensorineural hearing loss. The subjects will receive basic otologic examination, pure tone audiometry, questionnaire, and genotype analysis. Because gender and age would affect hearing loss significantly, The investigators will convert the hearing level of all subjects into a gender and age independent Z-score according to ISO 7029 standard. And, The investigators define subjects within higher 30 % of Z-score as the presbyacusis group, and subjects within lower 30% of Z-score as the control group. Finally, The investigators perform Chi square analysis to test the association between genotype of candidate genes or their combinations in both groups, and calculate the odds ratio for presbyacusis between different genotype of candidate genes. Further more, we will evaluate the effect of genotype of candidate genes, environment factors, and gene-environmental interaction on the severity of presbyacusis by multivariate logistic regression.

In the second stage, The investigators wish to know the pattern of genotype and hearing level in the high risk families, according to results from the first stage, by description and case-control study. The investigators will perform t-test to evaluate the difference of Z-score in both groups. Besides, The investigators try to evaluate the effects of genotypes, environment factors, and gene-environmental interaction on hearing level in high risk families by multivariate logistic regression.","[(29, 41, 'CONDITION', 'Hearing Loss'), (56, 68, 'CONDITION', 'hearing loss'), (755, 792, 'CONDITION', 'symmetric, sensorineural hearing loss'), (944, 956, 'CONDITION', 'hearing loss')]"
"['Mild', 'Cognitive', 'Impairment', 'and', 'Endurance', 'Exercise', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'overall', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'how', 'high', 'intensity', 'endurance', 'exercise', 'affects', 'both', 'cognition', 'and', 'the', 'signs', 'and', 'symptoms', 'of', 'Parkinson', ""'s"", 'disease', 'as', 'well', 'as', 'if', 'certain', 'brain', 'structures', 'and', 'functions', 'also', 'change', 'with', 'this', 'exercise', '.']","['B-COND', 'I-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O']",NCT03542474,NCT03542474,Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease | The overall objective of this study is to determine how high intensity endurance exercise affects both cognition and the signs and symptoms of Parkinson's disease as well as if certain brain structures and functions also change with this exercise.,"[(0, 25, 'CONDITION', 'Mild Cognitive Impairment'), (30, 48, 'PHYSICAL', 'Endurance Exercise'), (52, 71, 'CONDITION', ""Parkinson's Disease""), (130, 163, 'PHYSICAL', 'high intensity endurance exercise'), (217, 236, 'CONDITION', ""Parkinson's disease""), (312, 320, 'PHYSICAL', 'exercise')]"
"['Mind', '-', 'Body', 'Interventions', 'to', 'Mitigate', 'Effects', 'of', 'Media', 'Use', 'on', 'Sleep', '(', 'Sleepazoid', 'Study', ')', '|', 'Eliminating', 'media', 'use', 'is', 'neither', 'feasible', 'at', 'a', 'public', 'health', 'level', 'nor', 'perhaps', 'even', 'desirable', 'given', 'the', 'role', 'it', 'plays', 'in', 'the', 'lives', 'of', 'youth', 'and', 'adults', ',', 'but', 'mind', '-', 'body', 'interventions', 'have', 'the', 'potential', 'to', 'mitigate', 'state', 'arousal', 'effects', 'and', 'thus', 'reduce', 'negative', 'impacts', 'on', 'sleep', '.', 'Given', 'emerging', 'literature', 'on', 'links', 'between', 'intensive', 'media', 'use', ',', 'sensory', 'and', 'interoceptive', 'awareness', ',', 'and', 'self', '-', 'regulation', ',', 'this', 'study', 'will', 'examine', 'two', 'related', 'mind', '-', 'body', 'approaches', '--', 'a', 'mindfulness', 'sensory', 'awareness', 'exercises', 'and', 'mindful', 'body', 'awareness', 'check', '-', 'ins', '--', 'in', 'a', 'randomized', 'clinical', 'trial', 'of', 'early', 'adolescents', 'with', 'evening', 'media', 'use', 'and', 'sleep', 'problems', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04550507,NCT04550507,"Mind-Body Interventions to Mitigate Effects of Media Use on Sleep (Sleepazoid Study) | Eliminating media use is neither feasible at a public health level nor perhaps even desirable given the role it plays in the lives of youth and adults, but mind-body interventions have the potential to mitigate state arousal effects and thus reduce negative impacts on sleep. Given emerging literature on links between intensive media use, sensory and interoceptive awareness, and self-regulation, this study will examine two related mind-body approaches -- a mindfulness sensory awareness exercises and mindful body awareness check-ins -- in a randomized clinical trial of early adolescents with evening media use and sleep problems.","[(0, 23, 'OTHER', 'Mind-Body Interventions'), (243, 266, 'OTHER', 'mind-body interventions'), (521, 541, 'OTHER', 'mind-body approaches'), (547, 586, 'OTHER', 'mindfulness sensory awareness exercises'), (591, 623, 'OTHER', 'mindful body awareness check-ins'), (706, 720, 'CONDITION', 'sleep problems')]"
"['Studying', 'of', 'Acupuncture', 'for', 'Bell', ""'s"", 'Palsy', 'According', 'to', 'Different', 'Stages', '|', 'The', 'purpose', 'of', 'this', 'trial', 'will', 'certify', 'the', 'efficacy', 'of', 'using', 'staging', 'acupuncture', 'and', 'moxibustion', 'to', 'treat', 'Bell', ""'s"", 'Palsy']","['O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT00608660,NCT00608660,Studying of Acupuncture for Bell's Palsy According to Different Stages | The purpose of this trial will certify the efficacy of using staging acupuncture and moxibustion to treat Bell's Palsy,"[(12, 23, 'OTHER', 'Acupuncture'), (28, 40, 'CONDITION', ""Bell's Palsy""), (142, 153, 'OTHER', 'acupuncture'), (158, 169, 'OTHER', 'moxibustion'), (179, 191, 'CONDITION', ""Bell's Palsy"")]"
"['The', 'Optimal', 'Treatment', 'for', 'Treatment', '-', 'resistant', 'Schizophrenia', '|', 'The', 'Optimal', 'Treatment', 'for', 'Treatment', '-', 'resistant', 'Schizophrenia']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",NCT02926976,NCT02926976,The Optimal Treatment for Treatment-resistant Schizophrenia | The Optimal Treatment for Treatment-resistant Schizophrenia,"[(26, 59, 'CONDITION', 'Treatment-resistant Schizophrenia'), (88, 121, 'CONDITION', 'Treatment-resistant Schizophrenia')]"
"['The', 'Effects', 'Upon', 'the', 'Bladder', 'of', 'Transcutaneous', 'Tibial', 'Nerve', 'Stimulation', 'in', 'Acute', 'Traumatic', 'Spinal', 'Cord', 'Injury', '|', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'upon', 'the', 'bladder', 'of', 'electric', 'stimulation', 'of', 'the', 'leg', ""'s"", 'tibial', 'nerve', 'in', 'people', 'with', 'acute', 'spinal', 'cord', 'injury', 'with', 'an', 'intervention', 'called', 'transcutaneous', 'tibial', 'nerve', 'stimulation', '(', 'TTNS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O']",NCT02573402,NCT02573402,The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury | The purpose of this research study is to evaluate the effects upon the bladder of electric stimulation of the leg's tibial nerve in people with acute spinal cord injury with an intervention called transcutaneous tibial nerve stimulation (TTNS).,"[(32, 71, 'OTHER', 'Transcutaneous Tibial Nerve Stimulation'), (75, 109, 'CONDITION', 'Acute Traumatic Spinal Cord Injury'), (194, 240, 'OTHER', ""electric stimulation of the leg's tibial nerve""), (256, 280, 'CONDITION', 'acute spinal cord injury'), (309, 348, 'OTHER', 'transcutaneous tibial nerve stimulation'), (350, 354, 'OTHER', 'TTNS')]"
"['Comparison', 'of', 'Corticosteroid', 'and', 'Repeated', 'Dextrose', 'Hydro', '-', 'dissection', 'for', 'Carpal', 'Tunnel', 'Syndrome', 'Patients', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'the', 'most', 'prevalent', 'peripheral', 'nerve', 'entrapment', 'of', 'upper', 'limb', '.', 'Typical', 'symptoms', 'comprise', 'pain', ',', 'numbness', 'or', 'tingling', 'of', 'the', 'thumb', 'and', 'index', ',', 'middle', 'or', 'ring', 'fingers', '.', 'Thumb', 'weakness', 'and', 'decreased', 'grip', 'strength', 'can', 'occur', 'in', 'the', 'later', 'stage', '.', 'Currently', 'treatments', 'included', 'physical', 'modalities', '(', 'low', 'power', 'laser', ',', 'transcutaneous', 'electrical', 'nerve', 'stimulation', ',', 'ultrasound', ')', ',', 'medication', ',', 'splinting', ',', 'injection', 'and', 'surgery', '.', 'Ultrasound', 'guided', 'intracarpal', 'hydro', '-', 'dissection', 'of', 'median', 'nerve', 'had', 'been', 'proposed', 'based', 'on', 'its', 'accurate', 'localization', ',', 'while', 'the', 'injectates', 'were', 'diverse', '.', 'Corticosteroid', 'has', 'been', 'widely', 'used', 'for', 'CTS', 'for', 'decades', '.', 'However', ',', 'growing', 'evidences', 'suggested', 'that', '5', '%', 'dextrose', ',', 'normal', 'saline', ',', 'platelet', 'rich', 'plasma', 'injection', 'also', 'have', 'therapeutic', 'effects', 'on', 'alleviating', 'CTS', 'symptoms', '.', 'Among', 'the', 'injectates', ',', 'a', 'single', '5', '%', 'dextrose', 'injection', 'could', 'be', 'considered', 'as', 'a', 'substitute', 'of', 'corticosteroid', 'based', 'on', 'its', 'long', 'term', 'effect', 'up', 'to', 'six', 'months', '.', 'However', ',', 'the', 'clinical', 'efficacy', 'of', '5', '%', 'dextrose', 'injection', 'has', 'not', 'validated', 'by', 'the', 'further', 'study', '.', 'The', 'investigators', 'aim', 'to', 'compare', 'the', 'therapeutic', 'effect', 'of', '5', '%', 'dextrose', 'injection', 'with', 'corticosteroid', 'injection', 'in', 'patients', 'with', 'CTS', ',', 'up', 'to', '12', 'weeks', 'follow', 'up', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04579783,NCT04579783,"Comparison of Corticosteroid and Repeated Dextrose Hydro-dissection for Carpal Tunnel Syndrome Patients | Carpal tunnel syndrome (CTS) is the most prevalent peripheral nerve entrapment of upper limb. Typical symptoms comprise pain, numbness or tingling of the thumb and index, middle or ring fingers. Thumb weakness and decreased grip strength can occur in the later stage. Currently treatments included physical modalities (low power laser, transcutaneous electrical nerve stimulation, ultrasound), medication, splinting, injection and surgery. Ultrasound guided intracarpal hydro-dissection of median nerve had been proposed based on its accurate localization, while the injectates were diverse. Corticosteroid has been widely used for CTS for decades. However, growing evidences suggested that 5% dextrose, normal saline, platelet rich plasma injection also have therapeutic effects on alleviating CTS symptoms. Among the injectates, a single 5% dextrose injection could be considered as a substitute of corticosteroid based on its long term effect up to six months. However, the clinical efficacy of 5% dextrose injection has not validated by the further study. The investigators aim to compare the therapeutic effect of 5% dextrose injection with corticosteroid injection in patients with CTS, up to 12 weeks follow up.","[(14, 28, 'DRUG', 'Corticosteroid'), (42, 50, 'DRUG', 'Dextrose'), (72, 94, 'CONDITION', 'Carpal Tunnel Syndrome'), (106, 128, 'CONDITION', 'Carpal tunnel syndrome'), (130, 133, 'CONDITION', 'CTS'), (226, 230, 'CONDITION', 'pain'), (546, 592, 'OTHER', 'Ultrasound guided intracarpal hydro-dissection'), (698, 712, 'DRUG', 'Corticosteroid'), (738, 741, 'CONDITION', 'CTS'), (800, 808, 'DRUG', 'dextrose'), (817, 823, 'DRUG', 'saline'), (825, 845, 'DRUG', 'platelet rich plasma'), (901, 904, 'CONDITION', 'CTS'), (949, 957, 'DRUG', 'dextrose'), (1007, 1021, 'DRUG', 'corticosteroid'), (1107, 1115, 'DRUG', 'dextrose'), (1228, 1236, 'DRUG', 'dextrose'), (1252, 1266, 'DRUG', 'corticosteroid'), (1294, 1297, 'CONDITION', 'CTS')]"
"['Treatment', 'of', 'Tinnitus', 'With', 'Migraine', 'Medications', ':', 'A', 'Randomized', 'Clinical', 'Trial', '|', 'Tinnitus', 'represents', 'one', 'of', 'the', 'most', 'common', 'and', 'distressing', 'otologic', 'problems', ',', 'and', 'it', 'causes', 'various', 'somatic', 'and', 'psychological', 'disorders', 'that', 'interfere', 'with', 'the', 'quality', 'of', 'life', '.', 'It', 'is', 'well', '-', 'understood', 'that', 'many', 'factors', ',', 'such', 'as', 'poor', 'education', ',', 'lower', 'income', ',', 'or', 'occupational', ',', 'and', 'recreational', 'activity', 'associated', 'with', 'high', 'noise', 'exposure', ',', 'influences', 'the', 'prevalence', 'and', 'risk', 'of', 'tinnitus', '.', 'Although', 'the', 'economic', 'and', 'emotional', 'impact', 'of', 'tinnitus', 'is', 'large', ',', 'there', 'is', 'currently', 'no', 'FDA', '-', 'approved', 'medication', 'to', 'treat', 'this', 'condition', '.', 'However', ',', 'there', 'are', 'pharmacological', 'options', 'to', 'address', 'the', 'stress', ',', 'anxiety', ',', 'and', 'depression', 'that', 'are', 'caused', 'by', 'tinnitus', '.', 'In', 'this', 'project', ',', 'we', 'intend', 'to', 'use', 'medications', 'for', 'patients', 'with', 'tinnitus', 'in', 'order', 'to', 'decrease', 'the', 'impact', 'of', 'tinnitus', 'on', 'their', 'daily', 'life', 'and', 'activities', '.']","['O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04404439,NCT04404439,"Treatment of Tinnitus With Migraine Medications: A Randomized Clinical Trial | Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. It is well-understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influences the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, we intend to use medications for patients with tinnitus in order to decrease the impact of tinnitus on their daily life and activities.","[(13, 21, 'CONDITION', 'Tinnitus'), (27, 47, 'OTHER', 'Migraine Medications'), (79, 87, 'CONDITION', 'Tinnitus'), (453, 461, 'CONDITION', 'tinnitus'), (509, 517, 'CONDITION', 'tinnitus'), (657, 663, 'CONDITION', 'stress'), (665, 672, 'CONDITION', 'anxiety'), (678, 688, 'CONDITION', 'depression'), (708, 716, 'CONDITION', 'tinnitus'), (782, 790, 'CONDITION', 'tinnitus'), (826, 834, 'CONDITION', 'tinnitus')]"
"['Multi', '-', 'Center', 'Project', ':', 'Supported', 'Speed', 'Treadmill', 'Training', 'Exercise', 'Program', '(', 'SSTTEP', ')', 'for', 'Marginally', 'Ambulatory', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'The', 'investigators', 'are', 'studying', 'the', 'effects', 'of', 'a', '12', '-', 'week', 'exercise', 'program', ',', 'consisting', 'of', 'either', ':', '\n\n', 'Walking', 'on', 'a', 'treadmill', 'with', 'partial', 'body', 'weight', '\n', 'Functional', 'exercise', 'program', '\n\n', 'The', 'investigators', 'would', 'like', 'to', 'know', 'the', 'effects', 'these', 'two', 'exercise', 'programs', 'have', 'on', 'the', 'quality', 'of', 'life', ',', 'muscle', 'strength', 'and', 'control', ',', 'coordination', ',', 'walking', ',', 'and', 'functional', 'movement', 'of', 'children', 'with', 'cerebral', 'palsy', 'who', 'are', 'marginal', 'ambulators', '.', 'This', 'is', 'a', 'randomized', 'control', 'trial', 'with', 'subjects', 'randomly', 'assigned', 'to', 'one', 'of', 'the', '2', 'groups', '.', 'Subjects', 'in', 'both', 'groups', 'will', 'be', 'seen', 'twice', 'a', 'day', 'for', 'two', 'weeks', 'at', 'our', 'hospital', 'for', 'intervention', 'and', 'parent', 'training', ',', 'and', 'then', 'participate', 'in', 'a', '10', 'week', 'home', '-', 'based', 'program', '.', 'During', 'each', 'subject', ""'s"", 'two', '-', 'week', 'clinic', '-', 'based', 'training', ',', 'a', 'parent', 'or', 'caregiver', 'is', 'trained', 'in', 'all', 'home', 'program', 'exercises', 'and/or', 'equipment', 'usage', '.', 'This', 'person', 'must', 'be', 'able', 'to', 'safely', 'perform', 'the', 'exercise', 'program', 'with', 'the', 'child', '.', 'Each', 'subject', 'will', 'also', 'need', 'to', 'participate', 'in', 'three', 'separate', '5', '-', 'hour', 'long', 'data', 'collection', 'sessions', 'scheduled', 'over', 'the', '4', 'month', 'study', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00467415,NCT00467415,"Multi-Center Project: Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy | The investigators are studying the effects of a 12-week exercise program, consisting of either:

Walking on a treadmill with partial body weight
Functional exercise program

The investigators would like to know the effects these two exercise programs have on the quality of life, muscle strength and control, coordination, walking, and functional movement of children with cerebral palsy who are marginal ambulators. This is a randomized control trial with subjects randomly assigned to one of the 2 groups.Subjects in both groups will be seen twice a day for two weeks at our hospital for intervention and parent training, and then participate in a 10 week home-based program. During each subject's two-week clinic-based training, a parent or caregiver is trained in all home program exercises and/or equipment usage. This person must be able to safely perform the exercise program with the child. Each subject will also need to participate in three separate 5-hour long data collection sessions scheduled over the 4 month study period.","[(22, 73, 'PHYSICAL', 'Supported Speed Treadmill Training Exercise Program'), (75, 81, 'PHYSICAL', 'SSTTEP'), (123, 137, 'CONDITION', 'Cerebral Palsy'), (196, 212, 'PHYSICAL', 'exercise program'), (237, 284, 'PHYSICAL', 'Walking on a treadmill with partial body weight'), (285, 312, 'PHYSICAL', 'Functional exercise program'), (373, 390, 'PHYSICAL', 'exercise programs'), (513, 527, 'CONDITION', 'cerebral palsy'), (798, 816, 'PHYSICAL', 'home-based program'), (912, 934, 'PHYSICAL', 'home program exercises'), (1006, 1014, 'PHYSICAL', 'exercise')]"
"['Pilot', 'Study', 'of', 'Continuing', 'Aspirin', 'Versus', 'Switching', 'to', 'Clopidogrel', 'After', 'Stroke', 'or', 'Transient', 'Ischemic', 'Attack', '|', 'Pilot', 'study', 'of', 'continuing', 'aspirin', 'versus', 'switching', 'to', 'clopidogrel', 'after', 'stroke', 'or', 'transient', 'ischemic', 'attack', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00363753,NCT00363753,Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack | Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.,"[(26, 33, 'DRUG', 'Aspirin'), (54, 65, 'DRUG', 'Clopidogrel'), (72, 78, 'CONDITION', 'Stroke'), (82, 107, 'CONDITION', 'Transient Ischemic Attack'), (136, 143, 'DRUG', 'aspirin'), (164, 175, 'DRUG', 'clopidogrel'), (182, 188, 'CONDITION', 'stroke'), (192, 217, 'CONDITION', 'transient ischemic attack')]"
"['Local', 'Site', 'Tolerability', 'of', 'Multiple', 'Dose', 'Treatment', 'With', 'Deltoid', 'Intramuscular', 'Injection', 'of', 'RISPERDAL', 'CONSTA', 'in', 'Subjects', 'With', 'Chronic', 'Schizophrenia', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'discontinuation', 'rate', 'of', 'schizophrenia', 'patients', 'receiving', 'multiple', 'sequential', '2', 'mL', 'injections', 'of', 'long', 'acting', 'injectable', 'risperidone', '(', 'an', 'atypical', 'antipsychotic', 'medication', ')', 'when', 'administered', 'into', 'the', 'deltoid', 'muscle', 'once', 'every', '2', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00828958,NCT00828958,Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia. | The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when administered into the deltoid muscle once every 2 weeks.,"[(91, 100, 'DRUG', 'RISPERDAL'), (125, 146, 'CONDITION', 'Chronic Schizophrenia'), (218, 231, 'CONDITION', 'schizophrenia'), (313, 324, 'DRUG', 'risperidone')]"
"['Combination', 'of', 'Alpelisib', 'and', 'Trametinib', 'in', 'Progressive', 'Refractory', 'Meningiomas', ':', 'Phase', '1', 'Study', '|', 'Aggressive', 'growing', 'meningiomas', 'resistant', 'to', 'multiple', 'surgeries', 'and', 'radiotherapy', 'constitute', 'an', 'unmet', 'pharmaceutical', 'need', 'in', 'neurooncology', ',', 'leading', 'to', 'a', 'fatal', 'issue', 'within', 'a', 'few', 'months', '.', 'Grade', 'II', '-', 'III', 'meningiomas', 'progression', '-', 'free', 'survival', '(', 'PFS', ')', '6', 'is', 'at', '10', '-', '15', '%', '.', 'Median', 'PFS', 'grade', 'III', 'meningioma', 'is', 'approximate', '3', 'years', '.', '\n\n', 'Alpelisib', 'is', 'a', 'well', '-', 'tolerated', 'Phosphoinositide', '3', '-', 'kinase', '', '(', 'Pi3K', ')', 'specific', 'inhibitor', '.', 'However', ',', 'phosphatidylinositol-3', '-', 'kinase', '(', 'PI3', 'K', ')', 'and', 'the', 'mammalian', 'target', 'of', 'rapamycin', '(', 'mTOR', ')', 'inhibition', 'does', 'not', 'induce', 'apoptosis', 'in', 'vitro', 'and', 'induces', 'an', 'antiproliferative', 'effect', 'without', 'any', 'radiologic', 'response', 'in', 'most', 'treated', 'patients', '.', '\n\n', 'Trametinib', ',', 'a', 'mekinist', '(', 'MEK', ')', 'inhibitor', 'is', 'currently', 'used', 'in', 'combined', 'treatment', 'for', 'recurrent', 'melanomas', 'in', 'clinical', 'practice', 'with', 'a', 'good', 'clinical', 'tolerance', 'at', '1', '-', '2', 'mg', 'daily', '.', 'In', 'vitro', ',', 'on', 'meningioma', 'primary', 'cell', 'culture', ',', 'Trametinib', 'induces', 'cell', 'apoptosis', 'via', 'caspase', 'activity', '.', '\n\n', 'These', 'results', 'strongly', 'suggest', 'the', 'relevance', 'to', 'combine', 'Alpelisib', 'and', 'Trametinib', 'in', 'aggressive', 'and', 'recurrent', 'meningiomas', '.', '\n\n', 'Alpelisib', 'and', 'Trametinib', 'combination', 'has', 'not', 'been', 'studied', 'to', 'date', ',', 'despite', 'each', 'drugs', 'have', 'been', 'separately', 'studied', 'in', 'phase', '3', '.', '\n\n', 'Multicenter', ',', 'open', 'label', ',', 'dose', '-', 'finding', 'phase', 'I', 'study', 'of', 'Alpelisib', 'in', 'combination', 'with', 'Trametinib', 'administered', 'at', 'a', 'fixed', 'dose', '(', '1.5', 'mg', 'daily', ')', ',', 'both', 'drugs', 'will', 'be', 'administered', 'daily', '.', 'Starting', 'dose', 'of', 'Alpelisib', 'will', 'be', '160mg', '/', 'day', 'and', 'will', 'be', 'increased', 'to', '200mg', '/', 'day', 'or', 'decreased', 'to', '120mg', '/', 'day', 'depending', 'of', 'grade', '3', '-', '4', 'adverse', 'events', 'occurrence', ',', 'to', 'determine', 'maximal', 'tolerated', 'dose', '(', 'MTD', ')', 'and', 'recommended', 'dose', '.', '\n\n', 'Primary', 'Objective', 'is', 'to', 'determine', 'the', 'safety', 'profile', 'and', 'tolerability', 'of', 'Alpelisib', 'and', 'Trametinib', 'given', 'in', 'combination', 'in', 'patients', 'with', 'aggressive', 'and', 'refractory', 'meningiomas', 'in', 'terms', 'of', 'Dose', '-', 'Limiting', 'Toxicities', '(', 'DLT', ',', 'assessed', 'during', 'cycle', '1', ')', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03631953,NCT03631953,"Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study | Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy constitute an unmet pharmaceutical need in neurooncology, leading to a fatal issue within a few months. Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%. Median PFS grade III meningioma is approximate 3 years.

Alpelisib is a well-tolerated Phosphoinositide 3-kinase  (Pi3K) specific inhibitor. However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) inhibition does not induce apoptosis in vitro and induces an antiproliferative effect without any radiologic response in most treated patients.

Trametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for recurrent melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily. In vitro, on meningioma primary cell culture, Trametinib induces cell apoptosis via caspase activity.

These results strongly suggest the relevance to combine Alpelisib and Trametinib in aggressive and recurrent meningiomas.

Alpelisib and Trametinib combination has not been studied to date, despite each drugs have been separately studied in phase 3.

Multicenter, open label, dose-finding phase I study of Alpelisib in combination with Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine maximal tolerated dose (MTD) and recommended dose.

Primary Objective is to determine the safety profile and tolerability of Alpelisib and Trametinib given in combination in patients with aggressive and refractory meningiomas in terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).","[(15, 24, 'DRUG', 'Alpelisib'), (29, 39, 'DRUG', 'Trametinib'), (43, 77, 'CONDITION', 'Progressive Refractory Meningiomas'), (95, 174, 'CONDITION', 'Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy'), (279, 303, 'CONDITION', 'Grade II-III meningiomas'), (363, 383, 'CONDITION', 'grade III meningioma'), (409, 418, 'DRUG', 'Alpelisib'), (731, 741, 'DRUG', 'Trametinib'), (916, 926, 'CONDITION', 'meningioma'), (949, 959, 'DRUG', 'Trametinib'), (1062, 1071, 'DRUG', 'Alpelisib'), (1076, 1086, 'DRUG', 'Trametinib'), (1090, 1126, 'CONDITION', 'aggressive and recurrent meningiomas'), (1129, 1138, 'DRUG', 'Alpelisib'), (1143, 1153, 'DRUG', 'Trametinib'), (1312, 1321, 'DRUG', 'Alpelisib'), (1342, 1352, 'DRUG', 'Trametinib'), (1454, 1463, 'DRUG', 'Alpelisib'), (1731, 1740, 'DRUG', 'Alpelisib'), (1745, 1755, 'DRUG', 'Trametinib'), (1794, 1831, 'CONDITION', 'aggressive and refractory meningiomas')]"
"['Efficacy', 'of', 'Moxibustion', 'in', 'Diabetes', 'Peripheral', 'Neuropathy', '|', 'This', 'pragmatic', 'randomized', 'controlled', 'study', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'moxibustion', 'therapy', 'on', 'diabetes', 'peripheral', 'neuropathy', '.']","['O', 'O', 'B-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",NCT04894461,NCT04894461,Efficacy of Moxibustion in Diabetes Peripheral Neuropathy | This pragmatic randomized controlled study aimed to evaluate the effectiveness and safety of moxibustion therapy on diabetes peripheral neuropathy.,"[(12, 23, 'OTHER', 'Moxibustion'), (27, 35, 'CONDITION', 'Diabetes'), (36, 57, 'CONDITION', 'Peripheral Neuropathy'), (153, 172, 'OTHER', 'moxibustion therapy'), (176, 184, 'CONDITION', 'diabetes'), (185, 206, 'CONDITION', 'peripheral neuropathy')]"
"['A', 'Phase', '2', 'Extension', 'Study', 'to', 'Evaluate', 'the', 'Long', '-', 'Term', 'Safety', ',', 'Tolerability', ',', 'Efficacy', ',', 'Pharmacokinetics', ',', 'and', 'Pharmacodynamics', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'Patients', '|', 'AOC', '1001', '-', 'CS2', '(', 'MARINA', '-', 'OLE', ')', 'is', 'a', 'Phase', '2', 'extension', 'of', 'the', 'AOC', '1001', '-', 'CS1', '(', 'MARINA', ')', 'study', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'efficacy', ',', 'pharmacokinetics', 'and', 'pharmacodynamics', 'of', 'multiple', '-', 'doses', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'patients']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05479981,NCT05479981,"A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients | AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients","[(126, 134, 'DRUG', 'AOC 1001'), (171, 196, 'CONDITION', 'Myotonic Dystrophy Type 1'), (198, 201, 'CONDITION', 'DM1'), (405, 413, 'DRUG', 'AOC 1001'), (450, 475, 'CONDITION', 'Myotonic Dystrophy Type 1'), (477, 480, 'CONDITION', 'DM1')]"
"['Ovarian', 'Hormones', ',', 'Reward', 'Response', ',', 'and', 'Binge', 'Eating', 'in', 'Bulimia', 'Nervosa', ':', 'An', 'Experimental', 'Design', '|', 'This', 'pilot', 'study', 'experimentally', 'manipulates', 'ovarian', 'hormones', 'to', 'examine', 'the', 'direct', 'impact', 'of', 'estrogen', '(', 'E2', ')', 'and', 'progesterone', '(', 'P4', ')', 'on', 'binge', 'eating', 'symptom', 'burden', 'and', 'the', 'behavioral', 'reward', 'response', 'in', 'women', 'with', 'bulimia', 'nervosa', '(', 'n=15', ')', '.', 'This', 'is', 'completed', 'by', 'taking', 'medications', 'that', 'change', 'ovarian', 'hormone', 'levels', '.', 'This', 'line', 'of', 'research', 'could', 'lead', 'to', 'the', 'development', 'of', 'pharmacological', 'interventions', 'developed', 'to', 'target', 'specific', 'areas', 'of', 'the', 'brain', ',', 'brain', 'receptors', ',', 'or', 'pathways', 'identified', 'to', 'be', 'involved', 'in', 'the', 'mechanism', 'underlying', 'ovarian', 'hormone', 'change', 'and', 'binge', 'eating', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04225221,NCT04225221,"Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa: An Experimental Design | This pilot study experimentally manipulates ovarian hormones to examine the direct impact of estrogen (E2) and progesterone (P4) on binge eating symptom burden and the behavioral reward response in women with bulimia nervosa (n=15). This is completed by taking medications that change ovarian hormone levels. This line of research could lead to the development of pharmacological interventions developed to target specific areas of the brain, brain receptors, or pathways identified to be involved in the mechanism underlying ovarian hormone change and binge eating.","[(0, 16, 'OTHER', 'Ovarian Hormones'), (39, 51, 'CONDITION', 'Binge Eating'), (55, 70, 'CONDITION', 'Bulimia Nervosa'), (141, 157, 'OTHER', 'ovarian hormones'), (229, 241, 'CONDITION', 'binge eating'), (306, 321, 'CONDITION', 'bulimia nervosa'), (382, 397, 'OTHER', 'ovarian hormone'), (623, 638, 'OTHER', 'ovarian hormone'), (650, 662, 'CONDITION', 'binge eating')]"
"['Phase', '2/3', ',', 'Multistage', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Parallel', 'Group', 'Withdrawal', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Nipocalimab', 'Administered', 'to', 'Adults', 'With', 'Chronic', 'Inflammatory', 'Demyelinating', 'Polyneuropathy', '(', 'CIDP', ')', '|', 'The', 'main', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'nipocalimab', 'compared', 'to', 'placebo', 'in', 'delaying', 'relapse', 'in', 'adults', 'with', 'chronic', 'inflammatory', 'demyelinating', 'polyneuropathy', '(', 'CIDP', ')', 'who', 'initially', 'respond', 'to', 'nipocalimab', 'in', 'Stage', 'A.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O']",NCT05327114,NCT05327114,"Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.","[(62, 69, 'CONTROL', 'Placebo'), (152, 163, 'DRUG', 'Nipocalimab'), (192, 241, 'CONDITION', 'Chronic Inflammatory Demyelinating Polyneuropathy'), (243, 247, 'CONDITION', 'CIDP'), (324, 335, 'DRUG', 'nipocalimab'), (348, 355, 'CONTROL', 'placebo'), (391, 440, 'CONDITION', 'chronic inflammatory demyelinating polyneuropathy'), (442, 446, 'CONDITION', 'CIDP'), (473, 484, 'DRUG', 'nipocalimab')]"
"['The', 'Acute', 'Effect', 'of', 'Lumbo', '-', 'sacral', 'Mobilization', 'on', 'Functional', 'Activities', ',', 'Balance', 'and', 'Gait', 'in', 'Patients', 'With', 'Idiopathic', 'Parkinson', ""'s"", 'Disease', '|', 'Parkinson', ""'s"", 'disease', 'is', 'a', 'neurodegenerative', 'disease', 'including', 'resting', 'tremor', ',', 'bradykinesia', ',', 'rigidity', 'and', 'postural', 'instability', '.', 'In', 'addition', ',', 'postural', 'disorders', ',', 'motor', 'freezing', ',', 'gait', 'disturbances', ',', 'decreased', 'arm', 'swing', 'and', 'axial', 'rotation', 'loss', 'accompany', 'the', 'disease', '.', 'There', 'is', 'an', 'important', 'relationship', 'between', 'axial', 'rotation', 'and', 'turning', ',', 'which', 'is', 'one', 'of', 'many', 'activities', 'in', 'daily', 'life', '.', 'Parkinson', ""'s"", 'patients', 'with', 'loss', 'of', 'axial', 'rotation', 'have', 'a', 'difficulty', 'gait', ',', 'daily', 'living', 'activities', 'and', 'is', 'associated', 'with', 'falls', '.', '\n\n', 'Classical', 'physiotherapy', 'methods', 'for', 'Parkinson', ""'s"", 'patients', 'such', 'as', 'stretching', ',', 'strengthening', 'and', 'posture', 'exercises', ',', 'balance', ',', 'coordination', 'and', 'gait', 'training', ',', 'and', 'different', 'methods', 'such', 'as', 'motor', 'imagery', ',', 'sensory', 'stimuli', 'and', 'neurophysiological', 'approaches', 'can', 'be', 'used', 'in', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'patients', '.', 'Although', 'there', 'are', 'applications', 'that', 'can', 'increase', 'axial', 'rotation', 'in', 'physiotherapy', 'programs', ',', 'all', 'programs', 'may', 'be', 'able', 'to', 'focus', 'adequately', 'on', 'the', 'treatment', 'of', 'this', 'symptom', '.', 'In', 'addition', ',', 'according', 'to', 'the', 'literature', ',', 'the', 'effects', 'of', 'all', 'physiotherapy', 'approaches', 'emerge', 'as', 'a', 'result', 'of', 'long', '-', 'term', 'training', '.', '\n\n', 'Mobilization', 'techniques', 'are', 'applications', 'that', 'are', 'included', 'in', 'physiotherapy', 'programs', 'and', 'have', 'a', 'wide', 'area', 'of', 'use', '.', 'It', 'is', 'divided', 'into', 'three', 'subtitles', 'according', 'to', 'its', 'severity', 'and', 'degree', ':', 'Grade', 'A', '(', 'mobilization', ')', ',', 'grade', 'B', '(', 'mobilization', ')', 'and', 'grade', 'C', '(', 'manipulation', ')', '.', '\n\n', 'Considering', 'the', 'effects', 'of', 'mobilization', 'on', 'muscle', 'activation', 'and', 'balance', ',', 'grade', 'A', 'and', 'grade', 'B', 'mobilization', 'applications', 'are', 'likely', 'to', 'increase', 'the', 'mobility', 'of', 'this', 'area', 'when', 'applied', 'on', 'the', 'lumbosacral', 'region', '.', 'Therefore', ',', 'these', 'practices', 'can', 'affect', 'balance', ',', 'gait', 'and', 'functional', 'activities', 'by', 'regulating', 'muscle', 'tone', '(', 'rigidity', ')', 'and', 'muscle', 'activation', 'and', 'reducing', 'axial', 'symptoms', 'in', 'Parkinson', ""'s"", 'patients', '.', 'Based', 'on', 'this', 'information', ',', 'the', 'aim', 'of', 'our', 'study', 'is', 'to', 'investigate', 'the', 'acute', 'effect', 'of', 'lumbosacral', 'mobilization', 'on', 'balance', ',', 'gait', 'and', 'functional', 'activities', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04524182,NCT04524182,"The Acute Effect of Lumbo-sacral Mobilization on Functional Activities, Balance and Gait in Patients With Idiopathic Parkinson's Disease | Parkinson's disease is a neurodegenerative disease including resting tremor, bradykinesia, rigidity and postural instability. In addition, postural disorders, motor freezing, gait disturbances, decreased arm swing and axial rotation loss accompany the disease. There is an important relationship between axial rotation and turning, which is one of many activities in daily life. Parkinson's patients with loss of axial rotation have a difficulty gait, daily living activities and is associated with falls.

Classical physiotherapy methods for Parkinson's patients such as stretching, strengthening and posture exercises, balance, coordination and gait training, and different methods such as motor imagery, sensory stimuli and neurophysiological approaches can be used in the treatment of Parkinson's patients. Although there are applications that can increase axial rotation in physiotherapy programs, all programs may be able to focus adequately on the treatment of this symptom. In addition, according to the literature, the effects of all physiotherapy approaches emerge as a result of long-term training.

Mobilization techniques are applications that are included in physiotherapy programs and have a wide area of use. It is divided into three subtitles according to its severity and degree: Grade A (mobilization), grade B (mobilization) and grade C (manipulation).

Considering the effects of mobilization on muscle activation and balance, grade A and grade B mobilization applications are likely to increase the mobility of this area when applied on the lumbosacral region. Therefore, these practices can affect balance, gait and functional activities by regulating muscle tone (rigidity) and muscle activation and reducing axial symptoms in Parkinson's patients. Based on this information, the aim of our study is to investigate the acute effect of lumbosacral mobilization on balance, gait and functional activities in patients with Parkinson's disease.","[(20, 45, 'OTHER', 'Lumbo-sacral Mobilization'), (106, 136, 'CONDITION', ""Idiopathic Parkinson's Disease""), (139, 158, 'CONDITION', ""Parkinson's disease""), (518, 529, 'CONDITION', ""Parkinson's""), (544, 566, 'CONDITION', 'loss of axial rotation'), (682, 693, 'CONDITION', ""Parkinson's""), (928, 939, 'CONDITION', ""Parkinson's""), (1250, 1273, 'OTHER', 'Mobilization techniques'), (1446, 1458, 'OTHER', 'mobilization'), (1470, 1482, 'OTHER', 'mobilization'), (1497, 1509, 'OTHER', 'manipulation'), (1587, 1632, 'OTHER', 'grade A and grade B mobilization applications'), (1890, 1901, 'CONDITION', ""Parkinson's""), (1998, 2022, 'OTHER', 'lumbosacral mobilization'), (2083, 2102, 'CONDITION', ""Parkinson's disease"")]"
"['Effect', 'of', 'Individualized', 'rTMS', 'Based', 'on', 'fNIRS', 'on', 'the', 'Upper', 'Limb', 'Spasticity', 'After', 'Stroke', '|', 'Stroke', 'is', 'of', 'high', 'morbidity', 'and', 'mortality', ',', 'and', 'surviving', 'patients', 'are', 'often', 'unable', 'to', 'take', 'care', 'of', 'themselves', 'because', 'of', 'severe', 'motor', 'dysfunction', '.', 'The', 'brain', 'has', 'plasticity', ',', 'and', 'makes', 'adaptive', 'changes', 'after', 'stroke', ',', 'resulting', 'in', 'the', 'reorganization', 'and', 'compensation', 'of', 'neural', 'networks', '.', 'However', ',', 'the', 'muscle', 'tone', 'of', 'some', 'patients', 'will', 'significantly', 'increase', 'during', 'the', 'recovery', 'process', ',', 'which', 'affects', 'the', 'rehabilitation', 'effect', '.', 'Neuromodulation', 'techniques', 'such', 'as', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'have', 'been', 'widely', 'used', 'to', 'promote', 'brain', 'network', 'remodeling', 'after', 'stroke', '.', 'The', 'investigators', 'attempted', 'to', 'evaluate', 'the', 'motor', 'brain', 'network', 'characteristics', 'of', 'spastic', 'patients', 'by', 'fNIRS', ',', 'and', 'used', 'the', 'most', 'active', 'brain', 'regions', 'as', 'rTMS', 'stimulation', 'regions', 'to', 'evaluate', 'the', 'improvement', 'effect', 'of', 'this', 'individualized', 'treatment', 'on', 'post', '-', 'stroke', 'spasticity', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O']",NCT05318586,NCT05318586,"Effect of Individualized rTMS Based on fNIRS on the Upper Limb Spasticity After Stroke | Stroke is of high morbidity and mortality, and surviving patients are often unable to take care of themselves because of severe motor dysfunction. The brain has plasticity, and makes adaptive changes after stroke, resulting in the reorganization and compensation of neural networks. However, the muscle tone of some patients will significantly increase during the recovery process, which affects the rehabilitation effect. Neuromodulation techniques such as repetitive transcranial magnetic stimulation (rTMS) have been widely used to promote brain network remodeling after stroke. The investigators attempted to evaluate the motor brain network characteristics of spastic patients by fNIRS, and used the most active brain regions as rTMS stimulation regions to evaluate the improvement effect of this individualized treatment on post-stroke spasticity.","[(10, 29, 'OTHER', 'Individualized rTMS'), (63, 73, 'CONDITION', 'Spasticity'), (80, 86, 'CONDITION', 'Stroke'), (89, 95, 'CONDITION', 'Stroke'), (547, 591, 'OTHER', 'repetitive transcranial magnetic stimulation'), (593, 597, 'OTHER', 'rTMS'), (663, 669, 'CONDITION', 'stroke'), (754, 761, 'CONDITION', 'spastic'), (823, 827, 'OTHER', 'rTMS'), (924, 930, 'CONDITION', 'stroke'), (931, 941, 'CONDITION', 'spasticity')]"
"['The', 'Effect', 'of', 'a', 'Telerehabilitation', 'Virtual', 'Reality', 'Intervention', 'on', 'Functional', 'Upper', 'Limb', 'Activities', 'in', 'People', 'With', 'Multiple', 'Sclerosis', '|', 'This', 'study', 'aims', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'home', '-', 'based', 'telerehabilitation', 'program', 'specifically', 'designed', 'for', 'upper', 'limbs', ',', 'based', 'on', 'Virtual', 'Reality', '(', 'VR', ')', 'in', 'individuals', 'affected', 'by', 'Multiple', 'Sclerosis', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04032431,NCT04032431,"The Effect of a Telerehabilitation Virtual Reality Intervention on Functional Upper Limb Activities in People With Multiple Sclerosis | This study aims to investigate the effectiveness of a home-based telerehabilitation program specifically designed for upper limbs, based on Virtual Reality (VR) in individuals affected by Multiple Sclerosis.","[(16, 50, 'OTHER', 'Telerehabilitation Virtual Reality'), (115, 133, 'CONDITION', 'Multiple Sclerosis'), (201, 291, 'OTHER', 'telerehabilitation program specifically designed for upper limbs, based on Virtual Reality'), (293, 295, 'OTHER', 'VR'), (324, 342, 'CONDITION', 'Multiple Sclerosis')]"
"['Major', 'Research', 'Instrumentation', 'Program', ':', 'Development', 'of', 'an', 'Innovative', 'Instrument', 'on', 'Robot', '-', 'Aided', 'Virtual', 'Rehabilitation', 'for', 'Intelligent', 'Physical', 'Training', 'of', 'Individuals', 'With', 'Disabilities', '(', 'iRAPID', ')', '|', 'Investigate', 'development', 'of', 'an', 'Innovative', 'Instrument', 'on', 'Robot', '-', 'Aided', 'and', 'Virtual', 'Reality', 'Rehabilitation', 'for', 'Intelligent', 'Physical', 'Training', '(', 'i.e.', 'gait', 'and', 'stepping', ')', 'of', 'Individuals', 'post', '-', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04740060,NCT04740060,Major Research Instrumentation Program: Development of an Innovative Instrument on Robot-Aided Virtual Rehabilitation for Intelligent Physical Training of Individuals With Disabilities (iRAPID) | Investigate development of an Innovative Instrument on Robot-Aided and Virtual Reality Rehabilitation for Intelligent Physical Training (i.e. gait and stepping) of Individuals post-stroke.,"[(83, 117, 'PHYSICAL', 'Robot-Aided Virtual Rehabilitation'), (122, 151, 'PHYSICAL', 'Intelligent Physical Training'), (251, 297, 'PHYSICAL', 'Robot-Aided and Virtual Reality Rehabilitation'), (302, 331, 'PHYSICAL', 'Intelligent Physical Training'), (372, 383, 'CONDITION', 'post-stroke')]"
"['Phase', 'II', 'Study', 'of', 'JNS024ER', 'in', 'Japanese', 'Subjects', 'With', 'Chronic', 'Pain', 'Due', 'to', 'Diabetic', 'Neuropathic', 'Pain', 'or', 'Postherpetic', 'Neuralgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'tapentadol', 'extended', '-', 'release', '(', 'ER', ')', 'tablets', 'in', 'Japanese', 'participants', 'with', 'moderate', 'to', 'severe', 'chronic', '(', 'lasting', 'a', 'long', 'time', ')', 'pain', 'due', 'to', 'painful', 'diabetic', 'peripheral', 'neuropathy', '(', 'pain', 'in', 'the', 'extremities', 'related', 'to', 'diabetes', '-', 'induced', 'nerve', 'damage', ')', 'or', 'postherpetic', 'neuralgia', '(', 'pain', 'lasting', 'after', 'condition', 'has', 'healed', ')', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01124617,NCT01124617,Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia | The purpose of this study is to investigate the efficacy and safety of tapentadol extended-release (ER) tablets in Japanese participants with moderate to severe chronic (lasting a long time) pain due to painful diabetic peripheral neuropathy (pain in the extremities related to diabetes-induced nerve damage) or postherpetic neuralgia (pain lasting after condition has healed).,"[(18, 26, 'DRUG', 'JNS024ER'), (53, 65, 'CONDITION', 'Chronic Pain'), (73, 98, 'CONDITION', 'Diabetic Neuropathic Pain'), (102, 124, 'CONDITION', 'Postherpetic Neuralgia'), (198, 208, 'DRUG', 'tapentadol'), (269, 322, 'CONDITION', 'moderate to severe chronic (lasting a long time) pain'), (330, 368, 'CONDITION', 'painful diabetic peripheral neuropathy'), (370, 374, 'CONDITION', 'pain'), (405, 413, 'CONDITION', 'diabetes'), (439, 461, 'CONDITION', 'postherpetic neuralgia'), (463, 467, 'CONDITION', 'pain')]"
"['Evaluation', 'of', 'the', 'Benefit', 'Provided', 'by', 'Sessions', 'of', 'Sophrology', 'on', 'the', 'Intraoperative', 'Management', 'of', 'Parkinsonian', 'Patients', 'in', 'the', 'Context', 'of', 'Deep', 'Brain', 'Stimulation', 'Surgery', '.', '|', 'Deep', 'brain', 'stimulation', 'surgery', ',', 'which', 'consists', 'of', 'intracerebral', 'implantation', 'of', 'electrodes', ',', 'is', 'considered', 'one', 'of', 'the', 'most', 'effective', 'techniques', 'for', 'controlling', 'the', 'motor', 'fluctuations', 'of', 'Parkinson', ""'s"", 'disease', '.', 'The', 'particularity', 'of', 'this', 'surgery', 'is', 'the', 'necessity', 'of', 'the', 'awakening', 'of', 'the', 'patient', 'for', 'the', 'correct', 'positioning', 'of', 'the', 'electrodes', ',', 'it', 'is', 'therefore', 'a', 'difficult', 'test', 'for', 'the', 'patient', '.', '\n\n', 'Medical', 'sophrology', 'is', 'an', 'ideal', 'strategy', 'to', 'optimize', 'the', 'comfort', 'of', 'the', 'patient', 'during', 'the', 'operation', 'thanks', 'to', 'its', 'anxiolytic', 'and', 'analgesic', 'virtues', 'while', 'guaranteeing', 'the', 'maintenance', 'of', 'a', 'good', 'patient', 'vigilance', 'favoring', 'the', 'cooperation', 'with', 'the', 'operating', 'room', 'team', '.', 'Indeed', ',', 'sophrology', 'is', 'a', 'body', '-', 'mediated', 'set', 'of', 'techniques', ',', 'at', 'the', 'crossroads', 'between', 'hypnosis', 'and', 'yoga', ',', 'which', 'makes', 'it', 'possible', 'to', 'find', 'a', 'balance', 'between', 'emotions', ',', 'thoughts', 'and', 'behaviors', '.', 'It', 'has', 'already', 'been', 'applied', 'in', 'other', 'fields', 'such', 'as', 'oncology', ',', 'pain', 'management', ',', 'preparation', 'for', 'childbirth', ',', 'and', 'for', '5', 'years', 'at', 'the', 'CHU', 'of', 'Rennes', 'for', 'preparation', 'for', 'the', 'intervention', 'of', 'deep', 'brain', 'stimulation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT03273816,NCT03273816,"Evaluation of the Benefit Provided by Sessions of Sophrology on the Intraoperative Management of Parkinsonian Patients in the Context of Deep Brain Stimulation Surgery. | Deep brain stimulation surgery, which consists of intracerebral implantation of electrodes, is considered one of the most effective techniques for controlling the motor fluctuations of Parkinson's disease. The particularity of this surgery is the necessity of the awakening of the patient for the correct positioning of the electrodes, it is therefore a difficult test for the patient.

Medical sophrology is an ideal strategy to optimize the comfort of the patient during the operation thanks to its anxiolytic and analgesic virtues while guaranteeing the maintenance of a good patient vigilance favoring the cooperation with the operating room team. Indeed, sophrology is a body-mediated set of techniques, at the crossroads between hypnosis and yoga, which makes it possible to find a balance between emotions, thoughts and behaviors. It has already been applied in other fields such as oncology, pain management, preparation for childbirth, and for 5 years at the CHU of Rennes for preparation for the intervention of deep brain stimulation.","[(50, 60, 'BEHAVIOURAL', 'Sophrology'), (97, 109, 'CONDITION', 'Parkinsonian'), (137, 159, 'OTHER', 'Deep Brain Stimulation'), (171, 193, 'OTHER', 'Deep brain stimulation'), (356, 375, 'CONDITION', ""Parkinson's disease""), (566, 576, 'BEHAVIOURAL', 'sophrology'), (831, 841, 'BEHAVIOURAL', 'sophrology'), (1193, 1215, 'OTHER', 'deep brain stimulation')]"
"['""', 'Get', 'up', '""', '-', 'The', 'Sleep', 'Study', 'in', 'Oppegard', '(', 'St', 'Opp', '-', 'Svnstudien', 'i', 'Oppegrd', ')', '|', 'A', 'randomized', ',', 'controlled', 'study', 'to', 'examine', 'the', 'effect', 'of', 'group', 'treatment', 'for', 'insomnia', '(', 'CBT', '-', 'I', ')', 'in', 'an', 'outpatient', 'clinic', 'compared', 'with', 'waiting', 'list', 'and', 'treatment', '-', 'as', '-', 'usual', '(', 'sleep', '-', 'hygiene', 'based', 'educational', 'course', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT03177967,NCT03177967,"""Get up"" - The Sleep Study in Oppegard (St Opp - Svnstudien i Oppegrd) | A randomized, controlled study to examine the effect of group treatment for insomnia (CBT-I) in an outpatient clinic compared with waiting list and treatment-as-usual (sleep-hygiene based educational course)","[(132, 147, 'BEHAVIOURAL', 'group treatment'), (152, 160, 'CONDITION', 'insomnia'), (207, 219, 'CONTROL', 'waiting list'), (224, 242, 'CONTROL', 'treatment-as-usual'), (244, 282, 'CONTROL', 'sleep-hygiene based educational course')]"
"['Prospective', 'Study', 'on', 'the', 'Use', 'of', 'Middle', 'Meningeal', 'Artery', 'Embolization', 'for', 'Chronic', 'Subdural', 'Haematoma', '|', 'Subdural', 'haematoma', 'is', 'a', 'common', 'neurosurgical', 'condition', 'that', 'results', 'in', 'different', 'levels', 'of', 'neurological', 'deficits', 'in', 'patients', '.', 'It', 'can', 'be', 'further', 'classified', 'into', 'acute', 'and', 'chronic', ',', 'which', 'have', 'different', 'pathophysiology', '.', 'Acute', 'haematoma', 'is', 'a', 'common', 'result', 'of', 'traumatic', 'injuries', 'involving', 'the', 'tearing', 'of', 'the', 'bridging', 'veins', ',', 'while', 'chronic', 'subdural', 'haematoma', 'can', 'be', 'both', 'a', 'result', 'of', 'traumatic', 'injuries', 'or', 'recurrence', 'following', 'surgical', 'management', 'of', 'the', 'acute', 'counterpart', '.', 'For', 'symptomatic', 'patients', ',', 'they', 'are', 'often', 'surgically', 'managed', 'by', 'haematoma', 'drainage', 'via', 'burr', '-', 'hole', 'drainage', 'and', 'craniotomy', '.', 'Recurrent', 'bleeding', 'following', 'close', 'monitor', 'or', 'surgical', 'evacuation', 'of', 'haematoma', 'is', 'however', 'very', 'high', '.', 'Recent', 'studies', 'approximate', 'the', 'recurrence', 'rate', 'of', '2%-33.3', '%', '.', 'Recent', 'evidence', 'suggests', 'the', 'angiogenesis', 'of', 'middle', 'meningeal', 'arteries', '(', 'MMA', ')', 'in', 'response', 'to', 'inflammation', 'and', 'healing', 'process', 'contributes', 'to', 'the', 'development', 'of', 'chronic', 'subdural', 'haematoma', ',', 'and', 'its', 'high', 'recurrence', 'chance', '.', 'Several', 'studies', 'have', 'looked', 'into', 'the', 'use', 'of', 'middle', 'meningeal', 'artery', 'embolization', 'to', 'halt', 'the', 'bleeding', 'of', 'a', 'chronic', 'subdural', 'haematoma', ',', 'and', 'have', 'found', 'promising', 'results', 'in', 'terms', 'of', 'haematoma', 'reduction', 'and', 'prevention', 'of', 'surgical', 'rescues', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04500795,NCT04500795,"Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma | Subdural haematoma is a common neurosurgical condition that results in different levels of neurological deficits in patients. It can be further classified into acute and chronic, which have different pathophysiology. Acute haematoma is a common result of traumatic injuries involving the tearing of the bridging veins, while chronic subdural haematoma can be both a result of traumatic injuries or recurrence following surgical management of the acute counterpart. For symptomatic patients, they are often surgically managed by haematoma drainage via burr-hole drainage and craniotomy. Recurrent bleeding following close monitor or surgical evacuation of haematoma is however very high. Recent studies approximate the recurrence rate of 2%-33.3%. Recent evidence suggests the angiogenesis of middle meningeal arteries (MMA) in response to inflammation and healing process contributes to the development of chronic subdural haematoma, and its high recurrence chance. Several studies have looked into the use of middle meningeal artery embolization to halt the bleeding of a chronic subdural haematoma, and have found promising results in terms of haematoma reduction and prevention of surgical rescues.","[(32, 68, 'SURGICAL', 'Middle Meningeal Artery Embolization'), (73, 99, 'CONDITION', 'Chronic Subdural Haematoma'), (102, 120, 'CONDITION', 'Subdural haematoma'), (319, 334, 'CONDITION', 'Acute haematoma'), (427, 453, 'CONDITION', 'chronic subdural haematoma'), (630, 639, 'CONDITION', 'haematoma'), (757, 766, 'CONDITION', 'haematoma'), (1008, 1034, 'CONDITION', 'chronic subdural haematoma'), (1112, 1148, 'SURGICAL', 'middle meningeal artery embolization'), (1175, 1201, 'CONDITION', 'chronic subdural haematoma'), (1248, 1257, 'CONDITION', 'haematoma')]"
"['Effectiveness', 'Specific', 'Manual', 'Therapy', 'in', 'a', 'Multimodal', 'Physical', 'Therapy', 'Treatment', 'in', 'Patients', 'With', 'Tinnitus', 'and', 'Temporomandibular', 'Joint', 'Disorder', '.', '|', 'Tinnitus', 'is', 'one', 'of', 'the', 'most', 'prevalent', 'symptoms', 'that', 'causes', 'more', 'disability', 'in', 'patients', 'with', 'temporomandibular', 'disorder', '(', 'TMD', ')', '.', 'The', 'present', 'study', 'postulates', 'a', 'possible', 'link', 'between', 'temporomandibular', 'joint', '(', 'TMJ', ')', 'and', 'inner', 'ear', 'based', 'on', 'their', 'anatomical', ',', 'biomechanical', 'and', 'physiological', 'relationship', ',', 'proposing', 'a', 'physiotherapy', 'treatment', 'for', 'the', 'temporomandibular', 'joint', 'to', 'improve', 'tinnitus', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'adding', 'specific', 'manual', 'therapy', 'to', 'a', 'multimodal', 'physiotherapy', 'treatment', 'in', 'patients', 'with', 'tinnitus', 'and', 'temporomandibular', 'disorder', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT02850055,NCT02850055,"Effectiveness Specific Manual Therapy in a Multimodal Physical Therapy Treatment in Patients With Tinnitus and Temporomandibular Joint Disorder. | Tinnitus is one of the most prevalent symptoms that causes more disability in patients with temporomandibular disorder (TMD). The present study postulates a possible link between temporomandibular joint (TMJ) and inner ear based on their anatomical, biomechanical and physiological relationship, proposing a physiotherapy treatment for the temporomandibular joint to improve tinnitus. The aim of the study is to evaluate the effectiveness of adding specific manual therapy to a multimodal physiotherapy treatment in patients with tinnitus and temporomandibular disorder.","[(14, 37, 'OTHER', 'Specific Manual Therapy'), (43, 80, 'OTHER', 'Multimodal Physical Therapy Treatment'), (98, 106, 'CONDITION', 'Tinnitus'), (111, 143, 'CONDITION', 'Temporomandibular Joint Disorder'), (147, 155, 'CONDITION', 'Tinnitus'), (239, 265, 'CONDITION', 'temporomandibular disorder'), (267, 270, 'CONDITION', 'TMD'), (455, 510, 'OTHER', 'physiotherapy treatment for the temporomandibular joint'), (522, 530, 'CONDITION', 'tinnitus'), (596, 619, 'OTHER', 'specific manual therapy'), (625, 659, 'OTHER', 'multimodal physiotherapy treatment'), (677, 685, 'CONDITION', 'tinnitus'), (690, 716, 'CONDITION', 'temporomandibular disorder')]"
"['Tel', 'Aviv', 'Sourasky', 'Medical', 'Center', '|', 'Tourette', 'Syndrome', '(', 'TS', ')', 'is', 'a', 'disorder', 'characterized', 'by', 'motor', 'and', 'vocal', 'tics', '.', 'The', 'most', 'studied', 'and', 'promising', 'intervention', 'is', 'Habit', 'Reversal', 'Training', '(', 'HRT', ')', 'and', 'its', 'variations', ':', 'Behavioral', 'Comprehensive', 'Intervention', 'for', 'Tics', '(', 'CBIT', ')', '.', 'Group', 'intervention', 'for', 'children', 'with', 'TS', 'has', 'not', 'been', 'evaluated', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'efficacy', 'of', 'CBIT', 'group', 'intervention', 'compared', 'with', 'Psycho', '-', 'Educational', '-', 'Supportive', 'group', 'in', 'terms', 'of', 'tic', 'severity', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT02407951,NCT02407951,Tel Aviv Sourasky Medical Center | Tourette Syndrome (TS) is a disorder characterized by motor and vocal tics. The most studied and promising intervention is Habit Reversal Training (HRT) and its variations: Behavioral Comprehensive Intervention for Tics (CBIT). Group intervention for children with TS has not been evaluated. The aim of this study is to assess the efficacy of CBIT group intervention compared with Psycho-Educational-Supportive group in terms of tic severity.,"[(35, 52, 'CONDITION', 'Tourette Syndrome'), (54, 56, 'CONDITION', 'TS'), (89, 109, 'CONDITION', 'motor and vocal tics'), (158, 181, 'BEHAVIOURAL', 'Habit Reversal Training'), (183, 186, 'BEHAVIOURAL', 'HRT'), (208, 254, 'BEHAVIOURAL', 'Behavioral Comprehensive Intervention for Tics'), (256, 260, 'BEHAVIOURAL', 'CBIT'), (263, 281, 'BEHAVIOURAL', 'Group intervention'), (300, 302, 'CONDITION', 'TS'), (378, 401, 'BEHAVIOURAL', 'CBIT group intervention'), (416, 451, 'CONTROL', 'Psycho-Educational-Supportive group'), (464, 467, 'CONDITION', 'tic')]"
"['Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', 'in', 'Individuals', 'With', 'Spinal', 'Cord', 'Injury', ':', 'A', 'Pilot', 'Study', '|', 'This', 'study', 'will', 'investigate', 'how', 'repetitive', 'transcranial', 'magnetic', 'stimulation', 'delivered', 'as', 'a', 'protocol', 'called', ""'"", 'continuous', 'theta', '-', 'burst', 'stimulation', '(', 'cTBS', ')', ""'"", 'alters', 'motor', 'output', 'and', 'force', 'control', 'to', 'a', 'muscle', 'in', 'the', 'forearm', 'and', 'touch', 'perception', 'in', 'individuals', 'with', 'chronic', ',', 'incomplete', 'spinal', 'cord', 'injury', '.', 'CTBS', 'is', 'a', 'non', '-', 'invasive', 'technique', 'that', 'involved', 'repetitive', 'delivery', 'of', 'transcranial', 'magnetic', 'stimulation', 'at', 'a', 'frequency', 'of', '30', 'Hz', 'over', 'the', 'arm', 'representation', 'in', 'the', 'primary', 'motor', 'or', 'sensory', 'cortex', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'cTBS', 'is', 'an', 'effective', 'intervention', 'to', 'increase', 'motor', 'output', 'to', 'a', 'muscle', 'and', 'increase', 'force', 'control', 'of', 'that', 'muscle', 'and', 'also', 'improve', 'the', 'sense', 'of', 'touch', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02351921,NCT02351921,"Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study | This study will investigate how repetitive transcranial magnetic stimulation delivered as a protocol called 'continuous theta-burst stimulation (cTBS)' alters motor output and force control to a muscle in the forearm and touch perception in individuals with chronic, incomplete spinal cord injury. CTBS is a non-invasive technique that involved repetitive delivery of transcranial magnetic stimulation at a frequency of 30 Hz over the arm representation in the primary motor or sensory cortex. The purpose of this study is to determine whether cTBS is an effective intervention to increase motor output to a muscle and increase force control of that muscle and also improve the sense of touch.","[(0, 44, 'OTHER', 'Repetitive Transcranial Magnetic Stimulation'), (65, 83, 'CONDITION', 'Spinal Cord Injury'), (133, 177, 'OTHER', 'repetitive transcranial magnetic stimulation'), (210, 244, 'OTHER', 'continuous theta-burst stimulation'), (246, 250, 'OTHER', 'cTBS'), (359, 397, 'CONDITION', 'chronic, incomplete spinal cord injury'), (399, 403, 'OTHER', 'CTBS'), (469, 502, 'OTHER', 'transcranial magnetic stimulation'), (645, 649, 'OTHER', 'cTBS')]"
"['A', 'Double', 'Blind', 'Placebo', 'Controlled', 'Study', 'of', 'Guanfacine', 'Adjunctive', 'Treatment', 'to', 'Atypical', 'Antipsychotics', 'for', 'Cognitive', 'Dysfunction', 'in', 'Schizophrenia', '|', 'Our', 'overall', 'aim', 'is', 'to', 'determine', 'if', 'the', 'administration', 'of', 'guanfacine', 'in', 'combination', 'with', 'aripiprazole', ',', 'olanzapine', ',', 'quetiapine', ',', 'and/or', 'risperidone', 'is', 'significantly', 'more', 'effective', 'than', 'any', 'of', 'those', 'medications', 'alone', 'in', 'treating', 'some', 'of', 'the', 'cognitive', 'impairment', 'in', 'schizophrenia', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT00469664,NCT00469664,"A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia | Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia.","[(15, 22, 'CONTROL', 'Placebo'), (43, 53, 'DRUG', 'Guanfacine'), (131, 144, 'CONDITION', 'Schizophrenia'), (204, 214, 'DRUG', 'guanfacine'), (235, 247, 'DRUG', 'aripiprazole'), (249, 259, 'DRUG', 'olanzapine'), (261, 271, 'DRUG', 'quetiapine'), (280, 291, 'DRUG', 'risperidone'), (384, 404, 'CONDITION', 'cognitive impairment'), (408, 421, 'CONDITION', 'schizophrenia')]"
"['A', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', 'Study', 'for', 'the', 'Effect', 'of', 'IV', 'Amantadine', 'on', 'Freezing', 'of', 'Gait', '(', 'FOG', ')', 'Resistant', 'to', 'Dopaminergic', 'Therapy', '|', 'Tp', 'determine', 'the', 'effect', 'of', 'IV', 'amantadine', 'on', 'dopaminergic', '-', 'drug', '-', 'resistant', 'freezing', 'of', 'gait(FOG)in', 'patients', 'with', 'Parkinson', ""'s"", 'disease']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT01313819,NCT01313819,"A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy | Tp determine the effect of IV amantadine on dopaminergic-drug-resistant freezing of gait(FOG)in patients with Parkinson's disease","[(16, 23, 'CONTROL', 'Placebo'), (59, 72, 'DRUG', 'IV Amantadine'), (76, 92, 'CONDITION', 'Freezing of Gait'), (94, 97, 'CONDITION', 'FOG'), (99, 132, 'CONDITION', 'Resistant to Dopaminergic Therapy'), (162, 175, 'DRUG', 'IV amantadine'), (245, 264, 'CONDITION', ""Parkinson's disease"")]"
"['A', 'Randomised', 'Controlled', 'Trial', 'Evaluating', 'the', 'Effect', 'of', 'an', 'Individual', 'Auditory', 'Cueing', 'Device', 'on', 'Freezing', 'and', 'Gait', 'Speed', 'in', 'People', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'primary', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'an', 'IACD', 'i.e.', 'Apple', 'iPod', '-', 'shuffle', ',', 'on', 'freezing', 'and', 'gait', 'speed', 'in', 'people', 'with', 'a', 'diagnosis', 'of', 'PD', 'through', 'the', 'implementation', 'of', 'a', 'randomised', 'controlled', 'trial', '.', 'A', 'secondary', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'impact', 'of', 'such', 'a', 'device', 'on', 'the', 'quality', 'of', 'life', 'of', 'people', 'with', 'stroke', 'through', 'the', 'administration', 'of', 'a', 'self', '-', 'report', 'questionnaire', '.', 'The', 'IACD', 'will', 'be', 'pre', '-', 'loaded', 'with', 'an', 'individualised', 'auditory', 'cueing', 'frequency', '(', 'metronome', 'sound', ')', 'matched', 'to', 'the', 'walking', 'speed', 'of', 'the', 'individual', 'with', 'PD', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00727467,NCT00727467,"A Randomised Controlled Trial Evaluating the Effect of an Individual Auditory Cueing Device on Freezing and Gait Speed in People With Parkinson's Disease | The primary aim of the study is to evaluate the effect of an IACD i.e. Apple iPod-shuffle, on freezing and gait speed in people with a diagnosis of PD through the implementation of a randomised controlled trial. A secondary aim of the study is to evaluate the impact of such a device on the quality of life of people with stroke through the administration of a self-report questionnaire. The IACD will be pre-loaded with an individualised auditory cueing frequency (metronome sound) matched to the walking speed of the individual with PD.","[(58, 91, 'OTHER', 'Individual Auditory Cueing Device'), (134, 153, 'CONDITION', ""Parkinson's Disease""), (217, 221, 'OTHER', 'IACD'), (227, 245, 'OTHER', 'Apple iPod-shuffle'), (304, 306, 'CONDITION', 'PD'), (478, 484, 'CONDITION', 'stroke'), (548, 552, 'OTHER', 'IACD'), (580, 610, 'OTHER', 'individualised auditory cueing'), (691, 693, 'CONDITION', 'PD')]"
"['Diet', 'and', 'Muscle', 'Function', 'In', 'Older', 'Adults', '|', 'This', 'research', 'study', 'was', 'conducted', 'to', 'investigate', 'the', 'effects', 'of', 'a', 'high', 'protein', 'diet', 'on', 'the', 'efficiency', 'of', 'energy', 'use', 'at', 'rest', 'and', 'at', 'low', '-', 'levels', 'of', 'physical', 'activity', '.', 'The', 'hypothesis', 'was', 'that', 'a', 'high', 'intake', 'of', 'dietary', 'protein', 'would', 'result', 'in', 'a', 'less', 'efficient', 'use', 'of', 'energy', 'in', 'skeletal', 'muscle', 'in', 'older', 'adults', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02069314,NCT02069314,Diet and Muscle Function In Older Adults | This research study was conducted to investigate the effects of a high protein diet on the efficiency of energy use at rest and at low-levels of physical activity. The hypothesis was that a high intake of dietary protein would result in a less efficient use of energy in skeletal muscle in older adults.,"[(109, 126, 'OTHER', 'high protein diet'), (233, 263, 'OTHER', 'high intake of dietary protein')]"
"['A', 'Phase', '1', ',', 'Open', '-', 'Label', 'Study', 'to', 'Evaluate', 'the', 'Absorption', ',', 'Metabolism', ',', 'and', 'Excretion', 'of', '[', '14C]-BIIB074', 'in', 'Healthy', 'Male', 'Subjects', '|', 'The', 'primary', 'objectives', 'of', 'the', 'study', 'are', ':', 'To', 'determine', 'the', 'mass', 'balance', 'and', 'routes', 'of', 'elimination', 'of', 'BIIB074', 'and', 'its', 'known', 'metabolites', 'following', 'administration', 'of', 'a', 'single', 'oral', 'dose', 'of', 'BIIB074', 'in', 'healthy', 'male', 'participants', 'and', 'To', 'describe', 'the', 'pharmacokinetics', '(', 'PK', ')', 'of', 'BIIB074', 'and', 'its', 'known', 'metabolites', 'and', 'the', 'disposition', 'profiles', 'of', 'total', 'radioactivity', 'in', 'whole', 'blood', 'and', 'plasma', 'following', 'a', 'single', 'oral', 'dose', '.', 'The', 'secondary', 'objectives', 'of', 'this', 'study', 'are', ':', 'To', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'BIIB074', 'in', 'healthy', 'participants', 'and', 'To', 'identify', 'and', 'characterize', 'any', 'additional', 'metabolites', 'of', 'BIIB074', 'in', 'plasma', ',', 'urine', ',', 'and', 'feces', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02751905,NCT02751905,"A Phase 1, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-BIIB074 in Healthy Male Subjects | The primary objectives of the study are: To determine the mass balance and routes of elimination of BIIB074 and its known metabolites following administration of a single oral dose of BIIB074 in healthy male participants and To describe the pharmacokinetics (PK) of BIIB074 and its known metabolites and the disposition profiles of total radioactivity in whole blood and plasma following a single oral dose. The secondary objectives of this study are: To assess the safety and tolerability of BIIB074 in healthy participants and To identify and characterize any additional metabolites of BIIB074 in plasma, urine, and feces.","[(85, 98, 'DRUG', '[14C]-BIIB074'), (226, 233, 'DRUG', 'BIIB074'), (310, 317, 'DRUG', 'BIIB074'), (392, 399, 'DRUG', 'BIIB074'), (619, 626, 'DRUG', 'BIIB074'), (714, 721, 'DRUG', 'BIIB074')]"
"['Diz', 'Osteoartritinde', 'Farkl', 'Proprioseptif', 'Nromskler', 'Fasilitasyon', 'Tekniklerinin', ',', 'Ar', ',', 'Propriosepsiyon', ',', 'Postural', 'Kontrol', ',', 'Kas', 'Kuvveti', ',', 'Eklem', 'Hareket', 'Akl', 've', 'Diz', 'Fonksiyonlar', 'zerine', 'Olan', 'Etkileri', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', '6', '-', 'week', 'physiotherapy', 'and', 'rehabilitation', 'programs', 'involving', 'different', ""'"", 'Proprioceptive', 'Neuromuscular', 'Facilitation', ""'"", '(', 'PNF', ')', 'techniques', 'in', 'patients', 'with', 'knee', 'osteoarthritis', 'on', 'pain', ',', 'proprioception', ',', 'postural', 'control', ',', 'muscle', 'strength', ',', 'range', 'of', 'motion', 'and', 'knee', 'functions']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03615521,NCT03615521,"Diz Osteoartritinde Farkl Proprioseptif Nromskler Fasilitasyon Tekniklerinin, Ar, Propriosepsiyon, Postural Kontrol, Kas Kuvveti, Eklem Hareket Akl ve Diz Fonksiyonlar zerine Olan Etkileri | The aim of this study is to investigate the effects of 6-week physiotherapy and rehabilitation programs involving different 'Proprioceptive Neuromuscular Facilitation' (PNF) techniques in patients with knee osteoarthritis on pain, proprioception, postural control, muscle strength, range of motion and knee functions","[(266, 307, 'PHYSICAL', 'physiotherapy and rehabilitation programs'), (329, 370, 'PHYSICAL', 'Proprioceptive Neuromuscular Facilitation'), (373, 376, 'PHYSICAL', 'PNF'), (406, 425, 'CONDITION', 'knee osteoarthritis')]"
"['Effects', 'of', 'Psilocybin', 'in', 'Anorexia', 'Nervosa', '|', 'This', 'open', '-', 'label', 'pilot', 'study', 'seeks', 'to', 'investigate', 'the', 'safety', 'and', 'efficacy', 'of', 'psilocybin', 'in', 'persons', 'with', 'chronic', 'anorexia', 'nervosa', '(', 'AN', ')', '.', 'Psilocybin', 'has', 'previously', 'been', 'demonstrated', 'to', 'decrease', 'depression', 'and', 'anxiety', 'and', 'increase', 'long', '-', 'term', 'positive', 'behavior', 'change', 'in', 'other', 'populations', '.', 'The', 'investigators', 'seek', 'to', 'determine', 'whether', 'similar', 'changes', 'can', 'be', 'safely', 'produced', 'in', 'people', 'with', 'AN', 'when', 'psilocybin', 'is', 'administered', 'in', 'a', 'supportive', 'setting', 'with', 'close', 'follow', '-', 'up', '.', 'The', 'investigators', ""'"", 'primary', 'hypotheses', 'are', 'that', 'psilocybin', 'is', 'safe', 'to', 'administer', 'in', 'people', 'with', 'AN', ',', 'that', 'it', 'will', 'reduce', 'measures', 'of', 'anxiety', 'and', 'depression', ',', 'and', 'that', 'it', 'will', 'lead', 'to', 'increased', 'quality', 'of', 'life', '.', 'The', 'investigators', 'will', 'also', 'assess', 'a', 'number', 'of', 'exploratory', 'measures', 'related', 'to', 'eating', 'disorder', 'pathophysiology', '.']","['O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT04052568,NCT04052568,"Effects of Psilocybin in Anorexia Nervosa | This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.","[(11, 21, 'DRUG', 'Psilocybin'), (25, 41, 'CONDITION', 'Anorexia Nervosa'), (120, 130, 'DRUG', 'psilocybin'), (147, 171, 'CONDITION', 'chronic anorexia nervosa'), (173, 175, 'CONDITION', 'AN'), (178, 188, 'DRUG', 'Psilocybin'), (234, 244, 'CONDITION', 'depression'), (249, 256, 'CONDITION', 'anxiety'), (425, 427, 'CONDITION', 'AN'), (433, 443, 'DRUG', 'psilocybin'), (553, 563, 'DRUG', 'psilocybin'), (601, 603, 'CONDITION', 'AN'), (637, 644, 'CONDITION', 'anxiety'), (649, 659, 'CONDITION', 'depression'), (792, 807, 'CONDITION', 'eating disorder')]"
"['Compliance', ',', 'Tolerance', 'and', 'Acceptability', 'of', 'a', 'Tablet', 'Protein', 'Substitute', 'for', 'the', 'Dietary', 'Management', 'of', 'Phenylketonuria', '|', 'Thirty', 'eligible', 'PKU', 'patients', '(', '', '8', 'years', ')', ',', 'identified', 'as', 'tablet', 'protein', 'substitute', 'users', ',', 'will', 'be', 'recruited', '.', 'Patients', 'will', 'firstly', 'observe', 'a', '7', '-', 'day', 'baseline', 'period', ',', 'in', 'which', 'participants', 'will', 'continue', 'with', 'their', 'existing', 'diet', ',', 'protein', 'substitute', 'and', 'multi', 'vitamin', 'prescription', '.', 'Patients', 'will', 'then', 'receive', 'the', 'phaenylalanine', '-', 'free', 'protein', 'substitute', 'tablets', 'daily', 'for', '28', 'days', 'in', 'addition', 'to', 'appropriate', 'nutritional', 'management', '.', 'The', 'aim', 'of', 'this', 'prospective', ',', 'single', 'arm', 'trial', 'is', 'to', 'evaluate', 'the', 'acceptability', '(', 'compliance', ',', 'tolerance', 'and', 'palatability', ')', 'of', 'the', 'phenylalanine', '-', 'free', 'protein', 'substitute', 'tablets', 'in', 'patients', 'with', 'proven', 'PKU', '.', 'The', 'primary', 'outcome', 'measure', 'is', 'compliance', ',', 'with', 'secondary', 'outcome', 'measures', 'of', 'gastrointestinal', 'tolerance', ',', 'acceptability', ',', 'blood', 'amino', 'acids', ',', 'dietary', 'intake', ',', 'anthropometry', 'and', 'safety', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03333720,NCT03333720,"Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria | Thirty eligible PKU patients ( 8 years), identified as tablet protein substitute users, will be recruited. Patients will firstly observe a 7-day baseline period, in which participants will continue with their existing diet, protein substitute and multi vitamin prescription. Patients will then receive the phaenylalanine-free protein substitute tablets daily for 28 days in addition to appropriate nutritional management. The aim of this prospective, single arm trial is to evaluate the acceptability (compliance, tolerance and palatability) of the phenylalanine-free protein substitute tablets in patients with proven PKU. The primary outcome measure is compliance, with secondary outcome measures of gastrointestinal tolerance, acceptability, blood amino acids, dietary intake, anthropometry and safety.","[(52, 70, 'OTHER', 'Protein Substitute'), (101, 116, 'CONDITION', 'Phenylketonuria'), (135, 138, 'CONDITION', 'PKU'), (182, 200, 'OTHER', 'protein substitute'), (426, 464, 'OTHER', 'phaenylalanine-free protein substitute'), (669, 706, 'OTHER', 'phenylalanine-free protein substitute'), (739, 742, 'CONDITION', 'PKU')]"
"['A', 'Multicenter', ',', 'Open', '-', 'label', 'Extension', ',', 'Multiple', 'Dose', ',', 'Parallel', 'Group', 'Study', 'To', 'Investigate', 'The', 'Long', '-', 'term', 'Safety', 'And', 'Tolerability', 'Of', 'Aab-003', '(', 'Pf-05236812', ')', 'Administered', 'Intravenously', 'In', 'Subjects', 'With', 'Mild', 'To', 'Moderate', 'Alzheimer', ""'s"", 'Disease', 'Previously', 'Treated', 'With', 'Aab-003', 'Or', 'Placebo', 'In', 'Protocol', 'B2601001', '|', 'This', 'is', 'a', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'multiple', 'doses', 'of', 'AAB-003', '(', 'PF-05236812', ')', 'in', 'patients', 'with', 'mild', 'to', 'moderate', 'Alzheimer', ""'s"", 'Disease', '.', 'Patients', 'who', 'complete', 'study', 'B2601001', 'may', 'participate', 'in', 'this', 'trial', 'and', 'receive', 'AAB-003', '(', 'PF-05236812', ')', '.', 'Each', 'patient', ""'s"", 'participation', 'will', 'last', 'approximately', '52', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01369225,NCT01369225,"A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001 | This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.","[(129, 136, 'DRUG', 'Aab-003'), (138, 149, 'DRUG', 'Pf-05236812'), (195, 231, 'CONDITION', ""Mild To Moderate Alzheimer's Disease""), (256, 263, 'DRUG', 'Aab-003'), (267, 274, 'CONTROL', 'Placebo'), (375, 382, 'DRUG', 'AAB-003'), (384, 395, 'DRUG', 'PF-05236812'), (414, 450, 'CONDITION', ""mild to moderate Alzheimer's Disease""), (531, 538, 'DRUG', 'AAB-003'), (540, 551, 'DRUG', 'PF-05236812')]"
"['Evaluation', 'of', 'a', 'Program', 'to', 'Increase', 'Upper', 'Limb', 'Recovery', 'After', 'Stroke', '|', 'This', 'study', 'will', 'examine', 'the', 'feasibility', 'and', 'effect', 'of', 'a', 'program', 'that', 'combines', 'exercise', 'and', 'feedback', 'from', 'a', 'wearable', 'device', 'on', 'upper', 'limb', 'movement', 'practice', 'and', 'function', 'in', 'individuals', 'with', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04232163,NCT04232163,Evaluation of a Program to Increase Upper Limb Recovery After Stroke | This study will examine the feasibility and effect of a program that combines exercise and feedback from a wearable device on upper limb movement practice and function in individuals with stroke.,"[(62, 68, 'CONDITION', 'Stroke'), (149, 157, 'PHYSICAL', 'exercise'), (162, 193, 'OTHER', 'feedback from a wearable device'), (259, 265, 'CONDITION', 'stroke')]"
"['A', 'Prospective', ',', 'Randomized', 'Placebo', 'Controlled', 'Pilot', 'Study', 'to', 'Characterize', 'the', 'Intestinal', 'Microbiome', 'and', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Fecal', 'Microbiome', 'Changes', 'Following', 'Weekly', 'Administration', 'of', 'Lyophilized', 'PRIM', '-', 'DJ2727', 'Given', 'Orally', 'in', 'Subjects', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'characterize', 'the', 'intestinal', 'flora', 'in', 'subjects', 'with', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', 'and', 'to', 'determine', 'safety', 'and', 'trends', 'in', 'improvements', 'in', 'diversity', 'of', 'colonic', 'microbiome', 'following', 'fecal', 'microbiota', 'transplantation', '.']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT03026231,NCT03026231,"A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease | The purpose of this study is to characterize the intestinal flora in subjects with Parkinson's Disease (PD) and to determine safety and trends in improvements in diversity of colonic microbiome following fecal microbiota transplantation.","[(26, 33, 'CONTROL', 'Placebo'), (202, 213, 'DRUG', 'PRIM-DJ2727'), (244, 263, 'CONDITION', ""Parkinson's Disease""), (349, 368, 'CONDITION', ""Parkinson's Disease""), (370, 372, 'CONDITION', 'PD'), (470, 502, 'OTHER', 'fecal microbiota transplantation')]"
"['The', 'Effectiveness', 'of', 'Tibial', 'Nerve', 'Mobilization', 'in', 'Patients', 'With', 'Tarsal', 'Tunnel', 'Syndrome', '|', 'This', 'randomized', ',', 'clinical', ',', 'single', '-', 'blinded', ',', 'controlledstudywasinitiallyplannedtoinclude', '35', 'patients', 'diagnosed', 'with', 'tarsal', 'tunnel', 'who', 'applied', 'to', 'Ktahya', 'Health', 'Sciences', 'University', ',', 'Evliya', 'elebi', 'Training', 'and', 'Research', 'Hospital', ',', 'Physical', 'Medicine', 'and', 'Rehabilitation', 'outpatient', 'clinic', '.', 'Patients', 'aged', '20', '-', '55', 'years', 'who', 'were', 'diagnosed', 'with', 'tarsal', 'tunnel', 'syndrome', 'by', 'electromyography', '(', 'EMG', ')', 'in', 'the', 'last', '6', 'months', 'were', 'included', 'in', 'the', 'study', '.', 'The', 'patients', 'were', 'randomized', 'into', 'two', 'groups', 'using', 'the', 'computer', '-', 'assisted', 'randomization', 'method', '.', 'Tibial', 'nerve', 'mobilization', 'and', 'foot', '-', 'ankle', 'range', 'of', 'motion', 'exercises', 'will', 'be', 'given', 'to', 'the', 'study', 'group', ',', 'and', 'only', 'foot', '-', 'ankle', 'joint', 'range', 'of', 'motion', 'exercises', 'will', 'be', 'given', 'to', 'the', 'control', 'group', '.', 'All', 'the', 'patients', 'were', 'evaluated', 'with', 'the', 'Visual', 'Analog', 'Scale', '(', 'VAS', ')', ',', 'Foot', 'Functional', 'Index', '(', 'FFI', ')', ',', 'Neuropathic', 'Pain', 'QuestionnaireN', '(', 'NPQ', ')', 'and', 'Tibial', 'Nerve', 'ultrasonography', 'before', 'the', 'intervention', 'and', 'at', 'the', 'fourth', 'week', 'of', 'intervention', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05307354,NCT05307354,"The Effectiveness of Tibial Nerve Mobilization in Patients With Tarsal Tunnel Syndrome | This randomized, clinical, single-blinded, controlledstudywasinitiallyplannedtoinclude 35 patients diagnosed with tarsal tunnel who applied to Ktahya Health Sciences University, Evliya elebi Training and Research Hospital, Physical Medicine and Rehabilitation outpatient clinic.Patients aged 20-55 years who were diagnosed with tarsal tunnel syndrome by electromyography (EMG) in the last 6 months were included in the study. The patients were randomized into two groups using the computer-assisted randomization method. Tibial nerve mobilization and foot-ankle range of motion exercises will be given to the study group, and only foot-ankle joint range of motion exercises will be given to the control group. All the patients were evaluated with the Visual Analog Scale (VAS), Foot Functional Index (FFI), Neuropathic Pain QuestionnaireN (NPQ) and Tibial Nerve ultrasonography before the intervention and at the fourth week of intervention.","[(21, 46, 'PHYSICAL', 'Tibial Nerve Mobilization'), (64, 86, 'CONDITION', 'Tarsal Tunnel Syndrome'), (203, 216, 'CONDITION', 'tarsal tunnel'), (419, 441, 'CONDITION', 'tarsal tunnel syndrome'), (612, 637, 'PHYSICAL', 'Tibial nerve mobilization'), (642, 678, 'PHYSICAL', 'foot-ankle range of motion exercises'), (717, 764, 'CONTROL', 'only foot-ankle joint range of motion exercises')]"
"['Caregiver', 'Burden', 'and', 'Depression', ':', 'Caring', 'for', 'Those', 'Who', 'Care', 'for', 'Others', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effectiveness', 'of', 'support', 'group', 'intervention', 'for', 'primary', 'caregivers', 'of', 'a', 'person', 'with', 'dementia', 'or', 'similar', 'cognitive', 'impairment', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02690896,NCT02690896,Caregiver Burden and Depression: Caring for Those Who Care for Others | The purpose of this study is to examine the effectiveness of support group intervention for primary caregivers of a person with dementia or similar cognitive impairment.,"[(21, 31, 'CONDITION', 'Depression'), (133, 159, 'BEHAVIOURAL', 'support group intervention')]"
"['A', 'Brief', 'Intervention', 'Targeting', 'Anhedonia', 'in', 'Adolescents', ':', 'a', 'Feasibility', 'Randomised', 'Controlled', 'Trial', '|', 'Depression', 'is', 'a', 'common', 'mental', 'health', 'problem', 'that', 'often', 'begins', 'during', 'adolescence', '.', 'Onset', 'during', 'adolescence', 'can', 'be', 'disruptive', 'to', 'schoolwork', 'and', 'social', 'relationships', 'and', 'if', 'left', 'untreated', 'can', 'lead', 'to', 'recurrence', 'during', 'adulthood', ',', 'as', 'well', 'as', 'the', 'development', 'of', 'other', 'mental', 'health', 'problems', '.', 'Current', 'treatments', 'for', 'depression', '(', 'for', 'both', 'adults', 'and', 'young', 'people', ')', 'largely', 'focus', 'on', 'reducing', 'low', 'mood', 'and', 'do', 'not', 'effectively', 'tackle', 'the', 'other', 'hallmark', 'symptom', 'of', 'depression', ',', 'anhedonia', ',', 'which', 'is', 'characterised', 'as', 'a', 'loss', 'of', 'enjoyment/', 'pleasure', 'for', 'previously', 'enjoyed', 'activities', '.', 'Anhedonia', 'is', 'associated', 'with', 'increased', 'risk', 'of', 'suicidality', ',', 'so', 'should', 'be', 'an', 'important', 'treatment', 'target', '.', 'Whilst', 'some', 'adult', 'treatments', 'are', 'beginning', 'to', 'address', 'anhedonia', ',', 'little', 'research', 'has', 'focussed', 'on', 'young', 'people', '.', 'It', 'can', 'not', 'be', 'assumed', 'that', 'adult', 'treatments', 'will', 'work', 'identically', 'in', 'young', 'people', ',', 'particularly', 's', 'their', 'brains', 'are', 'still', 'maturing', 'compared', 'to', 'adults', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'complete', 'a', 'randomised', 'feasibility', 'trial', ',', 'to', 'see', 'if', 'it', 'is', 'possible', 'to', 'run', 'a', 'brief', 'talking', 'therapy', 'for', 'anhedonia', 'in', 'adolescent', 'depression', ',', 'by', 'targeting', 'one', 'promising', 'cognitive', 'factor', 'known', 'to', 'contribute', 'to', 'low', 'positive', 'affect', ':', 'positive', 'future', 'mental', 'imagery']","['O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05507385,NCT05507385,"A Brief Intervention Targeting Anhedonia in Adolescents: a Feasibility Randomised Controlled Trial | Depression is a common mental health problem that often begins during adolescence. Onset during adolescence can be disruptive to schoolwork and social relationships and if left untreated can lead to recurrence during adulthood, as well as the development of other mental health problems. Current treatments for depression (for both adults and young people) largely focus on reducing low mood and do not effectively tackle the other hallmark symptom of depression, anhedonia, which is characterised as a loss of enjoyment/ pleasure for previously enjoyed activities. Anhedonia is associated with increased risk of suicidality, so should be an important treatment target. Whilst some adult treatments are beginning to address anhedonia, little research has focussed on young people. It cannot be assumed that adult treatments will work identically in young people, particularly s their brains are still maturing compared to adults. The aim of this study is to complete a randomised feasibility trial, to see if it is possible to run a brief talking therapy for anhedonia in adolescent depression, by targeting one promising cognitive factor known to contribute to low positive affect: positive future mental imagery","[(31, 40, 'CONDITION', 'Anhedonia'), (101, 111, 'CONDITION', 'Depression'), (412, 422, 'CONDITION', 'depression'), (553, 563, 'CONDITION', 'depression'), (565, 574, 'CONDITION', 'anhedonia'), (667, 676, 'CONDITION', 'Anhedonia'), (825, 834, 'CONDITION', 'anhedonia'), (1134, 1155, 'BEHAVIOURAL', 'brief talking therapy'), (1160, 1169, 'CONDITION', 'anhedonia'), (1184, 1194, 'CONDITION', 'depression')]"
"['Evaluating', 'the', 'Use', 'of', 'Acute', 'Intermittent', 'Hypoxia', 'to', 'Improve', 'Symptoms', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'overall', 'objective', 'of', 'this', 'project', 'is', 'to', 'investigate', 'the', 'effectiveness', 'of', 'Acute', 'Intermittent', 'Hypoxia', '(', 'AIH', ')', ',', 'to', 'improve', 'muscle', 'strength', 'and', 'activity', 'level', 'in', 'individuals', 'with', 'relapsing', '-', 'remitting', 'MS', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04280484,NCT04280484,"Evaluating the Use of Acute Intermittent Hypoxia to Improve Symptoms in Persons With Multiple Sclerosis | The overall objective of this project is to investigate the effectiveness of Acute Intermittent Hypoxia (AIH), to improve muscle strength and activity level in individuals with relapsing-remitting MS.","[(22, 48, 'OTHER', 'Acute Intermittent Hypoxia'), (85, 103, 'CONDITION', 'Multiple Sclerosis'), (183, 209, 'OTHER', 'Acute Intermittent Hypoxia'), (211, 214, 'OTHER', 'AIH'), (283, 305, 'CONDITION', 'relapsing-remitting MS')]"
"['Efficacy', 'of', 'Inhaled', 'Cannabis', 'Versus', 'Placebo', 'for', 'the', 'Acute', 'Treatment', 'of', 'Migraine', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Crossover', 'Trial', '|', 'This', 'crossover', 'study', 'will', 'evaluate', '3', 'different', 'treatments', 'of', 'vaporized', 'cannabis', '(', 'THC', ',', 'THC', '/', 'CBD', 'mix', ',', 'and', 'CBD', ')', 'and', 'vaporized', 'placebo', 'cannabis', 'for', 'the', 'acute', 'treatment', 'of', 'migraine', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04360044,NCT04360044,"Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial | This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.","[(20, 28, 'OTHER', 'Cannabis'), (36, 43, 'CONTROL', 'Placebo'), (71, 79, 'CONDITION', 'Migraine'), (109, 116, 'CONTROL', 'Placebo'), (218, 226, 'OTHER', 'cannabis'), (228, 231, 'DRUG', 'THC'), (233, 236, 'DRUG', 'THC'), (237, 240, 'DRUG', 'CBD'), (250, 253, 'DRUG', 'CBD'), (259, 285, 'CONTROL', 'vaporized placebo cannabis'), (313, 321, 'CONDITION', 'migraine')]"
"['Memory', 'Consolidation', 'in', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'overarching', 'goal', 'of', 'the', 'research', 'proposed', 'here', 'is', 'to', 'test', 'the', 'hypothesis', '(', 'i', ')', 'that', 'the', 'pathophysiological', 'mechanisms', 'of', 'OSA', 'lead', 'to', 'deterioration', 'in', 'sleep', '-', 'dependent', 'memory', 'consolidation', 'across', 'memory', 'systems', ',', 'with', 'the', 'genetic', 'marker', 'APO4', 'as', 'a', 'modulator', ',', 'and', '(', 'ii', ')', 'that', 'CPAP', 'can', 'reverse', 'some', 'or', 'all', 'of', 'these', 'measured', 'memory', 'deficits', '.', '\n\n', 'In', 'addition', ',', 'we', 'are', 'exploring', 'which', 'aspects', 'of', 'OSA', '(', 'e.g.', ',', 'changes', 'in', 'sleep', 'architecture', ',', 'measures', 'of', 'hypoxemia', ',', 'or', 'the', 'EEG', 'power', 'spectrum', ')', 'most', 'likely', 'impact', 'sleep', '-', 'dependent', 'memory', 'processing', '.', 'To', 'this', 'end', ',', 'we', 'are', 'using', 'specific', 'cognitive', 'tasks', 'for', 'which', 'sleep', '-', 'dependent', 'memory', 'consolidation', 'processes', 'have', 'previously', 'been', 'demonstrated', 'by', 'our', 'group', 'and', 'others', '.', 'In', 'addition', ',', 'we', 'are', 'carrying', 'out', 'quantitative', 'EEG', 'power', 'spectral', 'analyses', ',', 'to', 'delineate', 'abnormal', 'functioning', 'of', 'brain', 'regions', 'with', 'more', 'precision', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01800786,NCT01800786,"Memory Consolidation in Obstructive Sleep Apnea | The overarching goal of the research proposed here is to test the hypothesis (i) that the pathophysiological mechanisms of OSA lead to deterioration in sleep-dependent memory consolidation across memory systems, with the genetic marker APO4 as a modulator, and (ii) that CPAP can reverse some or all of these measured memory deficits.

In addition, we are exploring which aspects of OSA (e.g., changes in sleep architecture, measures of hypoxemia, or the EEG power spectrum) most likely impact sleep-dependent memory processing.To this end, we are using specific cognitive tasks for which sleep-dependent memory consolidation processes have previously been demonstrated by our group and others. In addition, we are carrying out quantitative EEG power spectral analyses, to delineate abnormal functioning of brain regions with more precision.","[(24, 47, 'CONDITION', 'Obstructive Sleep Apnea'), (173, 176, 'CONDITION', 'OSA'), (322, 326, 'OTHER', 'CPAP'), (434, 437, 'CONDITION', 'OSA')]"
"['Effect', 'of', 'Normal', 'and', 'High', 'Protein', 'Diets', 'in', 'Lean', 'Mass', ',', 'Adiposity', ',', 'and', 'Strength', 'in', 'Postmenopausal', 'Women', 'Practitioners', 'of', 'Resistance', 'Exercise', '|', 'This', 'study', 'evaluates', 'the', 'effect', 'of', 'different', 'types', 'of', 'diets', '(', 'high', 'and', 'normal', 'protein', ')', 'on', 'lean', 'and', 'fat', 'mass', ',', 'and', 'strength', 'in', 'postmenopausal', 'women', 'practitioners', 'of', 'resistance', 'exercise', '.', 'Two', 'groups', 'will', 'be', 'created', ':', 'high', 'protein', '(', '1.2', 'protein', 'g', '/', 'body', 'mass', '/', 'day', ')', 'and', 'normal', 'protein', '(', '0.8', 'protein', 'g', '/', 'body', 'mass', '/', 'day', ')', '.', 'The', 'same', 'training', 'will', 'be', 'performed', 'for', 'both', 'groups', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03024125,NCT03024125,"Effect of Normal and High Protein Diets in Lean Mass, Adiposity, and Strength in Postmenopausal Women Practitioners of Resistance Exercise | This study evaluates the effect of different types of diets (high and normal protein) on lean and fat mass, and strength in postmenopausal women practitioners of resistance exercise. Two groups will be created: high protein (1.2 protein g/body mass/day) and normal protein (0.8 protein g/body mass/day). The same training will be performed for both groups.","[(10, 39, 'OTHER', 'Normal and High Protein Diets'), (54, 63, 'CONDITION', 'Adiposity'), (81, 95, 'CONDITION', 'Postmenopausal'), (202, 225, 'OTHER', 'high and normal protein'), (265, 279, 'CONDITION', 'postmenopausal'), (352, 364, 'OTHER', 'high protein'), (399, 413, 'CONTROL', 'normal protein')]"
"['The', 'primary', 'objective', 'was', 'to', 'assess', 'whether', 'long', '-', 'term', 'administration', 'of', 'antihypertensive', 'therapy', 'to', 'elderly', 'subjects', 'with', 'isolated', 'systolic', 'hypertension', 'reduced', 'the', 'combined', 'incidence', 'of', 'fatal', 'and', 'non', '-', 'fatal', 'stroke', '.', 'The', 'secondary', 'objectives', 'were', 'to', 'evaluate', ':', 'the', 'effect', 'of', 'long', '-', 'term', 'antihypertensive', 'therapy', 'on', 'mortality', 'from', 'any', 'cause', 'in', 'elderly', 'people', 'with', 'isolated', 'systolic', 'hypertension', ';', 'possible', 'adverse', 'effects', 'of', 'chronic', 'use', 'of', 'antihypertensive', 'drug', 'treatment', 'in', 'this', 'population', ';', 'the', 'effect', 'of', 'therapy', 'on', 'indices', 'of', 'quality', '-', 'of', '-', 'life', ';', 'the', 'natural', 'history', 'of', 'isolated', 'systolic', 'hypertension', 'in', 'the', 'placebo', 'population', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'O', 'O']",NCT00000514,NCT00000514,The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.,"[(72, 96, 'DRUG', 'antihypertensive therapy'), (122, 152, 'CONDITION', 'isolated systolic hypertension'), (207, 213, 'CONDITION', 'stroke'), (282, 306, 'DRUG', 'antihypertensive therapy'), (358, 388, 'CONDITION', 'isolated systolic hypertension'), (433, 464, 'DRUG', 'antihypertensive drug treatment'), (561, 591, 'CONDITION', 'isolated systolic hypertension'), (599, 606, 'CONTROL', 'placebo')]"
"['The', 'Effect', 'of', 'Functional', 'Electrical', 'Stimulation', 'and', 'Therapeutic', 'Exercise', 'on', 'Functional', 'Properties', 'of', 'Skeletal', 'Muscles', ',', 'Sitting', 'Postural', 'Stability', 'and', 'Quality', 'of', 'Life', 'in', 'Traumatic', 'Spinal', 'Cord', 'Injury', 'Patients', '|', 'Aim', 'of', 'the', 'current', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'functional', 'electrical', 'stimulation', 'and', 'therapeutic', 'exercise', 'on', 'traumatic', 'spinal', 'cord', 'injured', ""participants'skeletal"", 'muscle', 'characteristics', ',', 'sitting', 'balance', ',', 'lung', 'function', 'and', 'quality', 'of', 'life', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03517787,NCT03517787,"The Effect of Functional Electrical Stimulation and Therapeutic Exercise on Functional Properties of Skeletal Muscles, Sitting Postural Stability and Quality of Life in Traumatic Spinal Cord Injury Patients | Aim of the current study is to evaluate the effect functional electrical stimulation and therapeutic exercise on traumatic spinal cord injured participants'skeletal muscle characteristics, sitting balance, lung function and quality of life.","[(14, 47, 'OTHER', 'Functional Electrical Stimulation'), (52, 72, 'PHYSICAL', 'Therapeutic Exercise'), (169, 197, 'CONDITION', 'Traumatic Spinal Cord Injury'), (260, 293, 'OTHER', 'functional electrical stimulation'), (298, 318, 'PHYSICAL', 'therapeutic exercise'), (322, 351, 'CONDITION', 'traumatic spinal cord injured')]"
"['Efficacy', 'And', 'Safety', 'Of', 'Risperidone', 'In', 'The', 'Treatment', 'Of', 'Children', 'With', 'Autistic', 'Disorder', 'And', 'Other', 'Pervasive', 'Developmental', 'Disorders', ':', 'A', 'Canadian', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'an', 'oral', 'solution', 'of', 'risperidone', '(', 'an', 'antipsychotic', 'medication', ')', 'versus', 'placebo', 'in', 'the', 'treatment', 'of', 'behavioral', 'symptoms', 'in', 'children', 'with', 'Pervasive', 'Developmental', 'Disorders', '(', 'PDD', ')', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00261508,NCT00261508,"Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study | The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders (PDD).","[(23, 34, 'DRUG', 'Risperidone'), (69, 86, 'CONDITION', 'Autistic Disorder'), (97, 130, 'CONDITION', 'Pervasive Developmental Disorders'), (171, 178, 'CONTROL', 'Placebo'), (279, 290, 'DRUG', 'risperidone'), (295, 319, 'DRUG', 'antipsychotic medication'), (328, 335, 'CONTROL', 'placebo'), (393, 426, 'CONDITION', 'Pervasive Developmental Disorders'), (428, 431, 'CONDITION', 'PDD')]"
"['Multi', '-', 'centre', 'Randomised', 'Trial', 'to', 'Evaluate', 'the', 'Effect', 'of', 'Early', 'Hypothermia', 'on', 'Neurological', 'Function', 'in', 'Patients', 'With', 'Severe', 'Traumatic', 'Brain', 'Injury', '.', 'Including', 'Renal', 'Sub', 'Study', '|', 'Traumatic', 'brain', 'injury', '(', 'TBI', ')', 'is', 'a', 'leading', 'cause', 'of', 'death', 'and', 'long', 'term', 'disability', ',', 'particularly', 'in', 'young', 'adults', '.', 'Studies', 'from', 'Australia', 'have', 'shown', 'that', 'approximately', 'half', 'of', 'those', 'with', 'severe', 'traumatic', 'brain', 'injury', 'will', 'be', 'severely', 'disabled', 'or', 'dead', '6', 'months', 'post', 'injury', '.', 'Given', 'the', 'young', 'age', 'of', 'many', 'patients', 'with', 'severe', 'TBI', 'and', 'the', 'long', 'term', 'prevalence', 'of', 'major', 'disability', ',', 'the', 'economic', 'and', 'more', 'importantly', 'the', 'social', 'cost', 'to', 'the', 'community', 'is', 'very', 'high', '.', '\n\n', 'Pre', '-', 'hospital', 'and', 'hospital', 'management', 'of', 'patients', 'with', 'severe', 'brain', 'injury', 'focuses', 'on', 'prevention', 'of', 'additional', 'injury', 'due', 'primarily', 'to', 'lack', 'of', 'oxygen', 'and', 'insufficient', 'blood', 'pressure', '.', 'This', 'includes', 'optimising', 'sedation', 'and', 'ventilation', ',', 'maintaining', 'the', 'fluid', 'balance', 'and', 'draining', 'Cerebrospinal', 'Fluid', '(', 'CSF', ')', 'and', 'performing', 'surgery', 'where', 'appropriate', '.', 'In', 'recent', 'years', 'there', 'has', 'been', 'a', 'research', 'focus', 'on', 'specific', 'pharmacologic', 'interventions', ',', 'however', ',', 'to', 'date', ',', 'there', 'has', 'been', 'no', 'treatment', 'that', 'has', 'been', 'associated', 'with', 'improvement', 'of', 'neurological', 'outcomes', '.', '\n\n', 'One', 'treatment', 'that', 'shows', 'promise', 'is', 'the', 'application', 'of', 'hypothermia', '(', 'cooling', ')', '.', 'This', 'treatment', 'is', 'commonly', 'used', 'in', 'Australia', 'to', 'decrease', 'brain', 'injury', 'in', 'patients', 'with', 'brain', 'injury', 'following', 'out', '-', 'of', '-', 'hospital', 'cardiac', 'arrest', '.', 'Cooling', 'is', 'thought', 'to', 'protect', 'the', 'brain', 'using', 'a', 'number', 'of', 'mechanisms', '.', 'There', 'have', 'been', 'a', 'number', 'of', 'animal', 'studies', 'that', 'have', 'looked', 'at', 'how', 'cooling', 'is', 'protective', 'and', 'also', 'some', 'clinical', 'research', 'that', 'suggests', 'some', 'benefit', '.', 'However', 'at', 'the', 'current', 'time', 'there', 'is', 'insufficient', 'evidence', 'to', 'provide', 'enough', 'proof', 'that', 'cooling', 'should', 'be', 'used', 'routinely', 'for', 'patients', 'with', 'brain', 'injury', 'and', 'like', 'all', 'treatments', 'there', 'can', 'be', 'some', 'risks', 'and', 'side', 'effects', '.', '\n\n', 'The', 'POLAR', 'trial', 'has', 'been', 'developed', 'to', 'investigate', 'whether', 'early', 'cooling', 'of', 'patients', 'with', 'severe', 'traumatic', 'brain', 'injury', 'is', 'associated', 'with', 'better', 'outcomes', '.', 'It', 'is', 'a', 'randomised', 'controlled', 'trial', ',', 'which', 'is', 'a', 'type', 'of', 'trial', 'that', 'provides', 'the', 'highest', 'quality', 'of', 'evidence', '.', '\n\n', 'The', 'null', 'hypothesis', 'is', 'that', 'there', 'is', 'no', 'difference', 'in', 'the', 'proportion', 'of', 'favourable', 'neurological', 'outcomes', 'six', 'months', 'after', 'severe', 'traumatic', 'brain', 'injury', 'in', 'patients', 'treated', 'with', 'early', 'and', 'sustained', 'hypothermia', ',', 'compared', 'to', 'standard', 'normothermic', 'management', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT00987688,NCT00987688,"Multi-centre Randomised Trial to Evaluate the Effect of Early Hypothermia on Neurological Function in Patients With Severe Traumatic Brain Injury. Including Renal Sub Study | Traumatic brain injury (TBI) is a leading cause of death and long term disability, particularly in young adults. Studies from Australia have shown that approximately half of those with severe traumatic brain injury will be severely disabled or dead 6 months post injury. Given the young age of many patients with severe TBI and the long term prevalence of major disability, the economic and more importantly the social cost to the community is very high.

Pre-hospital and hospital management of patients with severe brain injury focuses on prevention of additional injury due primarily to lack of oxygen and insufficient blood pressure. This includes optimising sedation and ventilation, maintaining the fluid balance and draining Cerebrospinal Fluid (CSF) and performing surgery where appropriate. In recent years there has been a research focus on specific pharmacologic interventions, however, to date, there has been no treatment that has been associated with improvement of neurological outcomes.

One treatment that shows promise is the application of hypothermia (cooling). This treatment is commonly used in Australia to decrease brain injury in patients with brain injury following out-of-hospital cardiac arrest. Cooling is thought to protect the brain using a number of mechanisms. There have been a number of animal studies that have looked at how cooling is protective and also some clinical research that suggests some benefit. However at the current time there is insufficient evidence to provide enough proof that cooling should be used routinely for patients with brain injury and like all treatments there can be some risks and side effects.

The POLAR trial has been developed to investigate whether early cooling of patients with severe traumatic brain injury is associated with better outcomes. It is a randomised controlled trial, which is a type of trial that provides the highest quality of evidence.

The null hypothesis is that there is no difference in the proportion of favourable neurological outcomes six months after severe traumatic brain injury in patients treated with early and sustained hypothermia, compared to standard normothermic management.","[(62, 73, 'OTHER', 'Hypothermia'), (116, 145, 'CONDITION', 'Severe Traumatic Brain Injury'), (175, 197, 'CONDITION', 'Traumatic brain injury'), (199, 202, 'CONDITION', 'TBI'), (360, 389, 'CONDITION', 'severe traumatic brain injury'), (488, 498, 'CONDITION', 'severe TBI'), (685, 704, 'CONDITION', 'severe brain injury'), (1234, 1245, 'OTHER', 'hypothermia'), (1247, 1254, 'OTHER', 'cooling'), (1344, 1356, 'CONDITION', 'brain injury'), (1399, 1406, 'OTHER', 'Cooling'), (1536, 1543, 'OTHER', 'cooling'), (1706, 1713, 'OTHER', 'cooling'), (1757, 1769, 'CONDITION', 'brain injury'), (1901, 1908, 'OTHER', 'cooling'), (1926, 1955, 'CONDITION', 'severe traumatic brain injury'), (2224, 2253, 'CONDITION', 'severe traumatic brain injury'), (2299, 2310, 'OTHER', 'hypothermia'), (2324, 2356, 'CONTROL', 'standard normothermic management')]"
"['A', 'Phase', '1', 'Study', 'Evaluating', 'the', 'Safety', ',', 'Tolerability', 'and', 'Pharmacokinetics', 'of', 'ABT-888', 'in', 'Combination', 'With', 'Whole', 'Brain', 'Radiation', 'Therapy', 'in', 'Subjects', 'With', 'Brain', 'Metastases', '|', 'This', 'Phase', 'I', 'clinical', 'trial', 'is', 'studying', 'the', 'side', 'effects', 'and', 'best', 'dose', 'of', 'ABT-888', 'when', 'given', 'together', 'with', 'Whole', 'Brain', 'Radiation', 'Therapy', '(', 'WBRT', ')', 'in', 'treating', 'patients', 'with', 'brain', 'metastases', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00649207,NCT00649207,"A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases | This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.","[(76, 83, 'DRUG', 'ABT-888'), (104, 133, 'RADIOTHERAPY', 'Whole Brain Radiation Therapy'), (151, 167, 'CONDITION', 'Brain Metastases'), (244, 251, 'DRUG', 'ABT-888'), (277, 306, 'RADIOTHERAPY', 'Whole Brain Radiation Therapy'), (308, 312, 'RADIOTHERAPY', 'WBRT'), (340, 356, 'CONDITION', 'brain metastases')]"
"['Additional', 'Effects', 'of', 'Motor', 'Imagery', 'Practice', 'With', 'Dual', 'Task', 'Training', 'in', 'Stroke', 'Patients', '|', 'The', 'importance', 'of', 'potent', 'rehabilitation', 'with', 'dual', 'task', 'balance', 'and', 'gait', 'training', 'is', 'improving', 'and', 'also', 'there', 'have', 'been', 'divergent', 'opinions', 'about', 'the', 'effectiveness', 'of', 'Motor', 'Imagery', 'on', 'balance', 'and', 'gait', 'function', '.', 'Dual', 'tasking', 'has', 'also', 'proved', 'beneficial', 'results', 'on', 'stroke', 'patients', '.', 'Mental', 'stimulation', 'with', 'task', 'performance', 'is', 'a', 'new', 'intervention', '..', 'So', 'the', 'purpose', 'of', 'my', 'study', 'is', 'to', 'investigate', 'the', 'combination', 'of', 'Motor', 'Imagery', 'Practice', 'and', 'dual', 'task', 'rehabilitative', 'training', 'on', 'balance', 'and', 'gait', 'targeting', 'the', 'population', 'of', 'post', 'stroke', 'patients']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04086004,NCT04086004,Additional Effects of Motor Imagery Practice With Dual Task Training in Stroke Patients | The importance of potent rehabilitation with dual task balance and gait training is improving and also there have been divergent opinions about the effectiveness of Motor Imagery on balance and gait function. Dual tasking has also proved beneficial results on stroke patients. Mental stimulation with task performance is a new intervention.. So the purpose of my study is to investigate the combination of Motor Imagery Practice and dual task rehabilitative training on balance and gait targeting the population of post stroke patients,"[(22, 44, 'OTHER', 'Motor Imagery Practice'), (50, 68, 'PHYSICAL', 'Dual Task Training'), (72, 78, 'CONDITION', 'Stroke'), (135, 170, 'PHYSICAL', 'dual task balance and gait training'), (255, 268, 'OTHER', 'Motor Imagery'), (299, 311, 'PHYSICAL', 'Dual tasking'), (350, 356, 'CONDITION', 'stroke'), (496, 518, 'OTHER', 'Motor Imagery Practice'), (523, 576, 'PHYSICAL', 'dual task rehabilitative training on balance and gait'), (605, 616, 'CONDITION', 'post stroke')]"
"['A', 'Phase', 'IB', ',', 'Open', '-', 'Label', ',', 'Safety', 'Study', 'of', 'the', 'Combination', 'of', 'Sunitinib', 'and', 'Radiation', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Cancer', '|', 'This', 'study', 'is', 'using', 'the', 'combination', 'of', 'radiation', 'and', 'antiangiogenic', 'agents', '(', 'agents', 'that', 'destroy', 'existing', 'blood', 'vessels', ')', 'seems', 'to', 'be', 'an', 'approach', 'to', 'tumor', 'cure', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT00437372,NCT00437372,"A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer | This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.","[(59, 68, 'DRUG', 'Sunitinib'), (73, 82, 'RADIOTHERAPY', 'Radiation'), (118, 124, 'CONDITION', 'Cancer'), (166, 175, 'RADIOTHERAPY', 'radiation'), (274, 279, 'CONDITION', 'tumor')]"
"['Decreased', 'insulin', 'sensitivity', 'is', 'and', 'independent', 'risk', 'factor', 'for', 'stroke', 'despite', 'glycemic', 'control', '.', 'It', 'is', 'known', 'that', 'physical', 'exercise', 'increases', 'insulin', 'sensitivity', 'in', 'healthy', 'subjects', '.', 'Wether', 'stroke', 'patients', 'can', 'increase', 'insulin', 'sensitivity', 'via', 'physical', 'exercise', 'is', 'not', 'known', '.', '\n\n', 'Chronic', 'low', '-', 'grade', 'inflammation', 'is', 'associated', 'with', 'an', 'increased', 'risk', 'of', 'stroke', '.', 'Physical', 'exercise', 'has', 'shown', 'to', 'increase', 'IL-6', 'directly', 'after', 'exercise', 'in', 'untrained', 'subjects', '.', 'When', 'fitness', 'is', 'increased', 'in', 'each', 'subject', 'then', 'the', 'peak', 'IL-6', 'concentration', 'after', 'exercise', 'decreases', 'and', 'so', 'does', 'the', 'basal', 'level', 'of', 'IL-6', '.', 'It', 'is', 'not', 'known', 'whether', 'stroke', 'patients', 'can', 'increase', 'physical', 'activity', 'level', 'to', 'a', 'degree', 'where', 'chronic', 'inflammation', 'are', 'decreased', '.', '\n\n', 'This', 'study', 'is', 'designed', 'to', 'evaluate', 'if', 'physical', 'exercise', 'after', 'stroke', 'will', 'increases', 'insulin', 'sensitivity', 'and', 'reduce', 'low', '-', 'grade', 'chronic', 'inflammation', '.', '\n\n', 'Stroke', 'patients', 'have', 'been', 'randomized', 'to', 'intervention', 'with', 'physical', 'exercise', 'or', 'control', 'in', 'the', 'ExStroke', 'pilot', 'trial', 'and', 'followed', 'for', '2', 'years', '.', 'Using', 'the', 'study', 'population', 'from', 'the', 'ExStroke', 'pilot', 'trail', 'blood', 'samples', 'will', 'be', 'obtained', 'at', 'the', 'last', 'control', '.', 'Insulin', 'sensitivity', 'can', 'be', 'measured', 'from', 'fasting', 'glucose', 'and', 'insulin', 'using', 'the', 'Homeostasis', 'Model', 'Assessment', '(', 'HOMA', ')', '.', 'Interleukin-6', ',', 'TNF', '-', 'alfa', 'and', 'CRP', 'is', 'measured', 'to', 'estimate', 'chronic', 'inflammation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00376207,NCT00376207,"Decreased insulin sensitivity is and independent risk factor for stroke despite glycemic control. It is known that physical exercise increases insulin sensitivity in healthy subjects. Wether stroke patients can increase insulin sensitivity via physical exercise is not known.

Chronic low-grade inflammation is associated with an increased risk of stroke. Physical exercise has shown to increase IL-6 directly after exercise in untrained subjects. When fitness is increased in each subject then the peak IL-6 concentration after exercise decreases and so does the basal level of IL-6. It is not known whether stroke patients can increase physical activity level to a degree where chronic inflammation are decreased.

This study is designed to evaluate if physical exercise after stroke will increases insulin sensitivity and reduce low-grade chronic inflammation.

Stroke patients have been randomized to intervention with physical exercise or control in the ExStroke pilot trial and followed for 2 years. Using the study population from the ExStroke pilot trail blood samples will be obtained at the last control. Insulin sensitivity can be measured from fasting glucose and insulin using the Homeostasis Model Assessment (HOMA). Interleukin-6, TNF-alfa and CRP is measured to estimate chronic inflammation.","[(65, 71, 'CONDITION', 'stroke'), (115, 132, 'PHYSICAL', 'physical exercise'), (191, 197, 'CONDITION', 'stroke'), (244, 261, 'PHYSICAL', 'physical exercise'), (277, 307, 'CONDITION', 'Chronic low-grade inflammation'), (348, 354, 'CONDITION', 'stroke'), (356, 373, 'PHYSICAL', 'Physical exercise'), (609, 615, 'CONDITION', 'stroke'), (680, 700, 'CONDITION', 'chronic inflammation'), (755, 772, 'PHYSICAL', 'physical exercise'), (779, 785, 'CONDITION', 'stroke'), (832, 862, 'CONDITION', 'low-grade chronic inflammation'), (865, 871, 'CONDITION', 'Stroke'), (923, 940, 'PHYSICAL', 'physical exercise'), (944, 951, 'CONTROL', 'control'), (1287, 1307, 'CONDITION', 'chronic inflammation')]"
"['Weight', 'Management', 'in', 'Spinal', 'Cord', 'Injury', '-', 'Intervention', 'and', 'Monitoring', 'Via', 'Tele', '-', 'Nutrition', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'provide', 'tele', '-', 'nutrition', 'counseling', 'after', 'a', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'During', 'the', 'three', 'months', 'of', 'participation', ',', 'subjects', 'will', 'be', 'given', 'an', 'iPad', 'and', 'the', 'iPad', 'will', 'be', 'used', 'to', 'record', 'meals', 'using', 'a', 'photo', 'journal', 'application', ',', 'YouAte', '.', 'In', 'addition', ',', 'subjects', 'will', 'receive', 'dietary', 'advice', 'two', 'times', 'a', 'month', 'with', 'a', 'registered', 'dietitian', '(', 'RD', ')', '.', 'The', 'dietitian', 'role', 'in', 'the', 'study', 'will', 'be', 'to', 'educate', 'healthy', 'weight', 'management', 'and', 'accommodate', 'any', 'cultural', 'and', 'behavioral', 'habits', '.', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'show', 'that', 'the', 'proposed', 'tele', '-', 'nutrition', 'program', 'will', 'be', 'effective', 'with', 'weight', 'management', 'through', '3', '-', 'month', 'tele', '-', 'nutrition', 'counseling', 'via', 'iPad', 'FaceTime', '.', 'The', 'hypotheses', 'are', '1', ')', 'that', 'weight', 'and', 'waist', 'circumference', 'will', 'not', 'increase', 'after', '3', 'months', 'of', 'tele', '-', 'nutrition', 'program', ',', '2', ')', 'quality', 'of', 'life', 'will', 'improve', ',', 'and', '3', ')', 'quality', 'of', 'diet', 'will', 'improve', '.']","['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03714217,NCT03714217,"Weight Management in Spinal Cord Injury - Intervention and Monitoring Via Tele-Nutrition | The purpose of the study is to provide tele-nutrition counseling after a spinal cord injury (SCI). During the three months of participation, subjects will be given an iPad and the iPad will be used to record meals using a photo journal application, YouAte. In addition, subjects will receive dietary advice two times a month with a registered dietitian (RD). The dietitian role in the study will be to educate healthy weight management and accommodate any cultural and behavioral habits. The objective of this study is to show that the proposed tele-nutrition program will be effective with weight management through 3-month tele-nutrition counseling via iPad FaceTime. The hypotheses are 1) that weight and waist circumference will not increase after 3 months of tele-nutrition program, 2) quality of life will improve, and 3) quality of diet will improve.","[(0, 17, 'BEHAVIOURAL', 'Weight Management'), (21, 39, 'CONDITION', 'Spinal Cord Injury'), (74, 88, 'BEHAVIOURAL', 'Tele-Nutrition'), (130, 155, 'BEHAVIOURAL', 'tele-nutrition counseling'), (164, 182, 'CONDITION', 'spinal cord injury'), (184, 187, 'CONDITION', 'SCI'), (340, 346, 'BEHAVIOURAL', 'YouAte'), (383, 397, 'BEHAVIOURAL', 'dietary advice'), (509, 526, 'BEHAVIOURAL', 'weight management'), (636, 658, 'BEHAVIOURAL', 'tele-nutrition program')]"
"['Effect', 'of', 'Infraorbital', 'and', 'Infratrochlear', 'Nerve', 'Block', 'on', 'Emergence', 'Agitation', 'in', 'Patients', 'Undergoing', 'Septorhinoplasty', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'bilateral', 'infraorbital', 'and', 'infratrochlear', 'nerve', 'block', 'in', 'patients', 'undergoing', 'septorhinoplasty', 'are', 'effective', 'in', 'preventing', 'emergence', 'agitation', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02751268,NCT02751268,Effect of Infraorbital and Infratrochlear Nerve Block on Emergence Agitation in Patients Undergoing Septorhinoplasty: A Randomized Controlled Trial | The purpose of this study is to determine whether bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty are effective in preventing emergence agitation.,"[(10, 53, 'OTHER', 'Infraorbital and Infratrochlear Nerve Block'), (57, 76, 'CONDITION', 'Emergence Agitation'), (100, 116, 'CONDITION', 'Septorhinoplasty'), (200, 253, 'OTHER', 'bilateral infraorbital and infratrochlear nerve block'), (277, 293, 'CONDITION', 'septorhinoplasty'), (322, 341, 'CONDITION', 'emergence agitation')]"
"['Pathophysiology', 'of', 'Non', 'Motor', 'Signs', 'and', 'Compensatory', 'Mechanisms', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'Role', 'of', 'the', 'Serotoninergic', 'and', 'Dopaminergic', 'Lesions', 'Studied', 'by', 'PET', '|', 'Parkinson', ""'s"", 'disease', 'is', 'characterized', 'by', 'a', 'large', 'number', 'of', 'non', 'motor', ',', 'especially', 'neuropsychiatric', ',', 'signs', '.', 'Their', 'pathophysiology', 'is', 'complex', 'but', 'the', 'role', 'of', 'dopaminergic', 'and', 'serotoninergic', 'systems', 'dysfunction', 'is', 'suggested', 'by', 'several', 'studies', '.', 'In', 'addition', ',', 'the', 'serotoninergic', 'system', 'is', 'involved', 'in', 'the', 'pathophysiology', 'of', 'dyskinesias', '.', 'Very', 'few', 'studies', 'have', 'analyzed', 'the', 'abnormalities', 'of', 'these', 'two', 'neurotransmission', 'systems', 'at', 'disease', 'onset', ',', 'in', 'de', 'novo', 'PD', 'patients', '.', 'Furthermore', ',', 'the', 'parallel', 'evolution', 'of', 'the', 'degeneration', 'of', 'the', 'dopaminergic', 'and', 'serotoninergic', 'systems', 'with', 'disease', 'progression', 'remains', 'unknown', '.', 'Thus', 'the', 'present', 'study', 'aims', 'at', 'determining', ',', 'by', 'using', 'PET', 'and', '11C', '-', 'PE2I', 'and', '11C', '-', 'DASB', 'the', 'respective', 'role', 'of', 'the', 'serotoninergic', 'and', 'dopaminergic', 'systems', 'dysfunction', 'in', 'motor', 'and', 'non', 'motor', 'manifestations', 'in', 'PD', ',', 'at', 'different', 'evolution', 'stages', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02038608,NCT02038608,"Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET | Parkinson's disease is characterized by a large number of non motor, especially neuropsychiatric, signs. Their pathophysiology is complex but the role of dopaminergic and serotoninergic systems dysfunction is suggested by several studies. In addition, the serotoninergic system is involved in the pathophysiology of dyskinesias. Very few studies have analyzed the abnormalities of these two neurotransmission systems at disease onset, in de novo PD patients. Furthermore, the parallel evolution of the degeneration of the dopaminergic and serotoninergic systems with disease progression remains unknown. Thus the present study aims at determining, by using PET and 11C-PE2I and 11C-DASB the respective role of the serotoninergic and dopaminergic systems dysfunction in motor and non motor manifestations in PD, at different evolution stages.","[(66, 85, 'CONDITION', ""Parkinson's Disease""), (156, 175, 'CONDITION', ""Parkinson's disease""), (602, 604, 'CONDITION', 'PD'), (963, 965, 'CONDITION', 'PD')]"
"['Evaluation', 'of', 'Bioequivalence', 'of', 'Lamotrigine', 'Tablets', 'in', 'Epileptic', 'Patients', '|', 'In', 'this', 'study', ',', 'brand', 'name', 'lamotrigine', '(', 'LAMICTAL', ')', 'and', 'generic', 'lamotrigine', 'will', 'be', 'compared', 'in', 'patients', 'with', 'epilepsy', '.', 'Both', 'the', 'brand', 'name', 'and', 'generic', 'lamotrigine', 'are', 'approved', 'by', 'the', 'Food', 'and', 'Drug', 'Administration', '(', 'FDA', ')', 'and', 'are', 'commonly', 'used', 'to', 'treat', 'epilepsy', '.', 'Some', 'physicians', 'and', 'patients', 'with', 'epilepsy', 'have', 'believed', 'that', 'brand', 'and', 'generic', 'lamotrigine', 'have', 'had', 'clinically', 'significant', 'differences', 'in', 'efficacy', 'and', 'tolerability', '.', 'The', 'brand', 'name', 'and', 'generic', 'tablets', 'have', 'been', 'shown', 'to', 'be', 'the', 'same', 'when', 'blood', 'levels', 'were', 'measured', 'in', 'healthy', 'volunteers', 'without', 'epilepsy', ',', 'but', 'these', 'drugs', 'have', 'not', 'yet', 'been', 'compared', 'in', 'patients', 'with', 'epilepsy', '.', 'This', 'study', 'will', 'do', 'this', 'comparison', ',', 'by', 'switching', 'patients', 'between', 'brand', 'and', 'generic', 'in', 'a', 'very', 'structured', 'manner', ',', 'and', 'seeing', 'if', 'the', 'drugs', 'are', 'the', 'same', ',', 'primarily', 'in', 'terms', 'of', 'blood', 'levels', '.', 'Other', 'comparisons', 'will', 'also', 'be', 'made', 'secondarily', ',', 'looking', 'for', 'any', 'differences', 'in', 'adverse', 'effects', 'and', 'seizure', 'control', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT01995825,NCT01995825,"Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients | In this study, brand name lamotrigine (LAMICTAL) and generic lamotrigine will be compared in patients with epilepsy. Both the brand name and generic lamotrigine are approved by the Food and Drug Administration (FDA) and are commonly used to treat epilepsy. Some physicians and patients with epilepsy have believed that brand and generic lamotrigine have had clinically significant differences in efficacy and tolerability. The brand name and generic tablets have been shown to be the same when blood levels were measured in healthy volunteers without epilepsy, but these drugs have not yet been compared in patients with epilepsy. This study will do this comparison, by switching patients between brand and generic in a very structured manner, and seeing if the drugs are the same, primarily in terms of blood levels. Other comparisons will also be made secondarily, looking for any differences in adverse effects and seizure control.","[(32, 43, 'DRUG', 'Lamotrigine'), (55, 64, 'CONDITION', 'Epileptic'), (102, 113, 'DRUG', 'lamotrigine'), (115, 123, 'DRUG', 'LAMICTAL'), (137, 148, 'DRUG', 'lamotrigine'), (183, 191, 'CONDITION', 'epilepsy'), (225, 236, 'DRUG', 'lamotrigine'), (323, 331, 'CONDITION', 'epilepsy'), (367, 375, 'CONDITION', 'epilepsy'), (413, 424, 'DRUG', 'lamotrigine'), (627, 635, 'CONDITION', 'epilepsy'), (697, 705, 'CONDITION', 'epilepsy'), (994, 1001, 'CONDITION', 'seizure')]"
"['A', 'Single', '-', 'Center', 'Pharmacoeconomic', 'Pilot', 'Study', 'of', 'BOTOX', '', '(', 'Botulinum', 'Toxin', 'Type', 'A', ')', 'for', 'the', 'Prophylactic', 'Treatment', 'of', 'Migraine', 'Headaches', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', 'to', 'assess', 'whether', 'subjects', 'treated', 'with', 'BOTOX', 'will', ':', '\n\n', 'have', 'a', 'decrease', 'in', 'the', 'frequency', 'and', 'intensity', 'of', 'migraine', 'headaches', '\n', 'experience', 'improvements', 'in', 'quality', 'of', 'life', '\n', 'experience', 'a', 'reduction', 'in', 'the', 'frequency', 'of', 'health', 'care', 'services', 'obtained', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00850421,NCT00850421,"A Single-Center Pharmacoeconomic Pilot Study of BOTOX (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches | The purposes of this study are to assess whether subjects treated with BOTOX will:

have a decrease in the frequency and intensity of migraine headaches
experience improvements in quality of life
experience a reduction in the frequency of health care services obtained.","[(48, 53, 'DRUG', 'BOTOX'), (56, 78, 'DRUG', 'Botulinum Toxin Type A'), (114, 132, 'CONDITION', 'Migraine Headaches'), (206, 211, 'DRUG', 'BOTOX'), (269, 287, 'CONDITION', 'migraine headaches')]"
"['Effect', 'of', 'Augmentation', 'of', 'Cerebral', 'Blood', 'Flow', 'on', 'Neuropsychometric', 'Performance', 'After', 'Carotid', 'Endarterectomy', 'in', 'Type', 'II', 'Diabetic', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'we', 'can', 'reduce', 'the', 'incidence', 'of', 'cognitive', 'dysfunction', '-', 'difficulty', 'in', 'performing', 'certain', 'pencil', '-', 'paper', ',', 'memory', ',', 'finger', 'dexterity', 'and', 'thinking', 'type', 'of', 'tasks', 'called', 'neuropsychometric', 'tests', '-', 'in', 'patients', 'with', 'adult', 'onset', 'diabetes', 'mellitus', '(', 'DM', ')', 'undergoing', 'surgery', 'on', 'the', 'carotid', 'artery', '(', 'CEA', ')', '.', '\n\n', 'We', 'hypothesize', 'that', 'cognitive', 'dysfunction', 'can', 'be', 'decreased', 'in', 'patients', 'with', 'type', 'II', 'DM', 'by', 'augmenting', 'cerebral', 'blood', 'flow', 'with', 'a', 'shunt', 'during', 'carotid', 'endarterectomy', 'compared', 'to', 'patients', 'with', 'Type', 'II', 'DM', 'who', 'are', 'treated', 'with', '""', 'conventional', '""', 'management', 'in', 'which', 'a', 'shunt', 'is', 'placed', 'only', 'if', 'the', 'electroencephalogram', '(', 'EEG', ')', 'indicates', 'cerebral', 'ischemia', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00597545,NCT00597545,"Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients | The purpose of this study is to determine if we can reduce the incidence of cognitive dysfunction - difficulty in performing certain pencil-paper, memory, finger dexterity and thinking type of tasks called neuropsychometric tests - in patients with adult onset diabetes mellitus (DM) undergoing surgery on the carotid artery (CEA).

We hypothesize that cognitive dysfunction can be decreased in patients with type II DM by augmenting cerebral blood flow with a shunt during carotid endarterectomy compared to patients with Type II DM who are treated with ""conventional"" management in which a shunt is placed only if the electroencephalogram (EEG) indicates cerebral ischemia.","[(10, 45, 'OTHER', 'Augmentation of Cerebral Blood Flow'), (85, 107, 'CONDITION', 'Carotid Endarterectomy'), (111, 127, 'CONDITION', 'Type II Diabetic'), (215, 236, 'CONDITION', 'cognitive dysfunction'), (400, 417, 'CONDITION', 'diabetes mellitus'), (419, 421, 'CONDITION', 'DM'), (434, 463, 'CONDITION', 'surgery on the carotid artery'), (465, 468, 'CONDITION', 'CEA'), (492, 513, 'CONDITION', 'cognitive dysfunction'), (548, 558, 'CONDITION', 'type II DM'), (600, 605, 'OTHER', 'shunt'), (613, 635, 'CONDITION', 'carotid endarterectomy'), (662, 672, 'CONDITION', 'Type II DM'), (694, 719, 'CONTROL', '""conventional"" management'), (731, 736, 'OTHER', 'shunt'), (796, 813, 'CONDITION', 'cerebral ischemia')]"
"['A', 'Trial', 'of', 'Memantine', 'as', 'Symptomatic', 'Treatment', 'for', 'Early', 'Huntington', 'Disease', ';', 'a', 'Phase', 'IIb', 'Study', '|', 'Huntington', 'disease', 'is', 'characterized', 'by', 'difficulties', 'in', 'movement', 'and', 'thinking', '.', 'Psychological', 'disturbances', 'including', 'irritability', ',', 'aggression', ',', 'loss', 'of', 'interest', ',', 'depressed', 'mood', ',', 'obsessions', 'and', 'compulsions', ',', 'also', 'represent', 'common', 'symptoms', 'of', 'HD', '.', 'These', 'symptoms', 'are', 'distressing', 'both', 'for', 'HD', 'patients', 'and', 'their', 'caregivers', ',', 'contribute', 'to', 'the', 'loss', 'of', 'ability', 'to', 'carry', 'out', 'activities', 'of', 'daily', 'living', ',', 'and', 'present', 'a', 'major', 'treatment', 'challenge', 'for', 'physicians', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'memantine', 'on', 'movement', ',', 'thinking', 'and', 'emotional', 'difficulties', 'in', 'HD', 'patients', '.', 'Memantine', 'is', 'a', 'medication', 'originally', 'approved', 'for', 'the', 'treatment', 'of', 'aggression', 'and', 'agitation', 'in', 'patients', 'with', 'moderate', '-', 'to', '-', 'severe', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', ',', 'which', 'has', 'also', 'recently', 'been', 'shown', 'to', 'improve', 'the', 'behavioural', 'and', 'neuropathological', 'symptoms', 'in', 'a', 'mouse', 'model', 'of', 'Huntington', 'Disease', '(', 'HD', ')', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01458470,NCT01458470,"A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study | Huntington disease is characterized by difficulties in movement and thinking. Psychological disturbances including irritability, aggression, loss of interest, depressed mood, obsessions and compulsions, also represent common symptoms of HD. These symptoms are distressing both for HD patients and their caregivers, contribute to the loss of ability to carry out activities of daily living, and present a major treatment challenge for physicians. The goal of this study is to determine the effect of memantine on movement, thinking and emotional difficulties in HD patients. Memantine is a medication originally approved for the treatment of aggression and agitation in patients with moderate-to-severe Alzheimer's disease (AD), which has also recently been shown to improve the behavioural and neuropathological symptoms in a mouse model of Huntington Disease (HD).","[(11, 20, 'DRUG', 'Memantine'), (50, 74, 'CONDITION', 'Early Huntington Disease'), (96, 114, 'CONDITION', 'Huntington disease'), (211, 223, 'CONDITION', 'irritability'), (225, 235, 'CONDITION', 'aggression'), (237, 253, 'CONDITION', 'loss of interest'), (255, 264, 'CONDITION', 'depressed'), (271, 281, 'CONDITION', 'obsessions'), (286, 297, 'CONDITION', 'compulsions'), (333, 335, 'CONDITION', 'HD'), (377, 379, 'CONDITION', 'HD'), (595, 604, 'DRUG', 'memantine'), (657, 659, 'CONDITION', 'HD'), (670, 679, 'DRUG', 'Memantine'), (737, 747, 'CONDITION', 'aggression'), (752, 761, 'CONDITION', 'agitation'), (937, 955, 'CONDITION', 'Huntington Disease'), (957, 959, 'CONDITION', 'HD')]"
"['A', 'Long', '-', 'Term', 'Study', 'of', 'MP-214', 'in', 'Patients', 'With', 'Receiving', 'Multiple', 'Drugs', 'Schizophrenia', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', ',', 'tolerability', ',', 'and', 'efficacy', 'of', 'MP-214', 'in', 'patients', 'with', 'receiving', 'multiple', 'drugs', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01626885,NCT01626885,"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia | The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.","[(21, 27, 'DRUG', 'MP-214'), (45, 83, 'CONDITION', 'Receiving Multiple Drugs Schizophrenia'), (181, 187, 'DRUG', 'MP-214'), (205, 243, 'CONDITION', 'receiving multiple drugs schizophrenia')]"
"['Phase', 'I', ',', 'Open', '-', 'Label', ',', 'Randomized', ',', 'Parallel', 'Study', 'to', 'Evaluate', 'the', 'Pharmacokinetics', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'One', 'Intramuscular', 'Injection', 'of', 'Risperidone', 'ISM', '', 'at', 'Different', 'Dose', 'Strengths', 'in', 'Subjects', 'With', 'Schizophrenia', 'or', 'Schizoaffective', 'Disorder', '|', 'This', 'clinical', 'trial', 'is', 'designed', 'to', 'evaluate', 'different', 'dosages', 'of', 'risperidone', 'ISM', ',', 'a', 'new', 'long', '-', 'acting', 'injectable', 'form', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01788774,NCT01788774,"Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder | This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.","[(141, 152, 'DRUG', 'Risperidone'), (203, 216, 'CONDITION', 'Schizophrenia'), (220, 244, 'CONDITION', 'Schizoaffective Disorder'), (312, 323, 'DRUG', 'risperidone')]"
"['A', 'Pilot', 'Feasibility', 'Study', 'of', 'a', 'Co', '-', 'constructed', 'Program', '(', 'Patients', '-', 'Experts', ')', 'of', 'Mindfulness', 'Meditation', 'Adapted', 'to', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '.', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'feasibility', '(', 'primary', 'objective', ')', 'and', 'the', 'effects', '(', 'secondary', 'objectives', ')', 'of', 'an', 'Mindfulness', 'Based', 'Stress', 'Reduction', '(', 'MBSR', ')', 'program', 'adapted', 'specifically', 'for', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05622396,NCT05622396,A Pilot Feasibility Study of a Co-constructed Program (Patients - Experts) of Mindfulness Meditation Adapted to Patients With Parkinson's Disease. | The objective of this study is to determine the feasibility (primary objective) and the effects (secondary objectives) of an Mindfulness Based Stress Reduction (MBSR) program adapted specifically for patients with Parkinson's disease.,"[(78, 100, 'BEHAVIOURAL', 'Mindfulness Meditation'), (126, 145, 'CONDITION', ""Parkinson's Disease""), (274, 308, 'BEHAVIOURAL', 'Mindfulness Based Stress Reduction'), (310, 314, 'BEHAVIOURAL', 'MBSR'), (363, 382, 'CONDITION', ""Parkinson's disease"")]"
"['Interventional', 'Testing', 'of', 'Gene', '-', 'environment', 'Interactions', 'Via', 'the', 'Verifomics', 'Mobile', 'Application', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'interactions', 'between', 'genes', ',', 'lifestyle', 'environmental', 'factors', 'like', 'foods', ',', 'nutritional', 'supplements', 'and', 'non', '-', 'invasive', 'medical', 'devices', 'and', 'health', 'factors', 'that', 'can', 'be', 'measured', 'without', 'specialized', 'medical', 'equipment', 'in', 'order', 'to', 'develop', 'lifestyle', 'recommendations', 'tailored', 'to', 'individual', 'genetics', 'for', 'a', 'host', 'of', 'common', 'chronic', 'health', 'conditions', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02758990,NCT02758990,"Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application | The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized medical equipment in order to develop lifestyle recommendations tailored to individual genetics for a host of common chronic health conditions.",[]
"['Safety', 'and', 'Feasibility', 'of', 'a', 'Protocol', 'of', 'Targeted', 'Temperature', 'Management', 'After', 'Intracerebral', 'Hemorrhage', '|', 'Though', 'TTM', 'is', 'ubiquitously', 'used', 'in', 'the', 'neuro', '-', 'intensive', 'care', 'unit', ',', 'there', 'is', 'limited', 'experience', 'with', 'the', 'use', 'of', 'TTM', 'after', 'intracerebral', 'hemorrhage', '(', 'ICH', ')', ',', 'the', 'most', 'devastating', 'type', 'of', 'stroke', '.', 'TTM', 'may', 'be', 'a', 'an', 'intervention', 'to', 'improve', 'patient', 'outcomes', '.', 'This', 'trial', 'addresses', 'the', 'safety', 'and', 'tolerability', 'of', 'a', 'protocol', 'of', 'ultra', '-', 'early', 'TTM', 'after', 'ICH', '/', 'IPH', 'and', 'may', 'be', 'the', 'basis', 'for', 'future', 'larger', 'clinical', 'trials', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01607151,NCT01607151,"Safety and Feasibility of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage | Though TTM is ubiquitously used in the neuro-intensive care unit, there is limited experience with the use of TTM after intracerebral hemorrhage (ICH), the most devastating type of stroke. TTM may be a an intervention to improve patient outcomes. This trial addresses the safety and tolerability of a protocol of ultra-early TTM after ICH/IPH and may be the basis for future larger clinical trials.","[(40, 71, 'OTHER', 'Targeted Temperature Management'), (78, 102, 'CONDITION', 'Intracerebral Hemorrhage'), (112, 115, 'OTHER', 'TTM'), (215, 218, 'OTHER', 'TTM'), (225, 249, 'CONDITION', 'intracerebral hemorrhage'), (251, 254, 'CONDITION', 'ICH'), (286, 292, 'CONDITION', 'stroke'), (294, 297, 'OTHER', 'TTM'), (418, 433, 'OTHER', 'ultra-early TTM'), (440, 443, 'CONDITION', 'ICH'), (444, 447, 'CONDITION', 'IPH')]"
"['SHARED', 'DECISION', 'MAKING', 'ON', 'A', ""'"", 'LIFE', '-', 'AND', '-', 'CARE', 'PLAN', ""'"", 'IN', 'LONG', '-', 'TERM', 'CARE', 'FACILITIES', '|', 'Shared', 'Decision', 'Making', '(', 'SDM', ')', 'is', 'defined', 'as', 'a', 'process', 'where', 'healthcare', 'professionals', 'and', 'patients', 'make', 'decisions', 'together', ',', 'using', 'the', 'best', 'available', 'evidence', '.', 'SDM', ',', 'as', 'a', 'communication', 'and', 'decision', 'method', ',', 'can', 'be', 'used', 'also', 'with', 'persons', 'suffering', 'from', 'dementia', '.', 'Yet', ',', 'SDM', 'with', 'persons', 'with', 'dementia', 'or', 'even', 'with', 'their', 'family', 'caregivers', 'is', 'not', 'widespread', '.', '\n\n', 'The', 'present', 'research', 'project', 'aims', 'to', 'develop', 'and', 'evaluate', 'an', 'SDM', 'framework', 'in', 'care', 'planning', 'to', 'be', 'implemented', 'in', 'long', '-', 'term', 'care', 'facilities', ',', 'in', 'order', 'to', 'obtain', 'a', 'constantly', 'developing', 'care', 'plan', 'that', 'focuses', 'not', 'only', 'on', 'the', 'medical', ',', 'physical', ',', 'psychosocial', 'and', 'spiritual', 'needs', 'of', 'the', 'resident', ',', 'but', 'that', 'considers', 'and', 'documents', 'his', 'preferences', 'and', 'the', 'actions', 'taken', 'by', 'caregivers', 'to', 'meet', 'them', '.', '\n\n', 'The', 'current', 'project', 'is', 'a', 'controlled', 'exploratory', 'study', '.', 'Case', 'studies', 'that', 'involve', 'a', 'triad', 'in', 'each', 'case', ',', 'composed', 'by', 'the', 'resident', 'with', 'moderate', 'or', 'severe', 'dementia', ',', 'his', 'family', 'caregiver', 'and', 'the', 'professional', 'usually', 'taking', 'care', 'for', 'the', 'resident', ',', 'will', 'be', 'used', '(', 'n=16', 'professionals', ';', 'n=40', 'residents', ';', 'n=40', 'family', 'caregivers', ')', '.', 'Professional', 'caregivers', 'of', 'two', 'nursing', 'homes', ',', 'one', 'located', 'in', 'Italy', 'and', 'one', 'in', 'the', 'Netherlands', ',', 'will', 'receive', 'a', 'specific', 'training', 'in', 'SDM', 'principles', 'and', 'will', 'guide', 'the', 'SDM', 'interview', 'within', 'the', 'triad', '.', 'Primary', 'outcome', 'will', 'be', 'the', 'proportion', 'of', 'residents', 'whose', 'preferences', 'and', 'needs', ',', 'together', 'with', 'the', 'related', 'actions', 'to', 'meet', 'them', ',', 'are', 'known', ',', 'documented', 'and', 'satisfied', 'in', 'their', ""'"", 'life', '-', 'and', '-', 'care', 'plans', ""'"", '.', 'Secondary', 'outcomes', 'are', 'the', 'residents', ""'"", 'and', 'family', 'caregivers', ""'"", 'quality', 'of', 'life', ';', 'the', 'family', 'caregivers', ""'"", 'sense', 'of', 'competence', 'and', 'the', 'healthcare', 'professionals', ""'"", 'job', 'satisfaction', '.', 'Semi', '-', 'structured', 'interviews', 'and', 'focus', 'group', 'interviews', 'will', 'be', 'performed', 'to', 'assess', 'satisfaction', 'with', 'the', 'intervention', 'and', 'barriers', 'and', 'facilitators', 'to', 'its', 'implementation', '.', 'Assessments', 'are', 'performed', 'at', 'baseline', 'and', 'six', 'months', 'after', 'the', 'intervention', '.', '\n\n', 'We', 'hypothesize', 'that', 'the', 'use', 'of', 'the', 'SDM', 'process', 'in', 'care', 'planning', 'will', 'increase', 'the', 'number', 'of', 'met', 'needs', 'and', 'will', 'improve', 'the', 'residents', ""'"", 'and', 'family', 'caregivers', 'quality', 'of', 'life', ',', 'the', 'family', 'caregivers', ""'"", 'sense', 'of', 'competence', 'and', 'the', 'healthcare', 'professionals', ""'"", 'job', 'satisfaction', '.', '\n\n', 'The', 'key', 'element', 'of', 'this', 'study', 'is', 'that', 'it', 'will', 'contribute', 'to', 'our', 'knowledge', 'about', 'the', 'efficacy', 'and', 'feasibility', 'of', 'an', 'SDM', 'framework', 'in', 'care', 'planning', 'in', 'long', '-', 'term', 'care', 'facilities', 'with', 'persons', 'with', 'moderate', 'to', 'severe', 'dementia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT02118701,NCT02118701,"SHARED DECISION MAKING ON A 'LIFE-AND-CARE PLAN' IN LONG-TERM CARE FACILITIES | Shared Decision Making (SDM) is defined as a process where healthcare professionals and patients make decisions together, using the best available evidence. SDM, as a communication and decision method, can be used also with persons suffering from dementia. Yet, SDM with persons with dementia or even with their family caregivers is not widespread.

The present research project aims to develop and evaluate an SDM framework in care planning to be implemented in long-term care facilities, in order to obtain a constantly developing care plan that focuses not only on the medical, physical, psychosocial and spiritual needs of the resident, but that considers and documents his preferences and the actions taken by caregivers to meet them.

The current project is a controlled exploratory study. Case studies that involve a triad in each case, composed by the resident with moderate or severe dementia, his family caregiver and the professional usually taking care for the resident, will be used (n=16 professionals; n=40 residents; n=40 family caregivers). Professional caregivers of two nursing homes, one located in Italy and one in the Netherlands, will receive a specific training in SDM principles and will guide the SDM interview within the triad. Primary outcome will be the proportion of residents whose preferences and needs, together with the related actions to meet them, are known, documented and satisfied in their 'life-and-care plans'. Secondary outcomes are the residents' and family caregivers' quality of life; the family caregivers' sense of competence and the healthcare professionals' job satisfaction. Semi-structured interviews and focus group interviews will be performed to assess satisfaction with the intervention and barriers and facilitators to its implementation. Assessments are performed at baseline and six months after the intervention.

We hypothesize that the use of the SDM process in care planning will increase the number of met needs and will improve the residents' and family caregivers quality of life, the family caregivers' sense of competence and the healthcare professionals' job satisfaction.

The key element of this study is that it will contribute to our knowledge about the efficacy and feasibility of an SDM framework in care planning in long-term care facilities with persons with moderate to severe dementia.","[(80, 102, 'OTHER', 'Shared Decision Making'), (104, 107, 'OTHER', 'SDM'), (327, 335, 'CONDITION', 'dementia'), (342, 345, 'OTHER', 'SDM'), (364, 372, 'CONDITION', 'dementia'), (491, 494, 'OTHER', 'SDM'), (954, 981, 'CONDITION', 'moderate or severe dementia'), (1269, 1272, 'OTHER', 'SDM'), (1303, 1316, 'OTHER', 'SDM interview'), (1988, 1991, 'OTHER', 'SDM'), (2337, 2340, 'OTHER', 'SDM'), (2415, 2442, 'CONDITION', 'moderate to severe dementia')]"
"['A', 'Pilot', 'Study', 'of', 'Mitoxantrone', 'for', 'the', 'Treatment', 'of', 'Recurrent', 'Neuromyelitis', 'Optica', '(', 'Devic', ""'s"", 'Disease', ')', '|', 'Neuromyelitis', 'optica', '(', 'NMO', ')', 'is', 'a', 'severe', 'demyelinating', 'disease', 'that', 'selectively', 'involves', 'the', 'optic', 'nerves', 'and', 'the', 'spinal', 'cord', 'but', 'usually', 'spares', 'the', 'brain', '.', 'NMO', 'is', 'considered', 'to', 'have', 'a', 'B', 'cell', 'induced', 'pathogenesis', '.', 'Mitoxantrone', '(', 'MITO', ',', 'Novantrone', '', ')', ',', 'a', 'synthetic', 'anthracenedione', 'approved', 'for', 'worsening', 'relapsing', '-', 'remitting', 'multiple', 'sclerosis', '(', 'MS', ')', 'and', 'secondary', 'progressive', 'MS', ',', 'has', 'been', 'shown', 'to', 'primarily', 'suppress', 'the', 'humoral', 'response', '.', 'We', 'conducted', 'a', 'prospective', '2', '-', 'year', 'study', 'to', 'evaluate', 'the', 'benefit', 'of', 'MITO', 'in', 'five', 'relapsing', 'NMO', 'patients', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT00304291,NCT00304291,"A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) | Neuromyelitis optica (NMO) is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. NMO is considered to have a B cell induced pathogenesis. Mitoxantrone (MITO, Novantrone), a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, has been shown to primarily suppress the humoral response. We conducted a prospective 2-year study to evaluate the benefit of MITO in five relapsing NMO patients.","[(17, 29, 'DRUG', 'Mitoxantrone'), (51, 81, 'CONDITION', 'Recurrent Neuromyelitis Optica'), (83, 98, 'CONDITION', ""Devic's Disease""), (102, 122, 'CONDITION', 'Neuromyelitis optica'), (124, 127, 'CONDITION', 'NMO'), (256, 259, 'CONDITION', 'NMO'), (313, 325, 'DRUG', 'Mitoxantrone'), (327, 331, 'DRUG', 'MITO'), (333, 343, 'DRUG', 'Novantrone'), (359, 374, 'DRUG', 'anthracenedione'), (398, 436, 'CONDITION', 'relapsing-remitting multiple sclerosis'), (438, 440, 'CONDITION', 'MS'), (446, 470, 'CONDITION', 'secondary progressive MS'), (598, 602, 'DRUG', 'MITO'), (611, 624, 'CONDITION', 'relapsing NMO')]"
"['Phase', '2', 'Multi', 'Center', 'Prospective', 'Rand', '.', 'Double', 'Blind', 'Placebo', 'Cont', '.', 'Parallel', 'Design', 'Study', 'to', 'Evaluate', 'Safety', '&', 'Efficacy', 'of', 'Topical', 'Sirolimus', 'for', 'Cutaneous', 'Angiofibromas', 'in', 'Subjects', 'W/', 'Tuberous', 'Sclerosis', 'Complex', 'Followed', 'by', 'Opt', '.', 'Open', 'Label', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'sirolimus', '(', '0.2', '%', 'and', '0.4', '%', 'formulations', ')', 'and', 'its', 'vehicle', 'when', 'applied', 'topically', 'once', 'daily', 'for', '12', 'weeks', 'for', 'the', 'treatment', 'of', 'cutaneous', 'angiofibromas', 'in', 'pediatric', 'subjects', 'with', 'tuberous', 'sclerosis', 'complex', '(', 'TSC', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT03363763,NCT03363763,Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label | The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric subjects with tuberous sclerosis complex (TSC).,"[(129, 138, 'DRUG', 'Sirolimus'), (143, 166, 'CONDITION', 'Cutaneous Angiofibromas'), (182, 208, 'CONDITION', 'Tuberous Sclerosis Complex'), (309, 318, 'DRUG', 'sirolimus'), (432, 455, 'CONDITION', 'cutaneous angiofibromas'), (483, 509, 'CONDITION', 'tuberous sclerosis complex'), (511, 514, 'CONDITION', 'TSC')]"
"['The', 'Impact', 'of', 'Dementia', 'on', 'Care', 'and', 'Outcomes', 'Associated', 'With', 'a', 'Function', 'Focused', 'Care', 'Intervention', 'Among', 'Residents', 'in', 'Assisted', 'Living', 'Settings', '.', '|', 'This', 'study', 'will', 'evaluate', 'pain', ',', 'management', 'of', 'pain', ',', 'behavioral', 'symptoms', ',', 'and', 'the', 'quality', 'of', 'staff', '-', 'resident', 'interactions', 'between', 'residents', 'with', 'and', 'without', 'dementia', ',', 'test', 'the', 'relationship', 'of', 'these', 'variables', 'to', 'participation', 'in', 'function', 'focused', 'care', 'at', 'baseline', ',', 'and', 'consider', 'if', 'there', 'is', 'a', 'differential', 'impact', 'of', 'FFC', '-', 'AL', '-', 'EIT', 'between', 'those', 'with', 'and', 'without', 'dementia', 'with', 'regard', 'to', 'participation', 'in', 'function', 'focused', 'care', ',', 'functional', 'outcomes', 'and', 'physical', 'activity', 'over', 'the', '12', 'month', 'study', 'period', '.', 'Findings', 'from', 'this', 'study', 'will', 'provide', 'new', 'information', 'on', 'how', 'to', 'optimize', 'function', 'and', 'physical', 'activity', 'among', 'older', 'adults', 'with', 'dementia', 'in', 'assisted', 'living', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT03459118,NCT03459118,"The Impact of Dementia on Care and Outcomes Associated With a Function Focused Care Intervention Among Residents in Assisted Living Settings. | This study will evaluate pain, management of pain, behavioral symptoms, and the quality of staff-resident interactions between residents with and without dementia, test the relationship of these variables to participation in function focused care at baseline, and consider if there is a differential impact of FFC-AL-EIT between those with and without dementia with regard to participation in function focused care, functional outcomes and physical activity over the 12 month study period. Findings from this study will provide new information on how to optimize function and physical activity among older adults with dementia in assisted living.","[(14, 22, 'CONDITION', 'Dementia'), (62, 83, 'OTHER', 'Function Focused Care'), (169, 173, 'CONDITION', 'pain'), (189, 193, 'CONDITION', 'pain'), (298, 306, 'CONDITION', 'dementia'), (454, 464, 'OTHER', 'FFC-AL-EIT'), (496, 504, 'CONDITION', 'dementia'), (762, 770, 'CONDITION', 'dementia')]"
"['Complications', 'of', 'Exchange', 'Transfusion', 'in', 'Neonates', '|', 'Exchange', 'transfusion', 'is', 'effective', 'and', 'considered', 'to', 'be', 'safe', 'procedure', ';', 'however', ',', 'it', 'is', 'not', 'without', 'risks', '.', 'Complications', 'have', 'been', 'reported', 'and', 'mortality', 'rates', 'vary', 'from', '0.5', 'to', '3.3', '%', '.', 'therefore', ',', 'the', 'current', 'recommendation', 'for', 'performing', 'exchange', 'transfusion', 'are', 'based', 'on', 'balance', 'between', 'the', 'risks', 'of', 'encephalopathy', 'and', 'complications', 'related', 'to', 'the', 'procedure', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03195049,NCT03195049,"Complications of Exchange Transfusion in Neonates | Exchange transfusion is effective and considered to be safe procedure ; however, it is not without risks. Complications have been reported and mortality rates vary from 0.5 to 3.3%. therefore ,the current recommendation for performing exchange transfusion are based on balance between the risks of encephalopathy and complications related to the procedure .","[(17, 37, 'OTHER', 'Exchange Transfusion'), (52, 72, 'OTHER', 'Exchange transfusion'), (287, 307, 'OTHER', 'exchange transfusion'), (350, 364, 'CONDITION', 'encephalopathy')]"
"['Effectiveness', 'and', 'Cost', '-', 'effectiveness', 'of', 'Ozone', 'Therapy', 'in', 'Patients', 'With', 'Pain', 'Secondary', 'to', 'Chemotherapy', '-', 'induced', 'Peripheral', 'Neuropathy', '.', 'Randomized', ',', 'Triple', '-', 'blind', 'Clinical', 'Trial', '(', 'O3NPIQ', ')', '|', 'The', 'main', 'objective', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'cost', '-', 'effectiveness', 'of', 'adding', 'ozone', 'therapy', 'to', 'the', 'clinical', 'management', 'of', 'patients', 'with', 'pain', 'secondary', 'to', 'chemotherapy', '-', 'induced', 'peripheral', 'neuropathy']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",NCT04299893,NCT04299893,"Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ) | The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy","[(40, 45, 'DRUG', 'Ozone'), (71, 75, 'CONDITION', 'Pain'), (89, 131, 'CONDITION', 'Chemotherapy-induced Peripheral Neuropathy'), (292, 297, 'DRUG', 'ozone'), (350, 354, 'CONDITION', 'pain'), (368, 410, 'CONDITION', 'chemotherapy-induced peripheral neuropathy')]"
"['Effectiveness', 'of', 'a', 'Telehealth', 'Group', 'for', 'Improving', 'Peer', 'Relationships', 'for', 'Adolescents', 'With', 'Neurofibromatosis', 'Type', '1', '|', 'This', 'is', 'an', 'open', 'trial', 'of', 'the', 'UCLA', 'PEERS', 'protocol', 'delivered', 'via', 'Telehealth', 'with', 'teens', 'with', 'neurofibromatosis', 'type', '1', 'whose', 'parents', 'report', 'that', 'they', 'have', 'difficulty', 'making', 'and', 'keeping', 'friends', '.']","['O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04856514,NCT04856514,Effectiveness of a Telehealth Group for Improving Peer Relationships for Adolescents With Neurofibromatosis Type 1 | This is an open trial of the UCLA PEERS protocol delivered via Telehealth with teens with neurofibromatosis type 1 whose parents report that they have difficulty making and keeping friends.,"[(19, 35, 'BEHAVIOURAL', 'Telehealth Group'), (90, 114, 'CONDITION', 'Neurofibromatosis Type 1'), (180, 190, 'BEHAVIOURAL', 'Telehealth'), (207, 231, 'CONDITION', 'neurofibromatosis type 1')]"
"['Music', 'Intervention', 'and', 'Transcranial', 'Electrical', 'Stimulation', 'for', 'Treating', 'Neurological', 'Diseases', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'a', 'musical', 'interventionand', 'non', '-', 'invasive', 'brain', 'stimulation', 'in', 'neurological', 'patients', '.', 'The', 'main', 'questions', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'to', 'evaluate', 'the', 'residual', 'neuroplastic', 'processes', 'in', 'DOC', 'state', 'related', 'to', 'music', 'exposure', '\n', 'to', 'determine', 'the', 'putative', 'modulation', 'of', 'the', 'aforementioned', 'processes', 'and', 'the', 'clinical', 'outcome', 'of', 'DOC', 'patients', 'by', 'non', '-', 'pharmacological', 'strategies', ',', 'i.e.', ',', 'electric', '(', 'tDCS', ')', 'and', 'music', 'stimulation', '\n', 'to', 'evaluate', 'the', 'impact', 'of', 'this', 'intervention', 'on', 'caregiver', ""'s"", 'burden', 'and', 'psychological', 'distress', '.', '\n\n', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'three', 'different', 'music', '-', 'listening', 'intervention', 'groups', '.', 'Primary', 'outcomes', 'will', 'be', 'clinical', ',', 'that', 'is', 'based', 'on', 'the', 'neurologist', ""'s"", 'observations', 'of', 'clinical', 'improvement', ',', 'and', 'neurophysiological', ',', 'collected', 'pre', '-', 'intervention', ',', 'post', '-', 'intervention', 'and', 'post', '-', 'placebo', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",NCT05706831,NCT05706831,"Music Intervention and Transcranial Electrical Stimulation for Treating Neurological Diseases | The goal of this clinical trial is to evaluate the efficacy of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are:

to evaluate the residual neuroplastic processes in DOC state related to music exposure
to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation
to evaluate the impact of this intervention on caregiver's burden and psychological distress.

Participants will be randomly assigned to one of three different music-listening intervention groups. Primary outcomes will be clinical, that is based on the neurologist's observations of clinical improvement, and neurophysiological, collected pre-intervention, post-intervention and post-placebo.","[(0, 18, 'OTHER', 'Music Intervention'), (23, 58, 'OTHER', 'Transcranial Electrical Stimulation'), (72, 93, 'CONDITION', 'Neurological Diseases'), (185, 215, 'OTHER', 'non-invasive brain stimulation'), (357, 371, 'OTHER', 'music exposure'), (523, 560, 'OTHER', 'electric (tDCS) and music stimulation'), (721, 736, 'OTHER', 'music-listening'), (945, 952, 'CONTROL', 'placebo')]"
"['Acute', 'Effect', 'of', 'Whole', 'Body', 'Vibration', 'of', 'Different', 'Frequencies', 'on', 'Balance', 'and', 'Functional', 'Mobility', 'of', 'Patients', 'With', 'Parkinson', ':', 'Crossover', '-', 'type', 'Controlled', 'Clinical', 'Trial', '|', 'Parkinson', ""'s"", 'disease', 'has', 'innumerous', 'motor', 'symptoms', 'that', 'impacting', 'on', 'the', 'functional', 'level', 'of', 'the', 'patient', ',', 'such', 'as', 'impairment', 'in', 'functional', 'mobility', 'and', 'balance', '.', 'Previous', 'studies', 'have', 'already', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'whole', 'body', 'vibration', ',', 'but', 'without', 'methodological', 'criteria', '.', 'The', 'use', 'of', 'whole', 'body', 'vibration', 'may', 'be', 'an', 'alternative', 'for', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'disease', '.', 'Therefore', ',', 'the', 'objective', 'of', 'the', 'study', 'is', 'to', 'verify', 'which', 'frequency', 'of', 'vibration', 'is', 'able', 'to', 'improve', 'the', 'balance', 'and', 'mobility', 'of', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04507490,NCT04507490,"Acute Effect of Whole Body Vibration of Different Frequencies on Balance and Functional Mobility of Patients With Parkinson: Crossover-type Controlled Clinical Trial | Parkinson's disease has innumerous motor symptoms that impacting on the functional level of the patient, such as impairment in functional mobility and balance . Previous studies have already aimed to evaluate the effectiveness of whole body vibration, but without methodological criteria. The use of whole body vibration may be an alternative for the treatment of Parkinson's disease. Therefore, the objective of the study is to verify which frequency of vibration is able to improve the balance and mobility of patients with Parkinson's disease.","[(16, 36, 'OTHER', 'Whole Body Vibration'), (114, 123, 'CONDITION', 'Parkinson'), (168, 187, 'CONDITION', ""Parkinson's disease""), (398, 418, 'OTHER', 'whole body vibration'), (468, 488, 'OTHER', 'whole body vibration'), (532, 551, 'CONDITION', ""Parkinson's disease""), (694, 713, 'CONDITION', ""Parkinson's disease"")]"
"['Randomised', 'controlled', 'trial', 'of', 'the', 'use', 'of', 'phenobarbitone', 'and', 'carbamazepine', 'in', 'childhood', 'epilepsy', 'in', 'Bangladesh', 'with', 'particular', 'reference', 'to', 'behavioural', 'side', 'effects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00381537,NCT00381537,Randomised controlled trial of the use of phenobarbitone and carbamazepine in childhood epilepsy in Bangladesh with particular reference to behavioural side effects.,"[(42, 56, 'DRUG', 'phenobarbitone'), (61, 74, 'DRUG', 'carbamazepine'), (88, 96, 'CONDITION', 'epilepsy')]"
"['A', 'Study', 'to', 'Investigate', 'the', 'Genetic', 'Variation', 'of', 'Dopamine', 'Pathway', 'Associated', 'With', 'the', 'Observed', 'Effects', 'of', 'a', 'New', 'Treatment', 'in', 'Former', 'Studies', 'in', 'Patients', 'With', 'Chronic', 'Pain', '|', 'Patients', 'having', 'completed', 'former', 'trials', 'T1001', '-', '01', 'or', 'T1001', '-', '02', 'will', 'undergo', 'one', 'blood', 'sampling', 'for', 'genotyping', 'purposes', '.', 'In', 'addition', 'they', 'will', 'compete', 'the', 'personality', 'questionnaires', 'they', 'had', 'completed', 'in', 'the', 'former', 'trial', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02989792,NCT02989792,A Study to Investigate the Genetic Variation of Dopamine Pathway Associated With the Observed Effects of a New Treatment in Former Studies in Patients With Chronic Pain | Patients having completed former trials T1001-01 or T1001-02 will undergo one blood sampling for genotyping purposes. In addition they will compete the personality questionnaires they had completed in the former trial.,"[(156, 168, 'CONDITION', 'Chronic Pain')]"
"['EEG', 'Monitoring', 'Under', 'Anaesthesia', 'in', 'Children', ':', 'Towards', 'Personalized', 'Anaesthesia', 'Care', '|', 'Electroencephalographic', 'recordings', '(', 'EEG', ')', 'present', 'an', 'opportunity', 'to', 'monitor', 'changes', 'in', 'human', 'brain', 'electrical', 'activity', 'during', 'changing', 'states', 'of', 'consciousness', 'during', 'general', 'anesthesia', '.', '\n\n', 'The', 'investigators', 'aim', 'to', 'determine', 'if', 'EEG', '-', 'guided', 'anaesthesia', 'using', 'the', 'Masimo', 'Sedline', 'Root', 'monitor', 'will', 'result', 'in', 'different', 'anaesthetic', 'requirements', ',', 'different', 'anaesthetic', 'depth', ',', 'and', 'emergence', 'characteristics', 'in', 'children', 'under', '16', 'years', 'of', 'age', '.', '\n\n', '200', 'children', 'under', '16', 'years', 'undergoing', 'routine', 'general', 'anaesthesia', 'under', 'sevoflurane', 'will', 'be', 'randomized', 'to', 'either', 'EEG', 'monitoring', 'or', 'routine', 'care', '.', 'We', 'will', 'compare', 'the', 'anaesthetic', 'requirements', ',', 'the', 'patient', 'state', 'index', ',', 'number', 'of', 'episodes', 'of', 'burst', 'suppression', 'and', 'the', 'incidence', 'and', 'severity', 'of', 'emergence', 'delrium', 'between', 'the', 'two', 'groups', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT04103138,NCT04103138,"EEG Monitoring Under Anaesthesia in Children: Towards Personalized Anaesthesia Care | Electroencephalographic recordings (EEG) present an opportunity to monitor changes in human brain electrical activity during changing states of consciousness during general anesthesia.

The investigators aim to determine if EEG-guided anaesthesia using the Masimo Sedline Root monitor will result in different anaesthetic requirements, different anaesthetic depth, and emergence characteristics in children under 16 years of age.

200 children under 16 years undergoing routine general anaesthesia under sevoflurane will be randomized to either EEG monitoring or routine care. We will compare the anaesthetic requirements, the patient state index, number of episodes of burst suppression and the incidence and severity of emergence delrium between the two groups.","[(808, 825, 'CONDITION', 'emergence delrium')]"
"['Controlling', 'Femoral', 'Derotation', 'Osteotomy', 'In', 'Cerebral', 'Palsy', 'With', 'Electromagnetic', 'Tracking', '-', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'study', 'is', 'designed', 'to', 'evaluate', 'the', 'use', 'of', 'electromagnetic', 'tracking', 'in', 'transversal', 'plane', 'femoral', 'derotation', 'osteotomies', '.', 'The', 'goal', 'is', 'to', 'raise', 'the', 'precision', 'of', 'the', 'surgical', 'procedure', 'in', 'order', 'to', 'improve', 'the', 'outcome', 'in', 'short-', 'and', 'long', 'term', '.', 'All', 'patients', 'are', 'examined', 'with', 'an', 'instrumented', '3D', 'gait', 'analysis', 'pre-', 'and', 'one', 'year', 'postoperatively', '.', 'The', 'electromagnetic', 'tracking', 'system', 'is', 'evaluated', 'against', 'a', 'base', 'line', 'CT', 'or', 'MRI', 'scan', 'serving', 'as', 'reference', 'standard', 'pre-', 'and', 'postoperatively', '.']","['O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03518541,NCT03518541,Controlling Femoral Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking - A Randomized Controlled Trial | The study is designed to evaluate the use of electromagnetic tracking in transversal plane femoral derotation osteotomies. The goal is to raise the precision of the surgical procedure in order to improve the outcome in short- and long term. All patients are examined with an instrumented 3D gait analysis pre- and one year postoperatively. The electromagnetic tracking system is evaluated against a base line CT or MRI scan serving as reference standard pre- and postoperatively.,"[(12, 40, 'SURGICAL', 'Femoral Derotation Osteotomy'), (44, 58, 'CONDITION', 'Cerebral Palsy'), (64, 88, 'OTHER', 'Electromagnetic Tracking'), (168, 192, 'OTHER', 'electromagnetic tracking'), (214, 244, 'SURGICAL', 'femoral derotation osteotomies'), (467, 498, 'OTHER', 'electromagnetic tracking system')]"
"['Flexible', 'Representation', 'of', 'Speech', 'in', 'the', 'Supratemporal', 'Plane', '|', 'The', 'overarching', 'goal', 'of', 'this', 'exploratory', 'research', 'is', 'to', 'understand', 'the', 'dynamic', 'and', 'flexible', 'nature', 'of', 'speech', 'processing', 'in', 'the', 'human', 'supratemporal', 'plane', '.', 'The', 'temporal', 'lobe', 'has', 'long', 'been', 'established', 'as', 'a', 'region', 'of', 'interest', 'in', 'the', 'speech', 'perception', 'and', 'processing', 'literature', 'because', 'it', 'contains', 'the', 'auditory', 'cortex', '.', 'More', 'recently', ',', 'research', 'has', 'localized', 'the', 'supratemporal', 'plane', 'as', 'an', 'area', 'that', 'exhibits', 'response', 'specificity', 'to', 'acoustic', 'properties', 'of', 'complex', 'auditory', 'signals', 'like', 'speech', '.', 'The', 'supratemporal', 'plane', ',', 'comprised', 'of', 'Heschl', ""'s"", 'gyrus', ',', 'the', 'planum', 'polare', ',', 'and', 'the', 'planum', 'temporale', ',', 'is', 'capable', 'of', 'the', 'rapid', 'spectrotemporal', 'analysis', 'required', 'to', 'map', 'acoustic', 'information', 'to', 'linguistic', 'representation', '.', 'Neural', 'activity', 'in', 'this', 'area', ',', 'however', ',', 'is', 'rarely', 'studied', 'directly', 'because', 'it', 'is', 'difficult', 'to', 'access', 'with', 'non', '-', 'invasive', 'measures', 'like', 'scalp', 'electroencephalography', '(', 'EEG', ')', '.', 'Capitalizing', 'on', 'the', 'unique', 'opportunity', 'to', 'access', 'these', 'areas', 'via', 'routine', 'clinical', 'stereoelectroencephalography', '(', 'sEEG', ')', 'in', 'a', 'patient', 'population', ',', 'this', 'study', 'seeks', 'to', 'understand', 'how', 'cortical', 'responses', 'reflect', 'the', 'diagnosticity', 'of', 'two', 'acoustic', '-', 'phonetic', 'dimensions', 'of', 'interest', 'and', 'how', 'responses', 'rapidly', 'and', 'flexibly', 'adapt', 'to', 'changes', 'in', 'listening', 'demands', '.', 'Examining', 'how', 'neural', 'response', 'to', 'voice', 'onset', 'time', '(', 'VOT', ')', 'and', 'fundamental', 'frequency', '(', 'F0', ')', 'modulates', 'as', 'a', 'function', 'of', 'perceptual', 'weight', 'carried', 'in', 'signaling', 'phoneme', 'categories', ',', 'and', 'identifying', 'how', 'changes', 'in', 'listening', 'context', 'shift', 'perceptual', 'weight', ',', 'will', 'provide', 'invaluable', 'data', 'that', 'indicates', 'how', 'speech', 'processing', 'flexibly', 'adapts', 'to', 'short', '-', 'term', 'acoustic', 'patterns', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05209386,NCT05209386,"Flexible Representation of Speech in the Supratemporal Plane | The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane. The temporal lobe has long been established as a region of interest in the speech perception and processing literature because it contains the auditory cortex. More recently, research has localized the supratemporal plane as an area that exhibits response specificity to acoustic properties of complex auditory signals like speech. The supratemporal plane, comprised of Heschl's gyrus, the planum polare, and the planum temporale, is capable of the rapid spectrotemporal analysis required to map acoustic information to linguistic representation. Neural activity in this area, however, is rarely studied directly because it is difficult to access with non-invasive measures like scalp electroencephalography (EEG). Capitalizing on the unique opportunity to access these areas via routine clinical stereoelectroencephalography (sEEG) in a patient population, this study seeks to understand how cortical responses reflect the diagnosticity of two acoustic-phonetic dimensions of interest and how responses rapidly and flexibly adapt to changes in listening demands. Examining how neural response to voice onset time (VOT) and fundamental frequency (F0) modulates as a function of perceptual weight carried in signaling phoneme categories, and identifying how changes in listening context shift perceptual weight, will provide invaluable data that indicates how speech processing flexibly adapts to short-term acoustic patterns.",[]
"['Evaluate', 'the', 'Safety', 'and', 'Immunogenicity', 'of', 'a', 'Vero', 'Cell', '-', 'Derived', 'Inactivated', 'Japanese', 'Encephalitis', 'Vaccine', '(', 'JECEVAX', ')', 'Produced', 'by', 'VABIOTECH', '(', 'Vietnam', ')', 'in', 'Vietnamese', 'Children', 'Aged', '9', '-', '24', 'Months', '|', 'A', 'study', 'of', 'the', 'study', 'vaccine', '(', 'JECEVAX-', 'VABIOTECH', '-', 'Vietnam', ')', 'and', 'a', 'licensed', 'vaccine', '(', 'JEVAX', '-', 'VABIOTECH', '-', 'Vietnam', ')', 'is', 'conducted', 'in', 'Vietnamese', 'children', ',', 'aged', '9', 'to', '24', 'months', 'to', 'assess', 'the', 'safety', 'of', 'the', 'study', 'vaccine', 'compares', 'to', 'licenced', 'vaccine', '.', 'Two', 'hundred', 'and', 'twenty', 'children', 'are', 'enrolled', 'and', 'randomly', 'assigned', 'into', '2', 'groups', '(', '110', 'children', '/', 'group', ')', ',', 'each', 'of', 'which', 'receive', '2', 'doses', 'of', 'study', '/', 'control', 'vaccine', 'subcutaneously', ',', 'at', '28', '-', '34', 'days', 'interval', '.', 'Safety', 'data', 'included', 'immediate', 'reaction', 'at', 'the', 'injection', 'site', 'and', 'systemic', 'reaction', 'within', '30', 'min', 'of', 'administration', ',', 'solicited', 'and', 'unsolicited', 'adverse', 'events', 'occurs', 'from', 'the', '1st', 'dose', 'to', '28', '-', '34', 'days', 'after', 'first', 'dose', 'and', 'from', 'the', 'second', 'dose', 'to', '28', '-', '34', 'days', 'after', '2nd', 'dose', '.', 'SAE', '(', 'from', 'start', 'of', 'first', 'dose', 'to', '28', '-', '34', 'days', 'after', 'second', 'dose', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03282370,NCT03282370,"Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months | A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).","[(44, 105, 'DRUG', 'Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine'), (107, 114, 'DRUG', 'JECEVAX'), (220, 228, 'DRUG', 'JECEVAX-'), (254, 270, 'CONTROL', 'licensed vaccine'), (272, 277, 'DRUG', 'JEVAX'), (408, 424, 'CONTROL', 'licenced vaccine')]"
"['Cognitive', '-', 'based', 'Rehabilitation', 'Platform', 'of', 'Hand', 'Grasp', 'After', 'Spinal', 'Cord', 'Injury', 'Using', 'Virtual', 'Reality', 'and', 'Instrumented', 'Wearables', '|', 'Rehabilitation', 'of', 'functional', 'movements', 'after', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'requires', 'commitment', 'and', 'engagement', 'to', 'the', 'processes', 'of', 'physical', 'therapy', '.', 'Outcomes', 'may', 'be', 'improved', 'by', 'techniques', 'that', 'strengthen', 'cognitive', 'connections', 'between', 'users', 'and', 'physical', 'therapy', 'exercises', '.', '\n\n', 'The', 'investigators', 'will', 'investigate', 'combinations', 'of', 'virtual', 'reality', 'and', 'innovative', 'wearable', 'technology', 'to', 'accelerate', 'rehabilitation', 'of', 'hand', 'grasp', 'and', 'reach', '.', 'These', 'devices', 'use', 'multi', '-', 'sensory', 'feedback', 'to', 'enhance', 'the', 'sense', 'of', 'agency', ',', 'or', 'feelings', 'of', 'control', ',', 'and', 'better', 'train', 'movements', 'during', 'physical', 'rehabilitation', 'exercises', '.', 'The', 'investigators', 'will', 'measure', 'the', 'effect', 'of', 'these', 'devices', 'on', 'improving', 'the', 'speed', ',', 'efficiency', ',', 'and', 'accuracy', 'of', 'performed', 'movements', 'in', 'Veterans', 'with', 'SCI', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04577573,NCT04577573,"Cognitive-based Rehabilitation Platform of Hand Grasp After Spinal Cord Injury Using Virtual Reality and Instrumented Wearables | Rehabilitation of functional movements after spinal cord injury (SCI) requires commitment and engagement to the processes of physical therapy. Outcomes may be improved by techniques that strengthen cognitive connections between users and physical therapy exercises.

The investigators will investigate combinations of virtual reality and innovative wearable technology to accelerate rehabilitation of hand grasp and reach. These devices use multi-sensory feedback to enhance the sense of agency, or feelings of control, and better train movements during physical rehabilitation exercises. The investigators will measure the effect of these devices on improving the speed, efficiency, and accuracy of performed movements in Veterans with SCI.","[(0, 39, 'OTHER', 'Cognitive-based Rehabilitation Platform'), (60, 78, 'CONDITION', 'Spinal Cord Injury'), (85, 100, 'OTHER', 'Virtual Reality'), (105, 127, 'OTHER', 'Instrumented Wearables'), (175, 193, 'CONDITION', 'spinal cord injury'), (195, 198, 'CONDITION', 'SCI'), (255, 271, 'PHYSICAL', 'physical therapy'), (368, 394, 'PHYSICAL', 'physical therapy exercises'), (448, 463, 'OTHER', 'virtual reality'), (468, 498, 'OTHER', 'innovative wearable technology'), (571, 593, 'OTHER', 'multi-sensory feedback'), (684, 717, 'PHYSICAL', 'physical rehabilitation exercises'), (867, 870, 'CONDITION', 'SCI')]"
"['Studying', 'Human', 'Cognition', 'and', 'Neurological', 'Disorders', 'Using', 'ECoG', 'Electrodes', '|', 'The', 'overall', 'purpose', 'of', 'this', 'study', 'is', 'to', 'better', 'understand', 'human', 'cognition', 'and', 'human', 'epilepsy', 'by', 'working', 'with', 'patients', 'undergoing', 'clinical', 'treatment', 'for', 'pharmacologically', 'resistant', 'epilepsy', '.', 'The', 'investigators', 'will', 'investigate', 'human', 'cognition', 'by', 'conducting', 'controlled', 'experiments', 'that', 'focus', 'on', 'sensory', ',', 'motor', ',', 'and', 'cognitive', 'phenomena', 'such', 'as', 'sensory', 'processing', ',', 'memory', ',', 'and', 'language', '.', 'The', 'investigators', 'will', 'also', 'examine', 'the', 'neural', 'underpinnings', 'of', 'epilepsy', 'during', 'both', 'sleep', 'and', 'wakefulness', 'to', 'better', 'understand', 'both', 'the', 'foundations', 'of', 'epilepsy', 'and', 'how', 'epilepsy', 'affects', 'cognition', '.', 'The', 'investigators', 'hope', 'to', 'use', 'these', 'data', 'to', 'have', 'a', 'better', 'understanding', 'of', 'cognition', ',', 'epilepsy', ',', 'and', 'how', 'the', 'two', 'interact', '.', 'This', 'will', 'potentially', 'lead', 'to', 'better', 'markers', 'for', 'seizure', 'onsets', 'as', 'well', 'as', 'epilepsy', 'more', 'generally', '.', 'For', 'this', 'research', ',', 'the', 'investigators', 'will', 'use', 'ECoG', 'arrays', 'manufactured', 'by', 'commercial', 'partners', '.', 'These', 'arrays', 'have', 'passed', 'all', 'major', 'ISO', '10993', 'bio', '-', 'compatibility', 'tests', '.', 'Based', 'on', 'this', 'characterization', 'and', 'use', 'in', 'the', 'intraoperative', 'setting', '(', 'limited', 'duration', 'and', 'supervised', 'usage', ')', ',', 'these', 'devices', 'pose', 'a', 'minimal', 'risk', 'to', 'participants', '.', 'Data', 'will', 'be', 'analyzed', 'and', 'protected', 'using', 'the', 'Duke', 'SSRI', 'protected', 'research', 'data', 'network', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05132543,NCT05132543,"Studying Human Cognition and Neurological Disorders Using ECoG Electrodes | The overall purpose of this study is to better understand human cognition and human epilepsy by working with patients undergoing clinical treatment for pharmacologically resistant epilepsy. The investigators will investigate human cognition by conducting controlled experiments that focus on sensory, motor, and cognitive phenomena such as sensory processing, memory, and language. The investigators will also examine the neural underpinnings of epilepsy during both sleep and wakefulness to better understand both the foundations of epilepsy and how epilepsy affects cognition. The investigators hope to use these data to have a better understanding of cognition, epilepsy, and how the two interact. This will potentially lead to better markers for seizure onsets as well as epilepsy more generally. For this research, the investigators will use ECoG arrays manufactured by commercial partners. These arrays have passed all major ISO 10993 bio-compatibility tests. Based on this characterization and use in the intraoperative setting (limited duration and supervised usage), these devices pose a minimal risk to participants. Data will be analyzed and protected using the Duke SSRI protected research data network.",[]
"['Feasibility', 'Study', 'of', 'Tolerogenic', 'Fibroblasts', 'in', 'Patients', 'With', 'Refractory', 'Multiple', 'Sclerosis', '|', 'Fibroblasts', 'have', 'demonstrated', 'potent', 'immune', 'modulatory', 'and', 'therapeutic', 'activity', 'in', 'the', 'experimental', 'autoimmune', 'encephalomyelitis', '(', 'EAE', ')', 'model', 'of', 'multiple', 'sclerosis', ',', 'as', 'well', 'as', 'in', 'other', 'models', 'of', 'autoimmune', 'and', 'inflammatory', 'diseases', '.', '\n\n', 'This', 'study', 'will', 'assess', 'primary', 'safety', 'and', 'secondary', 'efficacy', 'endpoints', 'of', 'intravenous', 'administration', 'of', '100', 'million', 'tolerogenic', 'fibroblasts', 'to', '5', 'patients', 'with', 'relapsing', 'remitting', 'MS', 'resistant', 'to', 'interferon', '.', 'While', 'the', 'safety', 'of', 'fibroblasts', 'administered', 'clinically', 'is', 'established', ',', 'it', 'is', 'unknown', 'whether', 'these', 'cells', 'are', 'effective', 'in', 'the', 'treatment', 'of', 'multiple', 'sclerosis', '(', 'MS', ')', '.', '\n\n', 'Our', 'hypothesis', 'is', 'that', 'the', 'tolerogenic', 'fibroblasts', 'will', 'be', 'well', '-', 'tolerated', 'and', 'meet', 'our', 'primary', 'objective', '.', 'In', 'addition', ',', 'The', 'investigators', 'are', 'optimistic', 'that', 'they', 'will', 'see', 'signs', 'of', 'efficacy', 'based', 'on', 'the', 'following', ':', 'Neurological', 'assessment', 'of', 'the', 'MS', 'functional', 'composite', 'assessment', 'which', 'comprises', 'of', 'EDSS', ',', 'the', 'expanded', 'EDSS', '(', 'Rating', 'Neurologic', 'Impairment', 'in', 'Multiple', 'Sclerosis', ',', 'the', 'Scripps', 'neurological', 'rating', 'scale', '(', 'NRS', ')', ',', 'paced', 'auditory', 'serial', 'addition', 'test', '(', 'PASAT', ')', ',', 'the', 'nine', '-', 'hole', 'peg', 'test', ',', 'and', '25', '-', 'foot', 'walking', 'time', ',', 'short', '-', 'form', '36', '(', 'SF-36', ')', 'quality', 'of', 'life', 'questionnaire', 'and', 'gadolinium', '-', 'enhanced', 'MRI', 'scans', 'of', 'the', 'brain', 'and', 'cervical', 'spinal', 'cord', '.']","['O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05080270,NCT05080270,"Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis | Fibroblasts have demonstrated potent immune modulatory and therapeutic activity in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, as well as in other models of autoimmune and inflammatory diseases.

This study will assess primary safety and secondary efficacy endpoints of intravenous administration of 100 million tolerogenic fibroblasts to 5 patients with relapsing remitting MS resistant to interferon. While the safety of fibroblasts administered clinically is established, it is unknown whether these cells are effective in the treatment of multiple sclerosis (MS).

Our hypothesis is that the tolerogenic fibroblasts will be well-tolerated and meet our primary objective. In addition, The investigators are optimistic that they will see signs of efficacy based on the following: Neurological assessment of the MS functional composite assessment which comprises of EDSS, the expanded EDSS (Rating Neurologic Impairment in Multiple Sclerosis, the Scripps neurological rating scale (NRS), paced auditory serial addition test (PASAT), the nine-hole peg test, and 25-foot walking time, short-form 36 (SF-36) quality of life questionnaire and gadolinium-enhanced MRI scans of the brain and cervical spinal cord.","[(21, 44, 'SURGICAL', 'Tolerogenic Fibroblasts'), (62, 91, 'CONDITION', 'Refractory Multiple Sclerosis'), (94, 105, 'SURGICAL', 'Fibroblasts'), (238, 256, 'CONDITION', 'multiple sclerosis'), (443, 466, 'SURGICAL', 'tolerogenic fibroblasts'), (486, 508, 'CONDITION', 'relapsing remitting MS'), (554, 565, 'SURGICAL', 'fibroblasts'), (674, 692, 'CONDITION', 'multiple sclerosis'), (694, 696, 'CONDITION', 'MS'), (727, 750, 'SURGICAL', 'tolerogenic fibroblasts'), (944, 946, 'CONDITION', 'MS'), (1055, 1073, 'CONDITION', 'Multiple Sclerosis')]"
"['The', 'Ontario', 'Prehospital', 'Advanced', 'Life', 'Support', '(', 'OPALS', ')', 'Study', 'for', 'Critically', 'Ill', 'and', 'Injured', 'Pediatric', 'Patients', '|', 'The', 'OPALS', 'Pediatric', 'Study', 'will', 'examine', 'the', 'incremental', 'impact', 'of', 'introducing', 'a', 'prehospital', 'full', 'advanced', 'life', 'support', 'in', 'pediatric', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O']",NCT00298532,NCT00298532,The Ontario Prehospital Advanced Life Support (OPALS) Study for Critically Ill and Injured Pediatric Patients | The OPALS Pediatric Study will examine the incremental impact of introducing a prehospital full advanced life support in pediatric patients.,"[(64, 78, 'CONDITION', 'Critically Ill'), (191, 229, 'OTHER', 'prehospital full advanced life support')]"
"['A', 'Multi', '-', 'center', ',', 'Open', '-', 'label', ',', 'Uncontrolled', ',', 'Single', '-', 'arm', ',', 'Extension', 'Study', 'to', 'Determine', 'the', 'Long', '-', 'term', 'Safety', 'and', 'Tolerability', 'of', 'Oral', 'Lucerastat', 'in', 'Adult', 'Subjects', 'With', 'Fabry', 'Disease', '|', 'A', 'study', 'to', 'determine', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'oral', 'lucerastat', 'in', 'adult', 'subjects', 'with', 'Fabry', 'disease']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT03737214,NCT03737214,"A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease","[(129, 139, 'DRUG', 'Lucerastat'), (163, 176, 'CONDITION', 'Fabry Disease'), (246, 256, 'DRUG', 'lucerastat'), (280, 293, 'CONDITION', 'Fabry disease')]"
"['The', 'Effect', 'of', 'Low', '-', 'ntensity', 'Combined', 'Exercises', 'on', 'Fatigue', ',', 'Balance', 'and', 'Quality', 'of', 'Life', 'in', 'Patients', 'With', 'Early', 'Stage', 'ALS', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'low', '-', 'intensity', 'combined', 'exercises', 'on', 'balance', ',', 'fatigue', 'and', 'quality', 'of', 'life', 'applied', 'to', 'patients', 'with', 'ALS', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05716074,NCT05716074,"The Effect of Low-ntensity Combined Exercises on Fatigue, Balance and Quality of Life in Patients With Early Stage ALS | The aim of this study is to investigate the effects of low-intensity combined exercises on balance, fatigue and quality of life applied to patients with ALS.","[(14, 46, 'PHYSICAL', 'Low-ntensity Combined Exercises'), (50, 57, 'CONDITION', 'Fatigue'), (104, 119, 'CONDITION', 'Early Stage ALS'), (177, 209, 'PHYSICAL', 'low-intensity combined exercises'), (222, 229, 'CONDITION', 'fatigue'), (275, 278, 'CONDITION', 'ALS')]"
"['The', 'Effects', 'of', 'a', 'Biomechanical', 'Based', 'Tai', 'Chi', 'Intervention', 'Program', 'on', 'Postural', 'Stability', 'and', 'Gait', 'in', 'People', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'is', 'associated', 'with', 'changes', 'in', 'gait', 'and', 'posture', 'that', 'can', 'lead', 'to', 'a', 'higher', 'frequency', 'of', 'falls', 'and', 'injuries', 'in', 'this', 'population', '.', 'Research', 'has', 'shown', 'a', 'positive', 'effect', 'of', 'tai', 'chi', '(', 'TC', ')', 'training', 'on', 'the', 'movement', 'capacity', 'for', 'those', 'with', 'PD', ',', 'however', 'the', 'understanding', 'of', 'the', 'impact', 'of', 'TC', 'training', 'on', 'gait', 'and', 'postural', 'stability', 'in', 'PD', 'is', 'lacking', '.', 'This', 'study', 'aims', 'to', 'examine', 'the', 'impact', 'of', 'a', 'biomechanical', '-', 'based', 'TC', 'intervention', 'on', 'dynamic', 'postural', 'stability', 'and', 'how', 'it', 'relates', 'to', 'walking', 'performance', '.', 'It', 'is', 'hypothesized', 'that', 'the', 'effects', 'of', 'the', 'TC', 'intervention', 'will', 'help', 'to', 'improve', 'measures', 'relating', 'to', 'postural', 'stability', ',', 'gait', ',', 'and', 'cognition', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04644367,NCT04644367,"The Effects of a Biomechanical Based Tai Chi Intervention Program on Postural Stability and Gait in People With Parkinson's Disease | Parkinson's disease (PD) is associated with changes in gait and posture that can lead to a higher frequency of falls and injuries in this population. Research has shown a positive effect of tai chi (TC) training on the movement capacity for those with PD, however the understanding of the impact of TC training on gait and postural stability in PD is lacking. This study aims to examine the impact of a biomechanical-based TC intervention on dynamic postural stability and how it relates to walking performance. It is hypothesized that the effects of the TC intervention will help to improve measures relating to postural stability, gait, and cognition.","[(17, 65, 'PHYSICAL', 'Biomechanical Based Tai Chi Intervention Program'), (112, 131, 'CONDITION', ""Parkinson's Disease""), (134, 153, 'CONDITION', ""Parkinson's disease""), (155, 157, 'CONDITION', 'PD'), (324, 331, 'PHYSICAL', 'tai chi'), (333, 335, 'PHYSICAL', 'TC'), (386, 388, 'CONDITION', 'PD'), (433, 444, 'PHYSICAL', 'TC training'), (479, 481, 'CONDITION', 'PD'), (537, 572, 'OTHER', 'biomechanical-based TC intervention'), (689, 704, 'OTHER', 'TC intervention')]"
"['Effect', 'of', 'Atypical', 'Antipsychotics', 'on', 'Gene', 'Expression', 'in', 'Soft', 'Tissues', 'of', 'Healthy', 'Subjects', '-', 'A', 'Placebo', 'Controlled', 'Randomised', 'Pilot', 'Study', '|', 'Schizophrenia', 'is', 'a', 'severe', 'chronic', 'and', 'disabling', 'mental', 'disorder', 'and', 'is', 'associated', 'with', 'a', 'significant', 'reduction', 'in', 'life', 'expectancy', '.', 'Atypical', 'antipsychotic', 'treatment', 'compliance', 'may', 'be', 'jeopardized', 'because', 'of', 'drug', 'induced', 'weight', 'gain', 'and', 'abnormalities', 'in', 'carbohydrate', 'and', 'lipid', 'metabolism', '.', '\n\n', 'Aim', ':', 'to', 'gain', 'data', 'on', 'drug', 'related', 'effects', 'on', 'gene', 'expression', 'and', 'regulation', 'with', 'special', 'regard', 'to', 'glucose', 'metabolism', '.']","['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01185743,NCT01185743,"Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study | Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.

Aim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.","[(10, 33, 'DRUG', 'Atypical Antipsychotics'), (93, 100, 'CONTROL', 'Placebo'), (137, 150, 'CONDITION', 'Schizophrenia'), (268, 290, 'DRUG', 'Atypical antipsychotic')]"
"['U', '-', 'Health', 'Service', 'Using', 'Mobile', 'Device', 'for', 'Improvement', 'of', 'Post', '-', 'Stroke', 'Upper', 'Limb', 'Function', 'and', 'Aphasia', '|', 'Provides', 'mobile', 'programs', 'for', 'occupational', 'and', 'speech', 'therapy', 'to', 'patients', 'with', 'stroke', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O']",NCT01815905,NCT01815905,U-Health Service Using Mobile Device for Improvement of Post-Stroke Upper Limb Function and Aphasia | Provides mobile programs for occupational and speech therapy to patients with stroke.,"[(0, 36, 'OTHER', 'U-Health Service Using Mobile Device'), (56, 67, 'CONDITION', 'Post-Stroke'), (92, 99, 'CONDITION', 'Aphasia'), (111, 126, 'OTHER', 'mobile programs'), (131, 162, 'OTHER', 'occupational and speech therapy'), (180, 186, 'CONDITION', 'stroke')]"
"['Studio', 'Monocentrico', 'in', 'Doppio', 'Cieco', 'Randomizzato', ""Dell'Effetto"", 'di', 'Una', 'Miscela', 'di', 'Flavonoidi', 'ed', 'Acidi', 'Grassi', 'Naturali', 'in', 'Pazienti', 'Affetti', 'da', 'Distrofia', 'Muscolare', '|', 'The', 'study', 'aimed', 'to', 'assess', 'the', 'safety', 'and', ',', 'partially', ',', 'the', 'efficacy', 'of', 'dietary', 'supplementation', 'of', 'a', 'flavonoids-', ',', 'DHA-', 'and', 'EPA', '-', 'based', 'natural', 'supplement', 'in', 'non', '-', 'ambulant', 'DMD', 'boys', 'and', 'in', 'a', 'cohort', 'of', 'LGMD', 'and', 'FSHD', 'patients', 'to', 'compare', 'its', 'effect', 'in', 'MDs', 'of', 'different', 'aetiology', 'and', 'to', 'eventually', 'highlight', 'any', 'differences', 'in', 'inflammatory', 'involved', 'pathways', '.', 'To', 'assess', 'safety', ',', 'patient', ""'s"", 'laboratory', 'parameters', 'were', 'monitored', 'and', 'adverse', 'events', 'recorded', ',', 'while', 'efficacy', 'was', 'evaluated', 'through', 'performance', 'scale', 'questionnaire', 'and', 'strength', 'measurement', '(', '6', 'minute', 'walking', 'test', 'and', 'Biodex', 'System', '4', 'Dynamometer', 'parameter', 'evaluation', ')', '.', 'This', 'study', 'was', 'conceived', 'as', 'proof', 'of', 'principle', 'for', 'the', 'safe', 'use', 'of', 'flavonoids', '/', 'omega3s', '-', 'based', 'compound', 'as', 'an', 'adjuvant', 'in', 'the', 'management', 'of', 'neuromuscular', 'disorders', ';', 'besides', ',', 'its', 'efficacy', 'in', 'alleviating', 'symptoms', 'linked', 'to', 'secondary', 'effects', 'of', 'genetic', 'mutation', 'as', 'inflammation', ',', 'muscular', 'pain', 'and', 'weakness', 'was', 'assessed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT03317171,NCT03317171,"Studio Monocentrico in Doppio Cieco Randomizzato Dell'Effetto di Una Miscela di Flavonoidi ed Acidi Grassi Naturali in Pazienti Affetti da Distrofia Muscolare | The study aimed to assess the safety and, partially, the efficacy of dietary supplementation of a flavonoids-, DHA- and EPA-based natural supplement in non-ambulant DMD boys and in a cohort of LGMD and FSHD patients to compare its effect in MDs of different aetiology and to eventually highlight any differences in inflammatory involved pathways. To assess safety, patient's laboratory parameters were monitored and adverse events recorded, while efficacy was evaluated through performance scale questionnaire and strength measurement (6 minute walking test and Biodex System 4 Dynamometer parameter evaluation). This study was conceived as proof of principle for the safe use of flavonoids/omega3s-based compound as an adjuvant in the management of neuromuscular disorders; besides, its efficacy in alleviating symptoms linked to secondary effects of genetic mutation as inflammation, muscular pain and weakness was assessed.","[(259, 270, 'DRUG', 'flavonoids-'), (272, 276, 'DRUG', 'DHA-'), (281, 284, 'DRUG', 'EPA'), (326, 329, 'CONDITION', 'DMD'), (354, 358, 'CONDITION', 'LGMD'), (363, 367, 'CONDITION', 'FSHD'), (402, 405, 'CONDITION', 'MDs'), (841, 851, 'DRUG', 'flavonoids'), (852, 859, 'DRUG', 'omega3s'), (1033, 1045, 'CONDITION', 'inflammation'), (1047, 1060, 'CONDITION', 'muscular pain')]"
"['French', 'Language', 'Validation', 'of', 'the', 'Phone', 'Version', 'of', 'the', 'Montreal', 'Cognitive', 'Assessment', '(', 'MoCA', ')', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'validate', 'a', 'french', 'version', 'of', 'the', '5', 'minutes', 'version', 'of', 'the', 'Montreal', 'Cognitive', 'Assessment', 'as', 'compared', 'to', 'the', 'french', 'full', 'version', 'of', 'this', 'test', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03232697,NCT03232697,French Language Validation of the Phone Version of the Montreal Cognitive Assessment (MoCA) | The aim of the study is to validate a french version of the 5 minutes version of the Montreal Cognitive Assessment as compared to the french full version of this test.,[]
"['A', 'Pilot', 'Study', 'of', '68Ga', '-', 'Dotatate', 'PET', 'CT', 'for', 'Radiation', 'Treatment', 'Response', 'Assessment', 'in', 'Meningiomas', '|', 'This', 'phase', 'I', 'trial', 'studies', 'how', 'well', 'gallium', 'Ga', '68', '-', 'DOTATATE', 'positron', 'emission', 'tomography', '(', 'PET)/computed', 'tomography', '(', 'CT', ')', 'works', 'in', 'predicting', 'tumor', 'growth', 'in', 'patients', 'with', 'meningiomas', '.', 'Giving', 'Gallium', 'Ga', '68', '-', 'DOTATATE', 'before', 'PET', '/', 'CT', 'scan', 'may', 'work', 'better', 'in', 'predicting', 'tumor', 'growth', 'in', 'patients', 'with', 'meningiomas', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03953131,NCT03953131,A Pilot Study of 68Ga-Dotatate PET CT for Radiation Treatment Response Assessment in Meningiomas | This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas. Giving Gallium Ga 68-DOTATATE before PET/CT scan may work better in predicting tumor growth in patients with meningiomas.,"[(85, 96, 'CONDITION', 'Meningiomas'), (268, 279, 'CONDITION', 'meningiomas'), (390, 401, 'CONDITION', 'meningiomas')]"
"['Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', 'of', 'the', 'Lesioned', 'or', 'Non', '-', 'lesioned', 'Hemisphere', 'Plus', 'Computer', '-', 'assisted', 'Arm', 'Trainer', ':', 'a', 'Randomized', ',', 'Placebo', '-', 'controlled', 'Double', '-', 'blind', 'Multi', '-', 'centre', 'Study', 'in', 'Patients', 'With', 'Severe', 'Arm', 'Paresis', 'Early', 'After', 'Stroke', '|', 'Transcranial', 'galvanic', 'stimulation', '(', 'tDCS', ')', 'seems', 'to', 'promote', 'motor', 'recovery', 'after', 'stroke', 'by', 'stimulating', '(', 'anodal', ')', 'or', 'inhibiting', '(', 'cathodal', ')', 'neural', 'circuits', 'in', 'the', 'brain', '.', 'In', 'the', 'treatment', 'of', 'severe', 'arm', 'paresis', 'after', 'stroke', ',', 'robot', '-', 'assisted', 'arm', 'training', '(', 'AT', ')', 'proved', 'to', 'be', 'effective', ',', 'but', 'nevertheless', 'only', 'a', 'few', 'patients', 'could', 'use', 'their', 'affected', 'hand', 'functionally', 'in', 'daily', 'life', 'after', 'robot', 'training', '.', 'Therefore', 'the', 'present', 'study', 'intends', 'to', 'combine', 'both', 'approaches', ',', 'tDCS', '+', 'AT', ',', 'applied', 'at', 'the', 'same', 'time', 'every', 'day', 'for', 'six', 'weeks', '.', 'The', 'study', 'has', 'three', 'treatment', 'arms', ',', 'two', 'groups', 'will', 'receive', 'the', 'tDCS', ',', 'either', 'anodal', 'of', 'the', 'lesioned', 'or', 'cathodal', 'of', 'the', 'non', '-', 'lesioned', 'hemisphere', '.', 'The', 'anodal', 'stimulation', 'is', 'expected', 'to', 'facilitate', 'the', 'activity', 'of', 'the', 'arm', 'motor', 'area', 'of', 'the', 'lesioned', 'side', 'directly', ',', 'while', 'the', 'cathodal', 'stimulation', 'of', 'the', 'non', '-', 'lesioned', 'hemisphere', 'is', 'expected', 'to', 'facilitate', 'the', 'lesioned', 'side', 'indirectly', 'by', 'decreasing', 'inhibitory', 'inputs', '.', 'The', 'third', 'group', 'will', 'receive', 'a', 'sham', '-', 'stimulation', '.', 'All', 'patients', 'will', 'work', 'with', 'the', 'AT', 'simultaneously', 'to', 'the', 'tDCS', ',', 'respectively', 'sham', '-', 'tDCS', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT00407667,NCT00407667,"Transcranial Direct Current Stimulation (tDCS) of the Lesioned or Non-lesioned Hemisphere Plus Computer-assisted Arm Trainer: a Randomized, Placebo-controlled Double-blind Multi-centre Study in Patients With Severe Arm Paresis Early After Stroke | Transcranial galvanic stimulation (tDCS) seems to promote motor recovery after stroke by stimulating (anodal) or inhibiting (cathodal) neural circuits in the brain. In the treatment of severe arm paresis after stroke, robot-assisted arm training (AT) proved to be effective, but nevertheless only a few patients could use their affected hand functionally in daily life after robot training. Therefore the present study intends to combine both approaches, tDCS + AT, applied at the same time every day for six weeks. The study has three treatment arms, two groups will receive the tDCS, either anodal of the lesioned or cathodal of the non-lesioned hemisphere. The anodal stimulation is expected to facilitate the activity of the arm motor area of the lesioned side directly, while the cathodal stimulation of the non-lesioned hemisphere is expected to facilitate the lesioned side indirectly by decreasing inhibitory inputs. The third group will receive a sham-stimulation. All patients will work with the AT simultaneously to the tDCS, respectively sham-tDCS.","[(0, 39, 'OTHER', 'Transcranial Direct Current Stimulation'), (41, 45, 'OTHER', 'tDCS'), (95, 124, 'PHYSICAL', 'Computer-assisted Arm Trainer'), (140, 147, 'CONTROL', 'Placebo'), (208, 226, 'CONDITION', 'Severe Arm Paresis'), (227, 245, 'CONDITION', 'Early After Stroke'), (248, 281, 'OTHER', 'Transcranial galvanic stimulation'), (283, 287, 'OTHER', 'tDCS'), (327, 333, 'CONDITION', 'stroke'), (433, 451, 'CONDITION', 'severe arm paresis'), (452, 464, 'CONDITION', 'after stroke'), (466, 493, 'PHYSICAL', 'robot-assisted arm training'), (495, 497, 'PHYSICAL', 'AT'), (623, 637, 'PHYSICAL', 'robot training'), (703, 707, 'OTHER', 'tDCS'), (710, 712, 'PHYSICAL', 'AT'), (828, 832, 'OTHER', 'tDCS'), (1204, 1220, 'CONTROL', 'sham-stimulation'), (1254, 1256, 'PHYSICAL', 'AT'), (1279, 1283, 'OTHER', 'tDCS'), (1298, 1307, 'CONTROL', 'sham-tDCS')]"
"['Dementia', 'Pain', 'Management', 'Knowledge', 'Scale', 'Development', 'and', 'Impact', 'of', 'an', 'Educational', 'Program', 'on', 'Hospital', 'Nurses', ""'"", 'Knowledge', 'Evaluation', '|', 'This', 'study', 'aims', 'to', 'develop', 'and', 'test', 'a', 'scale', 'for', 'exploring', 'hospital', 'nurses', ""'"", 'knowledge', 'about', 'dementia', 'pain', 'and', 'dementia', 'pain', 'management', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04256382,NCT04256382,Dementia Pain Management Knowledge Scale Development and Impact of an Educational Program on Hospital Nurses' Knowledge Evaluation | This study aims to develop and test a scale for exploring hospital nurses' knowledge about dementia pain and dementia pain management.,"[(70, 89, 'BEHAVIOURAL', 'Educational Program')]"
"['A', 'Prospective', 'Study', 'on', 'Markers', 'of', 'Disease', 'Progression', 'and', 'Gait', 'Within', 'the', 'Parkinsonian', 'Population', '|', 'The', 'aim', 'of', 'the', 'project', 'is', 'to', 'evaluate', 'disease', 'progression', 'of', 'patients', 'with', 'Parkinsonian', 'syndrome', 'of', 'various', 'severity', 'through', 'regular', 'home', '-', 'based', 'gait', 'parameters', 'analysis', '.', '\n\n', 'We', 'identified', 'several', 'steps', 'in', 'this', 'project', ':', '\n\n', 'Acquisition', 'of', 'gait', 'data', 'in', '120', 'patients', 'with', 'Parkinsonism', 'at', 'different', 'stages', 'in', 'hospital', 'and', 'ecological', 'condition', '(', 'during', '10', 'days', 'at', 'home', ')', ',', 'in', 'a', 'repetitive', 'manner', ':', '\n\n', '30', 'Early', 'PD', 'patients', ',', 'before', '3', 'years', 'of', 'disease', 'duration', '(', 'MDS', 'criteria', ',', '2018', ')', '\n', '30', 'PD', 'patients', 'with', 'motor', 'fluctuations', '(', '5', 'to', '8', 'years', 'of', 'disease', 'duration', ')', '(', 'MDS', 'criteria', ',', '2018', ')', '\n', '30', 'PD', 'patients', 'with', 'FoG', '(', '10', 'years', 'of', 'disease', 'duration', ')', '(', 'MDS', 'criteria', ',', '2018', ')', '\n', '30', 'patients', 'with', 'MSA', '(', 'less', 'than', '5', 'years', 'after', 'the', 'first', 'symptom', ')', '\n', 'Control', 'groups', 'will', 'be', 'composed', 'by', '30', 'healthy', 'volunteers', 'Correlation', 'analysis', 'with', 'clinical', 'measurements', 'and', 'biomarkers', ',', 'namely', 'blood', 'biomarkers', 'for', 'neurodegeneration', '(', '4HN', ',', 'NFLT', '', ')', 'and', 'multimodal', 'MRI', 'repeated', 'assessments', '(', 'Iron', 'overload', ',', 'inflammation', 'and', 'degeneration', ')', 'and', 'genetic', 'panel', 'for', 'common', 'haplotypes', 'involved', 'in', 'Parkinsonism', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04653688,NCT04653688,"A Prospective Study on Markers of Disease Progression and Gait Within the Parkinsonian Population | The aim of the project is to evaluate disease progression of patients with Parkinsonian syndrome of various severity through regular home-based gait parameters analysis.

We identified several steps in this project:

Acquisition of gait data in 120 patients with Parkinsonism at different stages in hospital and ecological condition (during 10 days at home), in a repetitive manner:

30 Early PD patients, before 3 years of disease duration (MDS criteria, 2018)
30 PD patients with motor fluctuations (5 to 8 years of disease duration) (MDS criteria, 2018)
30 PD patients with FoG (10 years of disease duration) (MDS criteria, 2018)
30 patients with MSA (less than 5 years after the first symptom)
Control groups will be composed by 30 healthy volunteers Correlation analysis with clinical measurements and biomarkers, namely blood biomarkers for neurodegeneration (4HN, NFLT ) and multimodal MRI repeated assessments (Iron overload, inflammation and degeneration) and genetic panel for common haplotypes involved in Parkinsonism.","[(74, 86, 'CONDITION', 'Parkinsonian'), (175, 196, 'CONDITION', 'Parkinsonian syndrome'), (363, 375, 'CONDITION', 'Parkinsonism'), (487, 495, 'CONDITION', 'Early PD'), (565, 567, 'CONDITION', 'PD'), (660, 662, 'CONDITION', 'PD'), (1118, 1130, 'CONDITION', 'Parkinsonism')]"
"['Pre', '-', 'emptive', 'Intravenous', 'Morphine', 'for', 'Acute', 'Post', '-', 'craniotomy', 'Pain', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', '.', '|', 'We', 'propose', 'a', 'double', '-', 'blind', 'randomized', 'controlled', 'trial', 'to', 'evaluate', 'the', 'effect', 'of', 'intravenously', 'administered', 'morphine', 'at', 'surgery', 'conclusion', 'on', 'acute', 'postoperative', 'pain', 'in', 'patients', 'recovering', 'from', 'craniotomy', 'surgery', '.', 'Participating', 'adults', 'having', 'craniotomy', 'surgery', 'will', 'be', 'randomized', 'in', 'a', '1:1', 'ratio', 'to', 'intraoperative', 'intravenous', 'administration', 'of', '0.08', 'mg', '/', 'kg', 'morphine', 'at', 'dura', 'closure', ',', 'or', 'a', 'matching', 'placebo', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",NCT05117034,NCT05117034,"Pre-emptive Intravenous Morphine for Acute Post-craniotomy Pain: a Randomized, Double-blind, Placebo-controlled Trial. | We propose a double-blind randomized controlled trial to evaluate the effect of intravenously administered morphine at surgery conclusion on acute postoperative pain in patients recovering from craniotomy surgery. Participating adults having craniotomy surgery will be randomized in a 1:1 ratio to intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure, or a matching placebo.","[(24, 32, 'DRUG', 'Morphine'), (37, 63, 'CONDITION', 'Acute Post-craniotomy Pain'), (93, 100, 'CONTROL', 'Placebo'), (228, 236, 'DRUG', 'morphine'), (240, 247, 'CONDITION', 'surgery'), (262, 286, 'CONDITION', 'acute postoperative pain'), (315, 333, 'CONDITION', 'craniotomy surgery'), (363, 381, 'CONDITION', 'craniotomy surgery'), (475, 483, 'DRUG', 'morphine'), (515, 522, 'CONTROL', 'placebo')]"
"['Effect', 'of', 'Intensive', 'Cognitive', 'Rehabilitation', 'on', 'Cognitive', ',', 'Motor', ',', 'and', 'Language', 'Functional', 'Networks', 'in', 'Subacute', 'Stroke', 'Patient', '|', 'Altered', 'brain', 'networks', ',', 'including', 'cognitive', ',', 'motor', ',', 'and', 'language', 'networks', ',', 'are', 'investigated', 'by', 'intensive', 'cognitive', 'rehabilitation', 'in', 'subacute', 'stroke', 'patients', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT05254964,NCT05254964,"Effect of Intensive Cognitive Rehabilitation on Cognitive, Motor, and Language Functional Networks in Subacute Stroke Patient | Altered brain networks, including cognitive, motor, and language networks, are investigated by intensive cognitive rehabilitation in subacute stroke patients.","[(10, 44, 'OTHER', 'Intensive Cognitive Rehabilitation'), (102, 117, 'CONDITION', 'Subacute Stroke'), (223, 257, 'OTHER', 'intensive cognitive rehabilitation'), (261, 276, 'CONDITION', 'subacute stroke')]"
"['Effects', 'of', 'Hydrotherapy', 'on', 'Neuropathic', 'Pain', 'and', 'Pain', 'Catastrophization', 'in', 'Spinal', 'Cord', 'Injury', ':', 'Study', 'Protocol', 'for', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Spinal', 'Cord', 'Injury', '(', 'SCI', ')', 'is', 'a', 'spinal', 'cord', 'injury', 'of', 'traumatic', 'origin', 'with', 'its', 'main', 'etiology', 'being', 'violence', ',', 'which', 'constitutes', 'one', 'of', 'the', 'greatest', 'social', 'and', 'health', 'problems', 'worldwide', '.', 'One', 'of', 'the', 'complications', 'with', 'the', 'greatest', 'impact', 'in', 'people', 'with', 'SCI', 'is', 'Neuropathic', 'Pain', '(', 'NP', ')', '.', 'Pain', ',', 'mainly', 'chronic', 'pain', ',', 'has', 'an', 'effect', 'on', 'emotional', 'states', ',', 'cognition', 'regarding', 'pain', 'and', 'anticipation', 'which', 'leads', 'to', 'the', 'catastrophization', 'of', 'the', 'pain', '.', 'This', 'form', 'of', 'pain', 'is', 'related', 'to', 'chronic', 'diseases', 'that', 'develop', 'with', 'pain', 'of', 'poor', 'prognosis', 'and', 'are', 'detrimental', 'to', 'quality', 'of', 'life', 'therefore', 'having', 'enormous', 'impacts', 'on', 'health', 'systems', '.', 'The', 'physiological', 'mechanisms', 'of', 'Hydrotherapy', 'on', 'pain', 'are', 'clear', 'and', 'there', 'is', 'evidence', 'of', 'its', 'use', 'in', 'the', 'management', 'of', 'painful', 'syndromes', 'of', 'difficult', 'treatments', 'such', 'as', 'that', 'for', 'fibromyalgia', 'and', 'chronic', 'lumbar', 'pain', ',', 'as', 'well', 'as', 'its', 'positive', 'effect', 'on', 'pain', 'perception', '.', 'However', ',', 'the', 'effects', 'of', 'hydrotherapy', 'on', 'the', 'NP', 'of', 'patients', 'with', 'SCI', 'are', 'unknown', '.', '\n\n', 'Randomized', ',', 'controlled', 'clinical', 'trial', 'of', 'parallel', 'groups', '.', 'A', 'randomized', 'sequence', 'will', 'be', 'carried', 'out', 'in', 'balanced', 'blocks', 'to', 'assign', 'the', 'intervention', '(', 'Hydrotherapy', ')', 'or', 'the', 'control', '(', 'Standard', 'Physical', 'Therapy', ')', ',', 'to', 'a', 'sample', 'of', '28', 'participants', ',', '14', 'for', 'each', 'group', '.', 'Each', 'of', 'the', 'interventions', '(', 'hydrotherapy', 'and', 'physical', 'therapy', ')', 'will', 'last', '9', 'weeks', ',', 'for', 'a', 'total', 'of', '18', 'sessions', '(', '2', 'weekly', 'sessions', ')', '.', 'Two', 'measurements', 'will', 'be', 'made', ',', 'baseline', '(', 'pre', '-', 'intervention', ')', 'and', 'a', 'second', 'time', 'one', 'month', 'after', 'the', 'end', 'of', 'the', 'intervention', '.', 'The', 'validated', 'Spanish', 'scales', 'will', 'be', 'used', ':', 'NP-4', '(', 'NP', 'Screening', ')', ',', 'Numerical', 'Pain', 'Scale', '(', 'END', ')', ',', 'PCS', '(', 'Pain', 'Catastrophization', ')', ',', 'SF-36', '(', 'Health', '-', 'related', 'quality', 'of', 'life', ')', 'and', 'WHODAS', '2.0', '(', 'Disability', ')', '.', 'The', 'primary', 'outcome', 'is', 'the', 'level', 'of', 'NP', 'and', 'its', 'catastrophization', ',', 'and', 'the', 'secondary', 'outcomes', 'are', 'level', 'of', 'disability', 'and', 'quality', 'of', 'life', '.', 'With', '28', 'participants', 'fully', 'measured', ',', 'it', 'is', 'possible', 'to', 'have', '80', '%', 'power', 'to', 'find', 'differences', 'between', 'the', 'groups', 'with', 'respect', 'to', 'the', 'primary', 'outcomes', '.', 'All', 'information', 'will', 'be', 'analyzed', 'using', 'average', 'comparisons', 'with', '95', '%', 'confidence', '.', 'The', 'analysis', 'will', 'be', 'carried', 'out', 'by', 'Intention', 'to', 'Treat', '(', 'ITT', ')', 'taking', 'all', 'the', 'randomized', 'participants', '.', 'Missing', 'data', 'will', 'be', 'processed', 'through', 'multiple', 'imputation', 'chains', '.', 'Generalized', 'mixed', 'linear', 'models', 'will', 'be', 'used', 'comparing', 'the', 'standardized', 'baseline', 'and', 'post', '-', 'intervention', 'averages', 'of', 'each', 'group', 'and', 'between', 'each', 'group', ',', 'obtaining', '95', '%', 'confidence', 'intervals', 'and', 'p', '-', 'values', '.', 'Subgroup', 'analysis', 'will', 'be', 'performed', 'adjusting', 'confounders', 'and', 'interactions', '.', 'A', 'significant', 'difference', 'will', 'be', 'considered', 'when', 'the', 'value', 'of', 'p', 'is', 'less', 'than', '0.05', '.', 'Cohens', 'D', 'will', 'be', 'calculated', 'to', 'identify', 'the', 'size', 'of', 'the', 'intervention', 'effect', '.', '\n\n', 'Discussion', ':', 'The', 'results', 'will', 'reflect', 'the', 'effect', 'of', 'the', 'hydrotherapy', 'on', 'NP', 'in', 'patients', 'with', 'SCI', '.', 'They', 'will', 'also', 'permit', 'the', 'identification', 'of', 'potential', 'changes', 'in', 'functionality', 'levels', 'or', 'quality', 'of', 'life', 'in', 'the', 'intervened', 'population', '.']","['O', 'O', 'B-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04164810,NCT04164810,"Effects of Hydrotherapy on Neuropathic Pain and Pain Catastrophization in Spinal Cord Injury: Study Protocol for a Randomized Controlled Trial | Spinal Cord Injury (SCI) is a spinal cord injury of traumatic origin with its main etiology being violence, which constitutes one of the greatest social and health problems worldwide. One of the complications with the greatest impact in people with SCI is Neuropathic Pain (NP). Pain, mainly chronic pain, has an effect on emotional states, cognition regarding pain and anticipation which leads to the catastrophization of the pain. This form of pain is related to chronic diseases that develop with pain of poor prognosis and are detrimental to quality of life therefore having enormous impacts on health systems. The physiological mechanisms of Hydrotherapy on pain are clear and there is evidence of its use in the management of painful syndromes of difficult treatments such as that for fibromyalgia and chronic lumbar pain, as well as its positive effect on pain perception. However, the effects of hydrotherapy on the NP of patients with SCI are unknown.

Randomized, controlled clinical trial of parallel groups. A randomized sequence will be carried out in balanced blocks to assign the intervention (Hydrotherapy) or the control (Standard Physical Therapy), to a sample of 28 participants, 14 for each group. Each of the interventions (hydrotherapy and physical therapy) will last 9 weeks, for a total of 18 sessions (2 weekly sessions). Two measurements will be made, baseline (pre-intervention) and a second time one month after the end of the intervention. The validated Spanish scales will be used: NP-4 (NP Screening), Numerical Pain Scale (END), PCS (Pain Catastrophization), SF-36 (Health-related quality of life) and WHODAS 2.0 (Disability). The primary outcome is the level of NP and its catastrophization, and the secondary outcomes are level of disability and quality of life. With 28 participants fully measured, it is possible to have 80% power to find differences between the groups with respect to the primary outcomes. All information will be analyzed using average comparisons with 95% confidence. The analysis will be carried out by Intention to Treat (ITT) taking all the randomized participants. Missing data will be processed through multiple imputation chains. Generalized mixed linear models will be used comparing the standardized baseline and post-intervention averages of each group and between each group, obtaining 95% confidence intervals and p-values. Subgroup analysis will be performed adjusting confounders and interactions. A significant difference will be considered when the value of p is less than 0.05. Cohens D will be calculated to identify the size of the intervention effect.

Discussion: The results will reflect the effect of the hydrotherapy on NP in patients with SCI. They will also permit the identification of potential changes in functionality levels or quality of life in the intervened population.","[(11, 23, 'PHYSICAL', 'Hydrotherapy'), (27, 43, 'CONDITION', 'Neuropathic Pain'), (48, 70, 'CONDITION', 'Pain Catastrophization'), (74, 92, 'CONDITION', 'Spinal Cord Injury'), (145, 163, 'CONDITION', 'Spinal Cord Injury'), (165, 168, 'CONDITION', 'SCI'), (175, 193, 'CONDITION', 'spinal cord injury'), (394, 397, 'CONDITION', 'SCI'), (401, 417, 'CONDITION', 'Neuropathic Pain'), (419, 421, 'CONDITION', 'NP'), (424, 428, 'CONDITION', 'Pain'), (437, 449, 'CONDITION', 'chronic pain'), (506, 510, 'CONDITION', 'pain'), (572, 576, 'CONDITION', 'pain'), (591, 595, 'CONDITION', 'pain'), (645, 649, 'CONDITION', 'pain'), (792, 804, 'PHYSICAL', 'Hydrotherapy'), (808, 812, 'CONDITION', 'pain'), (968, 972, 'CONDITION', 'pain'), (1008, 1012, 'CONDITION', 'pain'), (1049, 1061, 'PHYSICAL', 'hydrotherapy'), (1069, 1071, 'CONDITION', 'NP'), (1089, 1092, 'CONDITION', 'SCI'), (1254, 1266, 'PHYSICAL', 'Hydrotherapy'), (1284, 1309, 'CONTROL', 'Standard Physical Therapy'), (1390, 1402, 'PHYSICAL', 'hydrotherapy'), (1407, 1423, 'CONTROL', 'physical therapy'), (1706, 1709, 'CONDITION', 'PCS'), (1711, 1733, 'CONDITION', 'Pain Catastrophization'), (1840, 1842, 'CONDITION', 'NP'), (2829, 2841, 'PHYSICAL', 'hydrotherapy'), (2845, 2847, 'CONDITION', 'NP'), (2865, 2868, 'CONDITION', 'SCI')]"
"['Intraoperative', 'Evaluation', 'of', 'Focused', 'Ultrasound', '-', 'induced', 'Blood', '-', 'brain', 'Barrier', 'Disruption', '|', 'This', 'study', 'seeks', 'to', 'determine', 'the', 'impact', 'of', 'focused', 'ultrasound', '(', 'FUS', ')', 'on', 'the', 'composition', 'of', 'the', 'tumor', 'extracellular', 'microenvironment', '.', 'Researchers', 'will', 'evaluate', 'regions', 'that', 'are', 'very', 'abnormal', ',', 'as', 'well', 'as', 'regions', 'that', 'have', 'less', 'evidence', 'of', 'disease', '.', 'A', 'sub', '-', 'portion', 'of', 'each', 'of', 'these', 'areas', 'will', 'be', 'targeted', 'by', 'focused', 'ultrasound', '.', 'Microdialysis', 'catheters', 'will', 'then', 'be', 'placd', 'into', 'each', 'region', 'that', 'has', 'and', 'has', 'not', 'been', 'exposed', 'to', 'FUS', '(', 'total', 'of', '4', 'catheters', ')', 'to', 'determine', 'how', 'FUS', 'impacts', 'the', 'the', 'brain', 'and', 'tumor', 'extracellular', 'metabolome', ',', 'including', 'concentration', 'of', 'routine', 'drugs', 'systemically', 'administered', 'prior', 'to', ',', 'and', 'during', 'surgery', '.', 'Researchers', 'hope', 'that', 'this', 'information', 'will', 'help', 'reveal', 'the', 'relative', 'contribution', 'of', 'blood', '-', 'derived', 'compounds', 'to', 'the', 'tumor', 'microenvironment', '.', 'If', 'successful', ',', 'microdialysis', 'could', 'be', 'leveraged', 'in', 'the', 'future', 'to', 'simultaneously', 'evaluate', 'pharmacokinetic', 'and', 'pharmacodynamic', 'impacts', 'of', 'future', 'candidate', 'therapies', ',', 'including', 'those', 'delivered', 'with', 'the', 'aid', 'of', 'FUS', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O']",NCT05733312,NCT05733312,"Intraoperative Evaluation of Focused Ultrasound-induced Blood-brain Barrier Disruption | This study seeks to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment. Researchers will evaluate regions that are very abnormal, as well as regions that have less evidence of disease. A sub-portion of each of these areas will be targeted by focused ultrasound. Microdialysis catheters will then be placd into each region that has and has not been exposed to FUS (total of 4 catheters) to determine how FUS impacts the the brain and tumor extracellular metabolome, including concentration of routine drugs systemically administered prior to, and during surgery. Researchers hope that this information will help reveal the relative contribution of blood-derived compounds to the tumor microenvironment. If successful, microdialysis could be leveraged in the future to simultaneously evaluate pharmacokinetic and pharmacodynamic impacts of future candidate therapies, including those delivered with the aid of FUS.","[(29, 86, 'OTHER', 'Focused Ultrasound-induced Blood-brain Barrier Disruption'), (133, 151, 'OTHER', 'focused ultrasound'), (153, 156, 'OTHER', 'FUS'), (184, 189, 'CONDITION', 'tumor'), (392, 410, 'OTHER', 'focused ultrasound'), (509, 512, 'OTHER', 'FUS'), (553, 556, 'OTHER', 'FUS'), (583, 588, 'CONDITION', 'tumor'), (828, 833, 'CONDITION', 'tumor'), (1058, 1061, 'OTHER', 'FUS')]"
"['The', 'Florida', 'REACH', 'Translation', 'Project', '|', 'The', 'primary', 'aim', 'of', 'this', 'study', 'is', 'to', 'test', 'feasibility', 'of', 'a', 'modified', 'REACH', 'II', 'intervention', 'in', 'an', 'outpatient', 'clinic', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04956874,NCT04956874,The Florida REACH Translation Project | The primary aim of this study is to test feasibility of a modified REACH II intervention in an outpatient clinic.,[]
"['Immune', 'Lot', 'Consistency', ',', 'Immunogenicity', ',', 'and', 'Safety', 'of', 'an', 'Investigational', 'Quadrivalent', 'Meningococcal', 'Conjugate', 'Vaccine', 'in', 'Adolescents', 'and', 'Adults', 'Aged', '10', 'to', '55', 'Years', '|', 'The', 'purpose', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'immune', 'lot', 'consistency', 'of', 'Meningococcal', 'Polysaccharide', '(', 'Serogroups', 'A', ',', 'C', ',', 'Y', 'and', 'W', ')', 'Tetanus', 'Toxoid', '(', 'MenACYW', ')', 'Conjugate', 'vaccine', 'and', 'the', 'immune', 'non', '-', 'inferiority', 'compared', 'to', 'the', 'licensed', 'vaccine', 'Menactra', '', ',', 'and', 'describe', 'the', 'safety', 'and', 'additional', 'immunogenicity', 'of', 'these', 'study', 'vaccines', 'in', 'adolescents', 'and', 'adults', '10', 'to', '55', 'years', 'of', 'age', 'in', 'the', 'United', 'States', '(', 'US', ')', '.', '\n\n', 'Primary', 'Objectives', ':', '\n\n', 'To', 'demonstrate', 'the', 'immune', 'lot', 'consistency', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'with', 'respect', 'to', 'serum', 'bactericidal', 'assay', 'using', 'human', 'complement', '(', 'hSBA', ')', 'geometric', 'mean', 'titers', '(', 'GMTs', ')', '.', '\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '', '.', '\n\n', 'Secondary', 'Objective', ':', '\n\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '', 'in', 'the', 'adult', 'population', '(', '18', 'to', '55', 'years', 'old', ')', '.', '\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '', 'in', 'the', 'adolescent', 'population', '(', '10', 'to', '17', 'years', 'old', ')', '.', '\n', 'To', 'compare', 'the', 'hSBA', 'vaccine', 'seroresponses', 'of', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'for', 'each', 'of', '3', 'lots', 'of', 'MenACYW', 'Conjugate', 'vaccine', '30', 'days', '(', '+14', 'days', ')', 'after', 'vaccination', '.', '\n', 'To', 'compare', 'the', 'hSBA', 'antibody', 'GMTs', 'of', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'Menactra', '', '.', '\n\n', 'Observational', 'Objectives', ':', '\n\n', 'To', 'describe', 'the', 'safety', 'profile', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'and', 'that', 'of', 'the', 'licensed', 'Menactra', '', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O']",NCT02842853,NCT02842853,"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years | The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US).

Primary Objectives:

To demonstrate the immune lot consistency of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).
To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra.

Secondary Objective:

To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra in the adult population (18 to 55 years old).
To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra in the adolescent population (10 to 17 years old).
To compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W for each of 3 lots of MenACYW Conjugate vaccine 30 days (+14 days) after vaccination.
To compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of Menactra.

Observational Objectives:

To describe the safety profile of MenACYW Conjugate vaccine and that of the licensed Menactra.","[(73, 117, 'DRUG', 'Quadrivalent Meningococcal Conjugate Vaccine'), (233, 331, 'DRUG', 'Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine'), (396, 404, 'DRUG', 'Menactra'), (742, 767, 'DRUG', 'MenACYW Conjugate vaccine'), (1022, 1047, 'DRUG', 'MenACYW Conjugate vaccine'), (1145, 1153, 'DRUG', 'Menactra'), (1332, 1357, 'DRUG', 'MenACYW Conjugate vaccine'), (1455, 1463, 'DRUG', 'Menactra'), (1664, 1689, 'DRUG', 'MenACYW Conjugate vaccine'), (1787, 1795, 'DRUG', 'Menactra'), (1955, 1980, 'DRUG', 'MenACYW Conjugate vaccine'), (2128, 2153, 'DRUG', 'MenACYW Conjugate vaccine'), (2204, 2212, 'DRUG', 'Menactra'), (2277, 2302, 'DRUG', 'MenACYW Conjugate vaccine'), (2328, 2336, 'DRUG', 'Menactra')]"
"['A', 'High', '-', 'Performance', 'ECoG', '-', 'based', 'Neural', 'Interface', 'for', 'Communication', 'and', 'Neuroprosthetic', 'Control', '|', 'Test', 'the', 'feasibility', 'of', 'using', 'electrocorticography', '(', 'ECoG', ')', 'signals', 'to', 'control', 'complex', 'devices', 'for', 'motor', 'and', 'speech', 'control', 'in', 'adults', 'severely', 'affected', 'by', 'neurological', 'disorders', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03698149,NCT03698149,A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control | Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.,"[(2, 46, 'OTHER', 'High-Performance ECoG-based Neural Interface')]"
